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Abstract   
In search of phytomedicine for diabetes, this preliminary screening was 
conducted on twelve (12) different plants for hypoglycemic activity and antioxidant 
potential in the in vitro and in vivo study models. Amongst all, Centratherum 
anthelminticum seeds demonstrated maximum hypoglycemic and antioxidant potential. 
Therefore, the defatted crude methanolic fraction of the Centratherum anthelminticum 
seeds (CAMFs) was selected for detailed antidiabetic activity on the in vitro cell-based 
biological studies on mouse pancreatic cells, β-TC6 and on type 1 and type 2 diabetic 
rats for 4-weeks. The results of this study indicate that CAMFs showed potential 
antidiabetic effect on β-TC6 cells and confirmed beneficial effects on type 2 diabetic 
rats by ameliorating hyperglycemia and augmenting insulin secretion without any toxic 
signs and lethality in acute toxicity studies. 
Furthermore, CAMFs was studied for H2O2-induced nuclear factor-κB (NF-κB) 
translocation effects on β-TC6 cells to investigate ROS-associated oxidative stress. 
Subsequently, a 12-week study was conducted on type 2 diabetic rats to determine 
biochemical parameters and their associated complications. The results of this  study 
showed that CAMFs prevented H2O2-induced NF-κB translocation in the β-TC6 cells 
and downregulated hyperglycemia, oxidative stress, dyslipidemia and inflammatory 
response in diabetic rats. 
Next, the crude fractions of Centratherum anthelminticum seeds were evaluated 
for pleotropic biological activities which had not been investigated on this plant. The 
result of this study showed that, defatted crude chloroform fraction (CACF) posesses 
the highest level of pleotropic bioactivities. CACF was tested on RAW264.7 
macrophages for tumor necrosis factor-α (TNF-α) inhibition and for cytotoxic effects on 
targeted A549, PC-3, MCF-7, and WRL-68 cancer cell lines, along with antioxidant 
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potential on DPPH, FRAP and ORAC assays. Results of this study demonstrated that 
CACF exhibited the strongest inhibitory effects on TNF-α secretion and possessed 
maximum cytotoxic effects on MCF-7 cancer cells, with antioxidant abilities. 
Furthermore, we observed dose-dependent inhibitory response of CACF on serum TNF-
α inhibition on lipopolysaccharides (LPS)-stimulated SD rats. Moreover, in line with 
the cytotoxic effects, CACF showed inhibitory role against the activation of NF-κB 
translocation in MCF-7 cells, dose-dependently.  
It was concluded that CAMFs may be of interest in the pharmaceutical industry 
to be developed as a dietary supplement for the management of type 2 diabetes and its 
associated complications. Moreover, CACF fraction could be suggested for the 
alleviation of elevated inflammatory response as well as in the management of breast 
cancer and oxidative stress.      
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Abstrak 
Dalam mencari ‘phytomedicine’ untuk diabetes, kami menjalankan penyaringan 
awal pada 12 tumbuhan yang berbeza untuk aktiviti hipoglisemik dan potensi 
antioksidan dalam model kajian in vitro dan in vivo. Di antara semua, biji-biji 
Centratherum anthelminticum menunjukkan potensi maksimum hipoglisemik dan 
antioksidan. Oleh itu, ekstrak metanol mentah biji Centratherum anthelminticum yg 
dihilangkan lemak (CAMFs) telah dipilih untuk kajian terperinci berasaskan sel biologi 
ke atas aktiviti antidiabetis secara in vitro pada  sel pankreas tikus, β-TC6 dan tikus 
diabetis  Jenis 1 dan Jenis 2, selama 4 minggu. Hasil kajian ini menunjukkan bahawa 
CAMFs mempamerkan keupayaan kesan antidiabetis ke atas sel-sel β-TC6 dan 
disahkan kesan yang baik pada tikus diabetik Jenis 2 boleh memperbaiki hiperglisemia 
dan menambahkan rembesan insulin tanpa sebarang tanda-tanda toksik dan maut dalam 
kajian toksisiti akut. 
Tambahan pula, CAMFs dikaji untuk faktor nuklear -κB diaruh oleh H2O2 (NF-
κB) kesan translokasi atas sel-sel β-TC6 untuk menyiasat tekanan oksidatif berkaitan 
ROS. Selepas itu, satu kajian 12-minggu telah dijalankan ke atas tikus diabetis jenis 2 
untuk menentukan parameter-parameter biokimia dan komplikasi yang berkaitan. 
Keputusan kajian ini menunjukkan bahawa CAMFs menghalang translokasi faktor 
nuklear NF-κB diaruh oleh H2O2 dalam sel-sel β-TC6 dan menurunkan hiperglisemia, 
tekanan oksidatif, dislipidemia dan tindak balas keradangan pada tikus diabetis. 
Seterusnya kami menilai biji Centratherum anthelminticum untuk aktiviti 
biologikal pleotropik yang tidak pernah disiasat pada tumbuhan ini. Hasil kajian kami 
menunjukkan bahawa ekstrak klorofom mentah yang dihilangkan lemak (CACF) 
mempunyai bioaktiviti pleotropik  pada tahap tertinggi. CACF telah diuji pada makrofaj 
RAW264.7 untuk perencatan tumor nekrosis faktor α (TNF-α) dan untuk kesan 
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sitotoksik  disasarkan pada barisan sel kanser A549, PC-3, MCF-7, dan WRL-68 , 
bersama-sama dengan potensi antioksidan pada cerakinan DPPH , FRAP dan ORAC. 
Keputusan kajian ini menunjukkan bahawa CACF mempamerkan kesan rencatan 
tertinggi  pada rembesan TNF-α dan mempunyai kesan sitotoksik maksimum pada sel-
sel kanser MCF-7, dengan keupayaan antioksidatif. Tambahan pula, kami perhatikan 
respon perencatan bergantung kepada dos pada CACF ke atas perencatan serum TNF-α 
pada lipopolysaccharides (LPS) dirangsang SD tikus. Selain itu, selaras dengan kesan 
sitotoksik, CACF menunjukkan peranan perencatan terhadap pengaktifan translokasi 
NF-κB dalam MCF-7 sel, bergantung pada dos. 
Sebagai rumusan, kami membuat kesimpulan bahawa penggunaan CAMFs 
mungkin penting dalam industri farmaseutikal untuk dibangunkan sebagai diet 
tambahan bagi pengurusan diabetes jenis 2 dan komplikasi yang berkaitan dengannya. 
Selain itu, ekstrak CACF boleh dicadangkan untuk mengurangkan tindak balas 
keradangan yang tinggi serta dalam pengurusan kanser payudara dan stress oksidatif. 
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Synopsis 
In search of phytomedicine for diabetes, the leaf methanolic extract of nine (9) 
different plants were screened for the hypoglycemic activity, such as Centratherum 
anthelminticum, Cissus quadrangularis, Madhuca indica, Parthenium hysterophorus L., 
Sida acuta Burm F., Vicoa indica Cass, Vanda tessellata (Roxb.), Woodfordia fruticosa 
Kurz and Xanthium strumarium L. The screening consisted of in vivo acute toxicity 
studies and hypoglycemic screening on normoglycemic rats through the intraperitoneal 
(i.p) or oral routes of administration, following the intraperitoneal glucose tolerance test 
(IPGTT) and oral glucose tolerance test (OGTT). From these screening tests, it was 
observed that the leaf extracts of Centratherum anthelminticum, Cissus quadrangularis 
and Woodfordia fruticosa Kurz possess maximum hypoglycemic effect without any 
acute toxic signs or lethality. 
Next, we studied three (3) plants, Terminalia arjuna, Terminalia bellerica and 
Terminalia chebula for their antioxidant properties in the in vitro, 1,1-diphenyl-2-
picrylhydrazyl (DPPH), oxygen radical absorbance capacity (ORAC) and ferric 
reducing/antioxidant power (FRAP) assays, along with acute toxicity and oral 
hypoglycemic tests on normal rats. The results of these tests indicate that the methanolic 
leaf extracts of the selected plants possess antioxidant and hypoglycemic properties, 
without any toxic effects. This positive effect may be due to the poly-phenolic 
compounds shown to be present in Terminalia species. 
Furthermore, by screening different parts of such selected plants, it was found 
that Centratherum anthelminticum seeds showed maximum hypoglycemic and 
antioxidant potential. Therefore, the seeds of this plant were used for detailed 
antidiabetic research including targeted biological studies. 
vii 
 
The defatted crude methanolic fraction of the Centratherum anthelminticum 
seeds (CAMFs) was selected for detailed antidiabetic studies on in vitro cell-based 
mechanistic approaches, including short-term studies on diabetic animals. CAMFs, was 
initially tested on mouse pancreatic β-TC6 cell line for cellular viability and 
proliferation, with 2-NBDG glucose uptake, insulin secretion and glucose transporter 
(GLUT-1, 2 and 4) protein expression. Next, CAMFs was subjected to acute toxicity 
studies through intraperitoneal (i.p) and oral routes of administration, following a four-
week study on Streptozotocin (STZ)-induced type 1 and STZ-nicotinamide-induced 
type 2 diabetic rats to determine blood glucose and insulin levels measuring the 
animals’ food and water intake as well as body weight. 
The results of this study on β-TC6 cell-line models demonstrate the non-
cytotoxic nature of CAMFs on β-TC6 cell proliferation. Furthermore, it showed dose-
dependent increase in glucose uptake, as well as insulin secretion was mediated by 
upregulating GLUT-2 and GLUT-4 protein expression. CAMFs significantly reduced 
hyperglycemia and augment insulin secretion in type 2 diabetic rats, without any 
toxicity in acute studies. In contrast, type 1 diabetic rats did not show much 
improvement in glycemic control with non-significant increase in insulin secretion. The 
antidiabetic effects of CAMFs may be attributed to its poly-phenolic constituents, as 
identified by the LCMS-MS as the major compounds. 
In continuation with the present study, an attempt was made to gain a better 
understanding of the effects of CAMFs in ROS-associated oxidative stress on insulin 
resistance signaling pathways by investigating the role of CAMFs in H2O2-induced NF-
κB activation on β-TC6 cells. The result of this study showed that CAMFs prevent 
H2O2-induced NF-κB translocation in the β-TC6 cells. Next, to confirm the beneficial 
effects of CAMFs produced by the β-TC6 cell line and animal model of type 2 diabetic 
rats, a 12-week (sub-chronic) study was carried out on type 2 diabetic complications in 
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STZ-nicotinamide-induced type 2 diabetic rats to determine biochemicals, enzyme and 
physiological parameters with markers of oxidative stress and pro-inflammatory 
cytokines. 
Results of this study revealed that CAMFs significantly reduced hyperglycemia 
by augmenting serum insulin, C-peptide, total protein, and albumin levels. Moreover, 
elevated glycated hemoglobin, lipids and enzyme activities of serum and tissues were 
also restored to near normal. CAMFs produced antioxidant effect by elevating 
glutathione (GSH) and by down-regulating malondialdehyde (MDA) levels in the tested 
serum and tissues. CAMFs also caused dose-dependent reduction of elevated pro-
inflammatory cytokines, tumor necrosis factor α (TNF-α) levels, as well as that of 
interleukin (IL)-1β and IL-6 in the serum and tissues of the diabetic rats. 
Histopathological studies showed that long term administration of CAMFs for 12 weeks 
prevent STZ-induced structural degeneration in the liver, kidney and pancreas of 
diabetic rats. Overall results established that CAMFs exert apparent antidiabetic effect 
suggesting that it may be a valuable candidate for insulin-resistant type 2 diabetes and 
its associated complications such as oxidative stress, dyslipidemia as well as in 
inflammatory response. 
Apart from antidiabetic property, several studies have investigated different 
pharmacological effects of the seeds of this plant in different ailments but investigations 
on the inflammatory cytokines and cytotoxic effects on different cancer cell lines have 
not been reported in the literature. Therefore, this study was planned to investigate the 
biological activities related to the inflammatory response on cytokines and cancer cells. 
The chloroform fraction of the Centratherum anthelminticum seeds (CACF) was 
investigated on RAW264.7 macrophage cells for the TNF-α inhibition response with 
cytotoxic effects on the targeted A549, PC-3, MCF-7, and WRL-68 cells. The study 
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results demonstrated that CACF inhibits TNF-α secretion in stimulated RAW264.7 
macrophage cells without affecting their viability. Cytotoxicity screening results 
indicate that among all the cell lines tested, CACF displayed maximum inhibitory effect 
on the breast cancer (MCF-7 ) cells. 
Furthermore, in line with the inhibitory effects of CACF on the TNF-α secretion, 
the effects on serum TNF-α in an in vivo model was confirmed; the results of the study 
demonstrate that CACF showed  dose-dependent inhibitory effects on serum TNF-α in 
LPS-stimulated SD rats, without any toxic signs and lethality in acute toxicity studies. 
Next, the effectiveness of CACF on a targeted MCF-7 cell line was tested by evaluating 
the linkage between NF-κB activation on the MCF-7 cells through a mechanistic 
approach. The results of this study showed that CACF dose-dependently inhibits the 
activation of NF-κB translocation in MCF-7 cells. Alongwith all these tests, the 
antioxidant potential of the CACF on DPPH, ORAC and FRAP assays were evaluated. 
Results of these tests showed that CACF also possesses antioxidant abilities and  the 
chemicals inside CACF could be responsible for such pleotropic biological activities. 
This study suggests that Centratherum anthelminticum seeds are corroborated 
with potential biological activities; this was exhibited in the defatted crude methanolic 
fraction (CAMFs) which might serve as a promising alternative as nutraceutical (dietary 
supplement) in the management of type 2 diabetes and in its associated complications. 
Moreover, crude chloroform fraction (CACF) also showed its potential to be effective in 
the management of inflammation and breast cancer with oxidative stress conditions.  
An overview of the research methods and approaches employed in this study is 
shown in Figure 3.1. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background 
To date, a huge number of plants have been studied as potential source of 
phytomedicine in the management of diabetes, oxidative stress, inflammation, cancer 
with many other disorders. Plants which are utilized in our study for the management of 
diabetes mellitus (DM) are either used individually or in the form of mixture in many 
formulations in the Indian system of medicine including various herbal and traditional 
medicines. 
The plants which were selected in this study are based on their traditional 
application within the region. We have selected the plants which are mostly utilized by 
the tribal community for the purpose of “Madhumeha” (Diabetes mellitus) with 
inflammatory conditions. These plants are mostly used by the Gond community near the 
satpuda ranges of forest in the surroundings areas such as Hoshangabad and Betul 
districts in the state of Madhya Pradesh, India, where these plants are grown in the 
forest or cultivated by the people for sale. The community use the leaf from these plants 
by boiling the fresh or dried leaves and consuming them orally by drinking the 
decoctions in the morning and evening. 
The plants tested were Centratherum anthelminticum, Parthenium 
hysterophorus L., Xanthium strumarium L., and Vicoa indica Cass, which are all from 
the Asteraceae family, together with five others from different families: Woodfordia 
fruticosa Kurz (Lythraceae), Sida acuta Burm F. (Malvaceae), Vanda tessellata (Roxb.) 
(Orchidaceae), Madhuca indica (Sapotaceae), and Cissus quadrangularis (Vitaceae). 
Three plants were from the same genus Terminalia such as T. arjuna, T. bellerica, and 
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T. chebula  from the Combretaceae family. The claim made by traditional healers made 
us include these plants in this study to scientifically validate such plants for their 
hypoglycemic potential, followed by selecting the most potent parts of the respective 
plants for other pleotropic biological evaluations as well. Some of these selected plants 
have already been scientifically validated and some of them have not. There are few 
reports on the hypoglycemic potential of different parts of Centratherum 
anthelminticum (Ani and Naidu., 2008; Fatima et al., 2010; Shah et al., 2008), 
Parthenium hysterophorus L. (Patel et al., 2008), Cissus quadrangularis (Chidambaram 
and Carani., 2010), Woodfordia fruticosa Kurz (Charve et al., 2010) and Terminalia 
species (Murali et al., 2007; Rao and Nammi., 2006; Sabu and Kuttan., 2002). 
Therefore, this study is focused on the scientific evaluations of the leaf extracts of the 
selected plants, followed by the selection of the most effective part of the single plant 
for the detailed pharmacological investigations.     
 
1.2 Objectives of the study  
The general research approach that was followed were; to initially screen 12 
Indian plants used by tribal peoples as folkflore medicine for diabetes and for 
antioxidative abilities; eventually to focus on the most potent part of the single plant 
with the strongest hypoglycemic activity and to further assess the extract/fraction of the 
potential parts using the in vitro cell-based study alongwith in vivo animal models 
through preclinical approaches for the antidiabetic effects and its associated 
complications. In addition, further assessment of its other biological activities which 
have not yet been investigated on the same plants through in vitro and in vivo study 
models.  
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Therefore, the specific objectives of the study were:  
a) To perform a hypoglycemic screening test on the selected plant extract/fraction using 
in vivo screening models on normal rats. 
b) To select the most potent part with maximum hypoglycemic and antioxidant effects 
from the tested plants with positive results.    
c) To test the selected part of the plant extract/fraction for antidiabetic effects on the in 
vitro cell-based mechanistic approaches in mouse pancreatic β-TC6 cells, alongwith 
short term study on the type 1 and type 2 diabetic animal models. 
d) To examine the role of the selected extract/fraction in ameliorating complications 
associated with diabetes through long term administration on the in vivo animal model 
and to analyse the possible major compounds present in the extract/fraction.      
e) To determine the potential biological activities which have not been investigated 
before in the selected part of the plant extract/fraction using cell-based in vitro studies 
alongwith in vivo model.   
 
1.3 Findings from this research  
1.3.1 Outcomes from the 1
st
 published paper  
In search of the most potent plant through the screening of twelve (12) different 
plants for hypoglycemic activity, we first investigated nine (9) such plants to evaluate 
the effects of the leaf extracts for antihyperglycemia. Initially, acute toxicity test and 
hypoglycemic screening were performed on normal rats whose blood glucose levels 
were measured previously following an oral or intraperitoneal (i.p.) administration of 
the extracts at different time periods. The results of acute oral and intraperitoneal 
4 
 
toxicity studies demonstrated that the methanolic extracts from all of the selected plant 
leaf except Parthenium hysterophorus L. were non-toxic up to a dose of 2500 mg/kg. 
Based on this finding, doses with 250 mg/kg and 500 mg/kg were chosen as the 
maximum dose for further experiments involving administration by the i.p and oral 
routes respectively. Among these, Centratherum anthelminticum (Asteraceae), Cissus 
quadrangularis (Vitaceae), and Woodfordia fruticosa Kurz (Lythraceae) significantly 
reduced postprandial blood glucose levels in normal glycemic rats (P<0.001), with 
slight reductions effected by Sida acuta Burm F. (P = 0.002) and Parthenium 
hysterophorus L. (P = 0.017). The extracts that reduced postprandial blood glucose 
levels both orally and i.p. in the hypoglycemic screening tests were evaluated further for 
glucose challenge through glucose tolerance tests with i.p and oral administration on 
overnight-fasted normal rats. The results of these tests showed that Centratherum 
anthelminticum, Cissus quadrangularis, and Woodfordia fruticosa extracts possess 
maximum hypoglycemic effects and could be suggested as a potential candidate for the 
management of postprandial hyperglycemia.   
1.3.2 Outcomes from the 2
nd
 published paper 
Furthermore, three (3) different Terminalia species, T. arjuna, T. bellerica, and 
T. chebula leaves methanolic extracts were evaluated for their antioxidant and 
hypoglycemic potential. Initially, extracts were evaluated for their total phenolic, 
flavonoid, and tannin content, with in vitro antioxidant potential on DPPH, ORAC, and 
FRAP assays and hypoglycemic activities of the extracts were evaluated through 
hypoglycemic screening and oral glucose tolerance test (OGTT) on normal rats. Results 
of all these experiments revealed that the methanolic extract of T. chebula leaves 
contained the maximum amount of total phenolic content (TPC), followed by those of 
T. bellerica and T. arjuna (266.16, 259.28, and 147.23 mg GAE/g extract, respectively). 
Likewise, the total flavonoid content (TFC) were 29.23, 16.15, and 8.19 mg Q/g extract, 
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respectively. T. chebula possessed the highest content of tannin (TTC), followed by T. 
arjuna and T. bellerica (8.36, 4.68 and 6.31 mg C/g extract, respectively). The 
scavenging capacity of T. chebula for the antioxidant DPPH was the highest among the 
extracts tested, as it recorded the lowest IC50 value (11.6 μg/mL) value of all 3 extracts. 
The results demonstrated that T. chebula extract was found to possess highest oxygen 
radical absorption capacity with the lowest ORAC (18.23 μM TE/mL) value. In the 
FRAP assay, the ferric reducing antioxidant abilities of the extracts showed that T. 
arjuna > T. chebula > T. bellerica. This correlates the potential of polyphenolic content 
enriched with antioxidant capabilities and substantiates the results of the hypoglycemic 
screening and OGTT, which determined that the T. chebula extract had a maximum 
hypoglycemic effect on normal rats (P<0.001) compared to that of T. bellerica and T. 
arjuna, respectively. Altogether, the results of this study showed that selected 
Terminalia species possess hypoglycemic potential with antioxidative abilities. Thus, it 
may be concluded that the use of selected Terminalia species leaf as food supplements 
may help in reducing oxidative stress and elevated blood glucose levels.   
1.3.3 Outcomes from the 3
rd
 published paper  
Based on the pilot screening result, the defatted crude methanolic fraction of the 
Centratherum anthelminticum seeds (CAMFs) was selected for further detailed studies 
on the mouse pancreatic β-TC6 cell line to determine its potential effect on diabetic 
conditions, thereby confirming its effect on type 1 and type 2 diabetic rat models. 
Initially, CAMFs was tested on β-TC6 cells for cellular viability and 
proliferation, 2-NBDG glucose uptake and insulin secretion with glucose transporter 
(GLUT-1, 2 and 4) protein expression. The result of cellular viability assay showed that 
CAMFs concentrations of up to100 µg/mL did not exert cytotoxic effects on β-TC6 cell 
viability as compared to untreated control cells. Next, we monitored treated β-TC6 cells 
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for three days using Xcelligence Real-time Cell Proliferation (RTCA) assays. RTCA 
data showed that β-TC6 cells treated with 50, 25, 12.5, 6.25 or 3.125 µg/mL of CAMFs 
proliferated in a similar manner with control cells throughout the 72-h treatment. 
The result of this study indicate that CAMFs increased glucose uptake by the 
endocytosis of fluorescent glucose analogue 2-NBDG in β-TC6 cells, and showed an 
increase in intracellular 2-NBDG fluorescence, which was visible in distinct groups of 
cells, suggesting that β-TC6 cells retain the heterogeneous glucose uptake activity of 
native β-cells. Interestingly, CAMFs increased insulin secretion in a dose-dependent 
manner at glucose concentrations of 6.25, 12.5, 25 and 50 mM. In particular, at 12.5 
µg/mL CAMFs elicited a marked increase in insulin secretion in the β-TC6 cells. The 
expression of glucose transporter protein GLUT-1, GLUT-2 and GLUT-4 on β-TC6 
cells were examined with western blotting analysis. The result demonstrated that 
CAMFs increased GLUT-2 and GLUT-4 protein levels in a dose-dependent manner 
compared to control β-actin, leading to increased glucose uptake in the pancreatic β-
TC6 cells. In contrast, CAMFs did not alter GLUT-1 protein expression, suggesting the 
essential role of CAMFs in the translocation of insulin-regulated glucose into the cells. 
The acute oral and i.p toxicity studies revealed the non-toxic nature of CAMFs; 
no lethality or toxic reactions were observed for any of the doses tested. Based on these 
findings, 100 mg/kg and 50 mg/kg doses were chosen as the maximum dose for further 
experiments involving i.p and oral routes of administration respectively on STZ-induced 
type 1 and STZ-nicotinamide-induced type 2 diabetic rats. The study results showed 
that CAMFs significantly reduced hyperglycemia in type 2 diabetic rats. At the end of 
the study week, 100 and 50 mg/kg doses of CAMFs produced the maximal decrease of 
blood glucose level (51.40% and 46.47%) respectively compared to the glibenclamide 
group, which achieved a 50% drop in blood glucose levels. At 100 and 50 mg/kg of 
CAMFs, type 1 diabetic rats demonstrated 23.21% and 21.05% reduction in blood 
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glucose levels at the end of the study week. In continuation with the insulin secretion in 
β-TC6, CAMFs significantly augmented insulin levels of type 2 diabetic rats, plausibly 
through enhancing glucose uptake and insulin secretion, whereas type 1 diabetic rats did 
not show significant improvement in the insulin secretion. 
As mentioned above, CAMFs demonstrated antidiabetic potential on β-TC6 cells 
and type 2 diabetic rats plausibly through enhancing glucose uptake and insulin 
secretion. The antidiabetic potential may be attributed to CAMFs constituents as 
phytochemical studies by LCMS-MS identified certain poly-phenolic principles: 
quercetin glycoside, 3,4-0-dicaffeoylquinic acid, caffeic acid, naringenin-7-0-glucoside 
and kaempferol as the major compounds.  
1.3.4 Outcomes from the 4
th
 published paper  
Moreover, to confirm the demonstrated activity on β-TC6 cells and type 2 
diabetic rats, further study was aimed to ascertain the potential of CAMFs in the 
management of type 2 diabetes and its associated complications. CAMFs, was initially 
tested on ROS-induced oxidative stress associated with insulin resistance signaling 
pathway to determine the NF-κB translocation effects in β-TC6 cells. The result of this 
study showed that treatment with 25 μg/mL of CAMFs significantly inhibited H2O2-
induced NF-κB translocation from the cytoplasm into the nucleus, suggesting the 
antioxidative role of CAMFs in oxidative stres conditions. 
Next, a 12-week sub-chronic CAMFs study was carried out on STZ-
nicotinamide-induced type 2 diabetic rats to evaluate glycemia, essential biochemical 
parameters, lipid levels, oxidative stress markers, and proinflammatory cytokines level. 
This study result demonstrated that CAMFs significantly reduced hyperglycemia. The 
percentages of the inhibition of blood glucose effected by 50, 25, and 10 mg/kg doses of 
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CAMFs were 75.86%, 69.82%, and 65.08%, respectively, as compared to that of 
glibenclamide (68.53%) at the end of the study week. 
Biochemical parameters result displayed that CAMFs significantly elevated 
serum insulin, C-peptide, total protein, and albumin levels in diabetic rats and inhibited 
glycated hemoglobin (HbA1c) significantly in a dose-dependent manner, indicating 
significant improvement of glycemic control by CAMFs. Moreover, CAMFs 
significantly down-regulated serum TG, TC, LDL-C, and FFA levels in a dose-
dependent manner, whereas HDL-C levels were significantly elevated. Similarly, 
CAMFs produced normalization of the enzyme, AST, ALT, ALP, and γ-GT activities in 
the serum, liver, and kidney of diabetic rats, dose-dependently. 
CAMFs revealed antioxidant potential as GSH levels in the liver and pancreas of 
diabetic rats were significantly elevated, although not much changes were observed in 
the kidney GSH levels. In contrast, CAMFs recorded maximum reduction of MDA 
levels in the liver of diabetic rats at all the doses, whereas in the kidney and pancreas, 
MDA levels showed a dose-dependent reduction. 
Next, CAMFs role was determined on pro-inflammatory cytokines. The study 
results showed that the elevation caused to TNF-α, IL-1β, and IL-6 in diabetic rats were 
significantly inhibited by CAMFs. TNF-α levels in the pancreas, kidney and serum of 
diabetic rats were significantly down-regulated. Likewise, CAMFs significantly reduced 
the IL-1β and IL-6 levels in the pancreas, with non-significant reduction observed in the 
serum and kidney tissues. Histopathological studies showed that long term 
administration of CAMFs for 12-weeks prevented STZ-induced structural degeneration 
in the liver, kidney and pancreas of diabetic rats. The liver of diabetic rats treated with 
CAMFs showed improvement in the hepatocytes with less cytoplasmic vacuolization, 
along with recovery in the inflammed mononuclear cells as compared to diabetic control 
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rats. However, a few hepatocytes with cytoplasmic vacuolization and pyknotic nuclei 
were still seen. Similarly, the kidneys of diabetic rats treated with CAMFs showed mild 
recovery in the inflammation and less infiltaration of cells were seen in the renal 
parenchyma compared to untreated diabetic rats with mild tubular epithelial atrophy, as 
well as improvement in the congestion of capillaries. Likewise, the pancreas 
demonstrated an increase in the mass of islet cells with a reduction of necrosis, 
vacuolations, hydropic cells and pyknotic nuclei in diabetic rats treated with CAMFs. 
Altogether, the in vitro and in vivo study results showed that CAMFs exerted 
apparent antidiabetic effects on pancreatic β-TC6 cells and type 2 diabetic rats. 
Therefore, it is concluded that CAMFs is a valuable candidate for insulin-resistant type 
2 diabetes and could be suggested in its associated complications such as dyslipidemia, 
oxidative stress, and inflammatory response.    
1.3.5 Outcomes from the 5
th
 published paper  
In line with other biological activities, Centratherum anthelminticum seeds 
chloroform fraction (CACF) was investigated for the pleotropic bioactivities by 
assessing antioxidant potential, cytotoxic effect, and TNF-α inhibition activity with the 
NF-κB activation response. The total phenolic content and antioxidant property of 
CACF was evaluated with DPPH, ORAC, and FRAP assays. The total phenolic content 
of CACF was observed to be 37.16 ± 0.85 μg GAE/mg extract. CACF exhibited a dose-
dependent inhibition of DPPH activity with an IC50 value of 22.56 ± 1.4 μg/mL. 
Maximal DPPH scavenging activity occurred at 41 ± 1.2 μg/mL of CACF with an 
inhibition of 89%. Likewise, CACF showed a FRAP value of 1048.3 μmol/L, while the 
positive control Ascorbic acid and BHT displayed a value of 6240 and 907.7 μmol/L, 
respectively. CACF had an ORAC value of 992.34 ± 45.12 μM trolox equivalent at 20 
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μg/mL. On the other hand, quercetin had an ORAC value of 1018.00 ± 34.82 μM of 
Trolox equivalent at 5 μg/mL. 
CACF effectively and dose-dependently inhibited TNF-α release in vitro and in 
vivo. CACF inhibited TNF-α secretion in stimulated RAW 264.7 macrophages with an 
IC50 of 0.012 μg/mL and exhibited maximal TNF inhibition of 90% at 0.31 μg/mL. This 
significant inhibitory effect was observed at non-cytotoxic doses ranging from 0.031 to 
0.002 μg/mL, without affecting their viability. The acute toxicity study revealed the 
non-toxic nature of CACF. CACF showed a dose-dependent inhibitory effect of serum 
TNF-α in LPS-stimulated rats; the observed effect in rats pretreated with 100 mg/kg was 
almost 61%, compared to that of dexamethasone which was 67%. The cytotoxicity of 
CACF was tested using the MTT assay; CACF effective inhibitory concentrations (IC50) 
for lung cancer (A549), prostate cancer (PC-3), breast cancer (MCF-7), and normal 
hepatic cells (WRL- 68) were 31.42 ± 5.4, 22.61 ± 1.7, 8.1 ± 0.9, and 54.93 ± 8.3 
μg/mL, respectively. Furthermore, we focussed on MCF-7 cells for cytotoxic activity 
towards a mechanistic approach. When MCF-7 cells were treated with different 
concentration of CACF (8, 4, and 2 μg/mL), exhibited dose-dependent inhibitory effects 
against the activation of NF-κB translocation. In parallel, the morphological changes of 
NF-κB translocation indicated by immunofluorescence staining also showed an 
inhibitory effect of CACF on TNF-α-induced NF-κB translocation in a dose-dependent 
manner. Altogether, the results of this study demonstrate the potential of CACF in the 
management of elevated inflammatory cytokines TNF-α, including breast cancer and 
associated oxidative stress conditions. 
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CHAPTER 2 
LITERATURE REVIEW (CRITICAL REVIEW) 
2.1 Diabetes and its complications 
Diabetes mellitus ranks among the top causes of mortality throughout the world 
(Wild et al., 2004). This syndrome is initially characterized by loss of glucose 
homeostasis as a result of defects in insulin secretion, insulin action or both, leading to 
impaired metabolism of glucose and other energy-yielding fuels such as lipids and 
proteins (American Diabetes Association (ADA), 2011).  
Diabetes is commonly referred to as type 1 (DM1) and type 2 (DM2). Both 
forms involve pancreatic islet β-cell abnormalities, characterized by death in type 1 and 
accelerated apoptosis in type 2. The global prevalence of diabetes was estimated to be 
6.4%, affecting 285 million adults in the year 2010 and its projections estimated to be 
7.7%, affecting 439 million adults in 2030 (Tamrakara et al., 2011).   
Malaysia is one of the top 10 countries in the estimation of diabetes prevalence 
in 2010 and 2030 at 11.6% and 13.8%, respectively (Shaw et al., 2010). According to 
the National Health and Morbidity Survey III which was conducted in the year 2006, 
15.5% of the general population in Malaysia was estimated to be suffering from chronic 
illnesses, where diabetes mellitus was recorded as the second most common chronic 
illness, constituting 4.0% out of 15.5% of the general population (Amal et al., 2011). 
As a chronic metabolic disorder, diabetes mellitus can affect all major organ 
systems of the body, leading to complications that may result in significant morbidity 
and premature mortality. Clinical, preclinical, and epidemiological studies indicate an 
association between oxidative stress and inflammation in the development of DM2 and 
its complications (Donath and Shoelson, 2011).    
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2.1.1 Oxidative stress  
Environmental factors and chemicals play a major role in the etiology of diabetic 
complications. Oxidative stress is caused by an imbalance between the production of 
ROS and antioxidant defences within the ability of a biological system to readily 
detoxify the reactive intermediates or repair the resulting damage. Disturbances in this 
normal redox state can cause toxic effects through the production of peroxides and free 
radicals and simultaneous decline in antioxidant defence mechanisms which can cause 
damage to all components of the cell, including proteins, lipids, and DNA which may 
inhibit their normal function (Karaca et al., 2006).   
Oxidative stress, as a consequence of hyperglycemia, changes in energy 
metabolism and inflammatory mediators play an important role in the pathophysiology 
of diabetes and its complications (Ferdinando and Michael, 2010).  In DM2, production 
of ROS is increased due to insulin resistance and hyperglycemia. Compared to healthy 
subjects, DM2 patients have a lower ratio of reduced glutathione (GSH) to oxidized 
glutathione (GSSG), a major endogenous antioxidant. In addition, malondialdehyde 
(MDA), a highly toxic by-product generated partially by lipid oxidation and ROS, leads 
to oxidative damage in the classical secondary targets of diabetes such as eyes, kidneys, 
nerves, and blood vessels. Islet cells of langerhans in the pancreas itself are the prime 
target, where the β-cell contains the lowest level of antioxidant enzyme activities 
compared to other tissues (Brownlee, 2001). A major manifestation of glucose toxicity 
in the β-cell is defective insulin gene expression, diminished insulin content, and insulin 
secretion due to defective glucose transporter protein (GLUT) or insulin receptor 
(Evans, 2007).   
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2.1.2 Dyslipidemia  
Obesity is the main risk factor in the development of metabolic syndrome. The 
precise pathogenesis of diabetic dyslipidemia is not known, while obesity may be the 
main risk factor accompanied by increased levels of leptin and cytokines in the 
circulation, which modulates the β-cell function and their survival (Maedler et al., 
2003). The combined elevation of cytokines such as IL-6 and IL-1β might affect lipid 
metabolism by acting on the liver to produce characteristic dyslipidemia in the 
metabolic syndrome, with high triglyceride and low HDL cholesterol levels as well as 
an increase in the concentration of small dense LDL-cholesterol. Likewise, the pro-
inflammatory cytokine TNF-α reduces insulin sensitivity in the muscle tissue and 
stimulates hepatic lipogenesis, leading to hyperlipidemia (Franckhauser et al., 2008).  
The lipid changes associated with diabetes mellitus attribute to increased free 
fatty acid (FFA) flux to insulin resistance (Roehrich et al., 2003; Donath et al., 2003). 
In diabetic dyslipidemia, it is also evident that NF-κB signaling is involved in the low-
grade inflammation which occurs in the liver (Cnop et al., 2002). As we know, NF-κB 
is one of the most important regulators of pro-inflammatory gene expression, which 
regulates β-cells by inducing apoptosis or promoting their survival. Depending on the 
kinetics and mode of induction involved in the etiology of insulin resistance, this 
signaling node may influence peripheral insulin resistance via actions in myeloid cells 
(Maedler et al., 2004). Hence, this supports the role of NF-κB in causing insulin 
resistance and impairing insulin secretion with dyslipidemia in type 2 diabetes.  
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2.1.3 Inflammatory response    
Recent evidence suggests that high levels of ROS and subsequent oxidative 
stress are the key contributors in the development of diabetic complications which 
weaken the antioxidant defences through an elevation in inflammation and 
inflammatory mediators by exerting major effects on signaling pathways, which further 
affects cellular metabolism and triggers a low-grade inflammatory reaction 
(Dominiczak, 2003). Lipid accumulation in adipose tissue and expansion of the fat mass 
in the liver initiate steatosis that promotes low-grade inflammation via activation of NF-
κB (Arkan et al., 2005) and provokes an inflammatory process accompanied by local 
production and secretion of pro-inflammatory cytokines and chemokines (Hotamisligil 
et al., 1995; Jager et al., 2007).  
It has been hypothesized that DM2 is a manifestation of an ongoing acute-phase 
response that is primarily characterized by alterations of the so-called acute-phase 
proteins such as the C-reactive protein (CRP) (Pickup and Crook, 1998; Pickup et al., 
1997), with other cytokines that are central mediators of inflammatory reactions, such as 
IL-6, IL-1β or tumor necrosis factor α (TNF-α). It is well-established that cytokines 
operate as a network in stimulating the production of acute-phase proteins. For example, 
the effects of IL-6 on CRP synthesis largely depend on its interaction with IL-1β 
(Spranger et al., 2003). TNF-α reduces insulin sensitivity in smooth muscles and 
tissues, thereby stimulating hepatic lipogenesis (Franckhauser et al., 2008).  
Investigations into the role of inflammatory mechanisms in diabetes and its 
complications are expected to provide insight into the processes and onset of 
progression in the disease. Such improved understanding of the inflammatory basis for 
diabetes may prove valuable in introducing novel approaches to treatment, alongside the 
currently used non-pharmacologic and pharmacological interventions.   
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2.2 Inflammatory cytokines and cancer  
Cytokines are molecular messengers that allow the cells of the immune system 
to communicate with one another to generate a coordination, robust, but self-limited 
response to a target antigen. The mixture of cytokines that is produced in the tumor 
microenvironment has an important role in cancer pathogenesis. Cytokines that are 
released in response to infection, inflammation and immunity may act to inhibit tumour 
development and progression. Alternatively, cancer cells can respond to host-derived 
cytokines that promote growth, attenuate apoptosis and facilitate invasion and 
metastasis (Glenn, 2004).   
Cancer is mediated through the inflammation process. In the inflammatory 
process, cytokines and pro-inflammatory cytokines mediate in the pathogenesis of 
carcinogenesis as well as tumor growth and spread; cytokines such as IL-1 and TNF-α 
induce chemokines that attract neutrophils. Neutrophils are the key players in the 
production of ROS and carcinogenesis which is induced by these cytokines and reflects 
in the type of genes they induce (Achyut and Yang, 2011).    
Cytokines such as TNF-α, IL-1 and IL-6 are primarily pro-inflammatory which 
are responsible for the induction of adhesion molecules and metalloproteinases, both of 
which provide mechanisms for tumor invasion.  
Up to 20% of all cancers arise in association with chronic inflammation, and 
most, if not all solid tumors, contain inflammatory infiltrates. Immune cells have a 
broad impact on tumor initiation, growth and progression which are mediated by 
proinflammatory cytokines (Yagi et al., 2002). Cytokines TNF-α, IL-1, IL-6 and IL-1β 
are master regulators of tumor-associated inflammation and tumorigenesis. This makes 
them attractive targets for adjuvant treatment in cancer. A more detailed understanding 
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of cytokine-tumor-cell interaction may provide opportunities for the development of a 
new plant-based cancer therapy.   
 
2.3 Antioxidant defence  
Antioxidants are substances that protect the body from damaging oxidation 
reaction by neutralizing free radicals and other ROS within the body through hindering 
the process of oxidation (Butkovic et al., 2004). Antioxidant defence involves several 
forms that include both enzymatic and non-enzymatic systems. The potent antioxidant 
activity exists in polyphenolics and may be the most important function, e.g. by 
scavenging or quenching free radicals,  chelating metal ions, or  inhibiting enzymatic 
systems responsible for free radical generation (Blaha et al. 2004; Dias et al. 2005).  
The activities of polyphenolic compounds and their benefits in oxidative stress-
related disorders have been widely studied. It is now widely accepted that dietary 
polyphenolics may play an important role in protecting the body against acute or 
chronic diseases such as diabetes, inflammation, cancer and cardiovascular diseases 
(Knekt et al. 2002; Karaca et al. 2006). Dietary polyphenols from fruits, vegetables and 
medicinal herbs possess wide therapeutic benefits in ameliorating diabetic 
complications. Flavonoids as phenolic compounds inhibit the polyol pathway and are 
also involved in preventing the overproduction of superoxide and in metal ion chelation 
processes (Abdallah et al., 2011; Boots et al., 2008). Thus, plants that are rich in 
flavonoids could be promising in the management of diabetes and its related 
complications.  
The antioxidant action of flavonoids, the best described biological activity of 
this group of natural polyphenolic substances, is covered by a large number of studies 
(Amic et al., 2007; Bischoff, 2008). Phenolic and flavonoids as naringenin, kaemferol, 
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quercetin, and caffeic acid demonstrated divergent activities such as anti-diabetic, anti-
oxidant, and anti-inflammatory activities with potential anticancer properties. (Jung et 
al., 2006; Ortiz-Andrade et al., 2007; Tsai et al., 2012; Zhang et al., 2009).   
2.3.1 Antioxidant testing 
Different antioxidants scavenge different free radicals and may be effective in 
different parts of the body. Antioxidant effectiveness is measured by monitoring the 
inhibition of oxidation of a suitable substrate. When the substrate is oxidized under a 
standard condition, the extent of oxidation (an end-point) is measured by chemical or 
biosensory methods. 
2.3.2   DPPH assay 
The measurement is based on the measurement of the scavenging activity of 
antioxidants towards the stable radical 2, 2-diphenyl-1-picryl-hydrazyl (DPPH). 
Antioxidants react with DPPH and are reduced to the DPPH-H; as a result, the 
absorbance decreases from the DPPH radical (purple) to the DPPH-H form (yellow). 
The level of discoloration indicates the scavenging potential of the antioxidant 
compounds (IH) in term of its hydrogen-donating ability. The discoloration of DPPH 
dissolved in methanol or ethanol is followed by monitoring the absorbance at 518 nm 
(Choi et al., 2002).  
                DPPH
- 
+ IH                                     DPPH – H + I- 
 
            DPPH assay is a rapid, simple, inexpensive and reproducible assay that 
employed a stable radical to evaluate the scavenging ability of the natural product to act 
as free radical scavengers or hydrogen donars.   
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2.3.3   ORAC assay   
ORAC stands for Oxygen Radical Absorbance Capacity method. The assay 
measures the oxidative degradation of the fluorescent molecule (either beta-
phycoerythrin or fluorescein) after being mixed with free radical generators such as azo-
initiator compounds. Azo-initiators are considered to produce the peroxyl radical by 
heating, which damages the fluorescent molecule and results in the loss of fluorescence. 
The fluorescent intensity decreases as the oxidative degeneration proceeds, and this 
intensity is typically recorded for 35 minutes after the addition of the azo-initiator (free 
radical generator). Antioxidants protect the fluorescent molecule from the oxidative 
degeneration. Curves of fluorescence intensity vs time are recorded, and the area under 
the curves, with and without the addition of an antioxidant, is calculated and compared 
to a standard curve generated using the antioxidant standard (Trolox) (Choi et al., 
2002).   
2.3.4   FRAP assay 
FRAP stands for Ferric Reducing/Antioxidant Power method. This method 
measures the ability of antioxidants to reduce ferric iron. It is based on the reduction of 
the complex of ferric iron and 2,3,5-triphenyl-1,3,4- triaza-2-azoniacyclopenta-1,4-
diene chloride (TPTZ) to the ferrous form at low pH. The reaction is non-specific, in 
that any half reaction that has lower redox potential than that of the ferric ferrous half 
reaction-under reaction conditions- will drive the ferrous (Fe III to Fe II) ion formation. 
This reduction is monitored by measuring the change in absorption at 593 nm. The 
change in absorbance is therefore directly related to the combined or “total” reducing 
power of the electron-donating antioxidants present in the reaction mixture (Benzie and 
Strain, 1996).     
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2.4 In vitro studies on cell lines 
Cells are considered to be the basic 'building blocks' of living organisms. There 
is a great need for physiologically-relevant human or animal cell-based studies that can 
provide important biomedical and toxicity data. With the current growth in new 
technologies, knowledge, and methods for complex data analysis, it now appears 
feasible that they will be able to be reassembled into models that can better predict 
human cells with their capabilities of generation and degeneration. Some of the recent 
developments and trends in cell-based assays that are relevant to the future of toxicity 
testing are important (Swedlow and Platani., 2002). Cell-based bio-assays can play an 
important role in the evaluation of natural products and other medicinal plants as an 
initial tool for screening, or as follow-up to animal or human studies in diabetes, 
inflammation and cancer research.    
2.4.1 Pancreatic β-cells  
In diabetes research, insulin-secreting cell lines have been developed in an 
attempt to establish and retain the characteristic features of β-cells. These cell lines are 
transformed using different techniques such as irradiation, viral transformation, and 
transgenic technology. They can therefore be different from primary β-cells in terms of 
their behaviour and responsiveness to insulin secretagogues. The most widely used β-
cells lines are β-TC6, RINm5F, HIT-T15, MIN6, INS-1, and BRIN-BD11 cells (Poitout 
et al., 1995).   
One such β-TC6 (insulinoma cell line derived from transgenic mice) is 
developed with higher hexokinase activity, resulting in an insulin secretory response to 
subphysiological glucose levels (Leira et al., 2002; Poitout et al., 1995). The advantage 
of this β-TC6 cell lines is that it can be used in the rapid analysis of cellular viability & 
20 
 
proliferation, insulin secretion, as well as glucose uptake with glucose transporter 
protein expression (Yamada et al., 2007; Zou et al., 2005).   
2.4.2 Murine macrophage cells   
Murine macrophage RAW 264.7 cells are widely used to determine the 
inflammatory pattern of the cytokines and chemokines. In this cell line, cytokine levels 
are triggered by using a certain stimulating agent to induce inflammatory response (Huo 
et al., 2012). Such an activator of macrophage is a Lipopolysaccharide (LPS), a cell 
wall component of gram-negative bacteria, which initiates Toll-like receptor 4 (TLR4)- 
associated innate immune response by triggering serial signal transduction events which 
lead to the activation of NF-κB and mitogen-activated protein kinases (MAPKs) 
(Dziarski et al., 2000; Van Snick, 1990). The activation of these proteins leads to the 
production of various inflammatory cytokines TNF-α, IL-1β, IL-6 and NO (Zhang and 
Dong, 2005; Medzhitov and Janeway, 1997). Thus, these cytokines are recognized as 
excellent biomarkers for inflammation in order to study inflammatory response within 
the living system (Huang et al., 2012; Yang et al., 2011).    
2.4.3 Cancer cells  
For decades, human immortal cancer cell lines have constituted an accessible, 
easily usable set of biological models with which to investigate cancer biology and 
explore the potential efficacy of anticancer agents. In cancer research, a wide range of 
human cancer and normal cell lines are utilized to study the efficacy of several natural 
products. Cancer cells are characterized by an uncontrolled, uncoordinated and 
undesirable cell division. Unlike normal cells, cancer cells continue to grow and divide 
for their whole lives, replicating into more and more harmful cells.  
Cancer cell lines allow scientists to conduct studies under reasonable conditions 
in the lab to study the communication between a tumor cell and a host cell. In our study, 
21 
 
we have selected lung cancer (A549), prostate cancer (PC-3), breast cancer (MCF-7), 
and normal hepatic (WRL-68) cell lines to evaluate the potential of our 
extracts/fractions in malignant neoplasm, which is a broad group of various diseases, all 
involving unregulated cell growth and can be studied for cell proliferation and 
apoptosis.   
2.4.4 Role of NF-κB in research 
NF-κB is a transcription factor involved in the gene encoding and regulation 
which may constitute immune and inflammatory responses by activating cell survival, 
signalling, proliferation, angiogenesis, and invasion, which are key features of the 
malignant phenotype (Baldwin, 1996; Haefner, 2002). NF-κB is believed to play an 
important role in the regulation of insulin signalling pathway and inflammatory 
response associated with cancer therapy in copious inflammatory and cancer-related 
ailments and has developed as a foremost target in drug discovery (Collins et al., 1995; 
Das and White, 1997).   
 
2.5 In vivo studies on animal models  
 Studies using biological systems help us to understand the detailed mechanism 
of the targeted candidate for further drug development. Preclinical studies on animal 
model play an important role in discovering the efficacy and safety of the candidate. In 
preliminary screening, normal animals are sensitive enough to be used in determining 
the effectiveness and safety of natural products (Hoa et al., 2009). Target animal models 
are developed in normal animals with stimulating agent or substances for detailed 
studies.   
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2.5.1 Type 1 diabetes in animals  
In diabetes research, diabetic rat models are mostly utilized to determine the 
potential of natural products for the management of diabetes. Chemically-induced 
diabetes in animals is considered as a conventional model of type 1 or insulin dependent 
diabetes mellitus (IDDM) because the chemical selectively destructs β-cells of the 
pancreas, leading to a decrease in insulin synthesis (Ahmed, 2006; Kundusen et al., 
2011). However, the incomplete loss of β-cells mass and persistent hyperglycemia can 
also result in insulin resistance which is a characteristic feature of non-insulin-
dependent diabetes mellitus (NIDDM) (Shima et al., 1998).  
Streptozotocin (STZ) is the cytotoxic substance used conventionally to produce 
diabetes and hyperglycemia in experimental animals by selectively destroying β-cells 
(Masiello et al., 1998). STZ is a 1-methyl-l-nitrosourea attached to the carbon- 2 
position of glucose that causes β-cell necrosis and induces ‘‘experimental diabetes’’ in 
animals (Thulesen et al., 1997). The glucose moiety of STZ allows preferential uptake 
of STZ into β-cells, probably via the glucose transporter-2 (GLUT-2) and causes 
alkylation of DNA (Jin et al., 2009). Because STZ is an alkylating agent, it causes DNA 
strand breaks that induce the activation of poly-ADP-ribose synthetase followed by 
lethal nicotinamide adenine dinucleotide (NAD) depletion (Viraj and Szabo., 2002).   
This NAD depletion is also mediated by cytokine, T-helper cell and 
macrophages. Activated macrophages produce a variety of free radicals, nitric oxide 
(NO) as well as IL-6 and IL-1β, which have been found to activate the inducible form of 
nitric oxide synthase (iNOS), thus causing an increased production of NO within the β-
cell. The potential problem with STZ due to its toxic effects is not restricted to 
pancreatic β-cells, since it may also cause renal injury, oxidative stress, inflammation, 
and endothelial dysfunction (Hyun et al., 2010).  
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2.5.2 Type 2 diabetes in animals    
Type 2 diabetes in animals is established by a suitable dose of nicotinamide 
(NA) prior to STZ administration, which exerts a partial protection against the cytotoxic 
effects of STZ (Masiello et al., 1998; Yang and Wright, 2002). Nicotinamide (vitamin 
B3), a water-soluble vitamin and a poly-ADP-ribose synthetase inhibitor, protects the 
functionality of β-cells by protecting the level of NAD and proinsulin from depleting, 
which improves the energy status in ischemic tissues and exhibits antioxidant effects. 
This leads to metabolic improvements through the inhibition of the apoptosis of β-cell 
mass by partially reversing the inhibition of insulin secretion to prevent the complete 
aggravation of β-cells destruction following the administration of β-cell toxins, STZ 
(Shima et al., 1998).  
This established a new experimental diabetic syndrome in rats that appears 
closer to human type 2 diabetes than other available models (e.g. neonatally STZ-
injected rats, GK rats). This condition contributes a number of features similar to DM2, 
and is exemplified by stable hyperglycemia, glucose intolerance, and significantly 
altered glucose-stimulated insulin secretion (Like and Rossini., 1976).  
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Figure 2.1: Hypothetical diagram displaying STZ-induced diabetic complications.  
When normal animals are induced by STZ, they develop hyperglycemia and associated 
complications such as hyperlipidemia, oxidative stress and inflammatory response. 
These elevated responses may be primary targets for the type 2 diabetes (DM2) research 
(Shi et al., 2011). 
 
This study model through preclinical approach may help us to evaluate whether 
the samples can further pave the way for the development of medication, particularly for 
the management of diabetic conditions and its complications that arise during this 
metabolic syndrome.  
2.5.3 Inflammatory response in animals 
Inflammatory response on targeted cytokines can be achieved by stimulating 
animals with certain doses of LPS (Achoui et al., 2010). The mechanism by which LPS 
induces these events is only partly understood. At physiological concentrations, LPS 
binds to the serum protein LPS-binding protein (LBP). This complex then interacts with 
glycosylphosphatidylinositol-linked protein (CD14) on macrophages or neutrophils 
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(Palsson-McDermott and O’Neill, 2004). CD14 lacks an intracellular domain, and when 
LPS-LBP complex binds to CD14, it results in rapid phosphorylation of various proteins 
on tyrosyl residues, which in turn provokes proinflammatory cytokines (Remick et al., 
2000). During this process, inflammatory cytokine TNF-α is commonly released by 
macrophages and plays a central role in initiating and sustaining the inflammatory 
response; this can cause severe tissue damage, septic shock, atherosclerosis and 
systemic inflammatory response syndrome (Chiang et al., 2012; Hseu et al., 2005; 
Garlanda et al., 2007). 
This LPS-induced inflammatory response of cytokines would help us to 
determine the effectiveness of the samples against different cytokines which were 
activated.  
 
2.6 Plants Selection  
The rationale behind the selection of the following plant species are their 
traditional use by the villagers and traditional healers. Plants selected were 
Centratherum anthelminticum L., Parthenium hysterophorus L., Xanthium strumarium 
L., and Vicoa indica Cass, which are all from the Asteraceae family, together with five 
others from different families: Woodfordia fruticosa Kurz (Lythraceae), Sida acuta 
Burm F. (Malvaceae), Vanda tessellata Roxb (Orchidaceae), Madhuca indica 
(Sapotaceae) and Cissus quadrangularis (Vitaceae).  Three others are from the same 
family (Combretaceae) and the same genus Terminalia such as T. arjuna, T. bellerica, 
and T. chebula.   
Out of all these plants, Centratherum anthelminticum seeds were discovered to 
be the most prominent in terms of their hypoglycemic and antioxidant activities. 
Therefore, Centratherum anthelminticum seeds were further selected in our study for 
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the purpose of detailed pharmacological evaluations on diabetes, inflammatory response 
and cancer. 
2.7 Centratherum anthelminticum (L.) Kuntze  
Centratherum anthelminticum (L) Kuntze (Family: Asteraceae) (Synonyms: 
Vernonia anthelmintica) is an erect, pubescent annual herb found widely in the Indian 
sub-continent. The stem grows to a height of 90 cm. The leaves are elliptical, nearly 9 
cm long and 3.5 cm wide with an acute apex and tapering base. The margins are 
coarsely serrated and both sides of the leaves are pubescent. The flowers are purple or 
violet, homogenous, solitary, axillary or terminal heads with a linear bract at the top of 
the peduncle. Each flower head consists of 30-40 minute branches. The fruits are small, 
cylindrical and hairy with 10 narrow ridges. The seeds of the plant have a sharp, bitter 
taste and possess wide therapeutic applications (Rastogi and Mehrotra, 1995).  
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 Figure 2.2: Picture of Centratherum anthelminticum (L.) Kuntze  
                   (A) whole plant, (B) flowering twigs (C) dried seeds. 
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2.7.1 Chemical Constituents  
 
Table 2.1: Chemical constituents from Centratherum anthelminticum seeds reported in 
literature 
 
Compounds References 
Glycosides, carbohydrates, phenolic compounds, tannins, 
flavonoids, proteins, saponins, sterols, lipids and fats 
Bhatia et al., 2008 
Flavonoids : 
2’,3,4,4’-tetrahydroxychalcone ( butein), 
5,6,7,4’-tetrahydroxyflavone (scutellarein) and 7,3’,4’-
trihydroxydihydroflavone (butin). 
Tian et al., 2004 
Sterols: 
4 alpha-methylvernosterol, 
vernosterol, avernosterol . 
Akihisa et al., 1992 
glycosylated triterpene, saponin: hederagenin and six sugar 
residues forming two glycosyl chains. 
Mehta et al., 2004 
Steroids : 
(24alpha/R)-stigmasta-7-en-3-one, 24 (alpha/R)-stigmasta-7, 
9(11)-dien-3-one, 24(alpha/S)-stigmasta-5, 22-dien-3ß-ol and 
stigmasta-7, 22-dien-3ß-ol 
Mehta et al., 2005 
Saponins:  
3-O-[beta-D-glucopyranosyl-(1-->2)-alpha-L-rhamnopyranosyl-(1 
--> 2)-alpha-L-arabinopyranosyl]-28-O-[beta-D-xylopyranosyl-(1-
->4)-alpha-L-rhamnopyranosyl-(1-->3)-beta-D-glucopyranosyl]-
23-hydroxyolean-12-en-28-oic acid and 3-O-[beta-D-
glucopyranosyl-(1 --> 2)-alpha-L-rhamnopyranosyl-(1 -->2)-
alpha-L-arabinopyranosyl]-28-O-[beta-D-glucoyranosyl-(1-->3)-
beta-D glucopyranosyl]-23-hydroxyolean-12-en-28-oic acid 
Mehta et al., 2010 
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2.7.2 Pharmacological activities  
 Centratherum anthelminticum seeds are used in Ayurvedic preparations due to 
their febrifugal, anthelmintic, antiphlegmatic, and diuretics as well as their digestive 
stimulant properties (Kirtikar and Basu, 1987).   
Singh et al (1985) demonstrated in vitro anthelmintic activity on the alcoholic 
extract of Centratherum anthelminticum seeds against Fasciolopsis buski, Ascaris 
lumbricoides and Hymenolepis nana worms. Next, Sharma and Mehta (1991) 
determined in vitro antimicrobial effects of Centratherum anthelminticum seeds. 
Further, Singhal et al (1992) reported antifilarial activities on Setaria cervi in the 
aqueous and alcoholic extract of Centratherum anthelminticum seeds. 
 Iqbal et al (2006) demonstrated in vivo anthelmintic activity of Centratherum 
anthelminticum seeds in sheep naturally infected with gastrointestinal nematodes. 
Furthermore, Nisha et al (2007) showed in vitro macrofilaricidal activity of 
Centratherum anthelminticum seeds against adult Setaria digitata, the cattle filarial 
worm.  
 Koti and Purnima (2008) reported a potent diuretic and electrolyte excretion 
activities in the chloroform and alcohol extracts of C. anthelminticum seeds. Srivastava 
et al (2008) observed that the petroleum ether extract of Centratherum anthelminticum 
fruits exhibited significant larvicidal activity against the vector of malaria, Anopheles 
stephensi.  
 Purnima et al (2009) established in vivo analgesic and antipyretic effects in the 
petroleum ether and alcohol extracts of Centratherum anthelminticum seeds. The same 
co-workers in the year 2010 reported antiinflammatory activity in the in vivo models of 
acute and subacute inflammation. The results showed that these extracts exert 
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antiinflammatory activity through prostaglandin inhibition by reducing 
myeloperoxidase transduction.  
 Ani and Naidu (2011) determined the antioxidant potential of Centratherum 
anthelminticum seeds in certain in vitro models. Moreover, Faheem and Koay (2011) 
reviewed the studies on the chemical constituents and pharmacology of Centratherum 
anthelminticum. Recently, Himanshu et al (2012) demonstrated wound healing 
properties in the in vivo experiment on the aquous methanolic extract of Centratherum 
anthelminticum seeds.  
2.7.3 Antidiabetic activity  
 Ani and Naidu (2008) showed antidiabetic effects of the phenolic compounds 
fractionated from Centratherum anthelminticum seeds on the rat intestinal α-
glucosidases, human salivary α-amylase and postprandial hyperglycemia in rats. The 
results showed that the polyphenolic components significantly inhibited postprandial 
hyperglycemia in rats by altering α-amylase and α-glucosidase activity.    
 Next, Bhatia et al (2008) established antidiabetic activities on the aqueous 
extract of Centratherum anthelminticum seeds in alloxan-induced diabetic rats. The 
results displayed that dose-dependent administration of the extract reduced plasma 
glucose and the results were comparable with the oral hypoglycemic drug 
glibenclamide.  
 Shah et al (2008) showed antihyperglycemic, antihyperlipidemic and antioxidant 
potential of Centratherum anthelminticum seeds on STZ-induced diabetic rats in a short 
term study model. Next, Fatima et al (2010) demonstrated antidiabetic and 
antihyperlipidemic activities of ethyl-acetate:isopropanol (1:1) fraction of Vernonia 
anthelmintica seeds in STZ-induced diabetic rats, without any toxicity in normal rats. 
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2.7.4 Antiinflammatory activity  
 To date, there are no scientific reports on the antiinflammatory responses of the 
extract/fractions of the Centratherum anthelminticum seeds on the targeted cytokines in 
the cell-based in vitro and in vivo study models.    
2.7.5 Anticancer activity  
 Thus far, Centratherum anthelminticum has not been evaluated for its anticancer 
effects and hence, there are no reports on its activities on any type of cancer cells.   
2.7.6 Knowledge (study) gap  
 To date, there are no reports of mechanistic studies on the antidiabetic effects of 
Centratherum anthelminticum seeds on the pancreatic β-cells for cellular viability, 
glucose uptake, insulin secretion, glucose transporter protein expression as well as on 
the NF-κB translocation effects in ROS-induced oxidative stress. Moreover, there are no 
indications on the in vivo type 1 and type 2 diabetic rat models to elucidate the role of 
this plant seeds in diabetic conditions. In addition, there are no studies on type 2 
diabetic animals to determine the protective and toxic effects of the selected 
extract/fraction when administered for a long term period of 12-weeks on the DM2 
complications such as oxidative stress, dyslipidemia and elevated pro-inflammatory 
cytokines.  
 Other pleotropic biological activities on inflammation and cancer are yet to be 
investigated on this plant seeds, which include activities such as inflammatory 
responses of cytokine TNF-α in the in vitro and in vivo study models as well as on 
certain targeted cancer cell lines such as A549, PC-3, MCF-7, and WRL-68 cells, 
alongwith mechanistic studies on the targeted cancer cells.  
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3.2 An overview of the research approach employed in this study 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: An overview of the research approach employed in this study. For detailed  
                  methodology, see published papers in the section 3.3 
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Abstract: The traditional use of certain plants by the tribal community in 
central India involves using the young leaves for several ailments, including 
hyperglycaemia; this study was performed to evaluate the effects of the leaf 
extracts from 9 such plants in the management of diabetes. Initially, 
hypoglycemic screening was performed on normal rats whose blood glucose 
levels were measured before and after oral or intraperitoneal (i.p.) 
administration of the extracts at different periods. The plants were screened at 
doses of 250 mg/kg i.p. or 500 mg/kg orally. Of these, only Centratherum 
anthelminticum (Asteraceae), Cissus quadrangularis (Vitaceae), and 
Woodfordia fruticosa Kurz (Lythraceae) significantly reduced postprandial 
blood glucose levels in normal glycemic rats (P <0.001), with slight 
reductions effected by Sida acuta Burm F. (P = 0.002) and Parthenium 
hysterophorus L. (P = 0.017). The extracts that reduced postprandial blood 
glucose levels both orally and i.p. in the hypoglycemic screening tests were 
evaluated for glucose challenge in glucose tolerance tests with i.p and oral 
administration in overnight-fasted normal rats. The results of these tests 
potentiate the screening data in the management of diabetes mellitus, which 
requires further studies on the plants that yielded positive results to determine 
the active compounds in the different plant parts that are responsible for the 
activity. 
 
Keywords: Hypoglycemic activity, Traditional medicine, Herbals, Glucose tolerance 
test,Centratherum anthelminticum, Cissus quadrangularis, Woodfordia fruticosa. 
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Introduction 
Diabetes mellitus (DM) has attained pestilencein the current century. It is the most prevalent 
disease in the world affecting 7% of population, or 285 million people worldwide. It is 
predicted that this number will exceed to 435 million in 2030.
1
 Approximately, 90-95% of 
patients with diabetes have type 2 diabetes (T2D) or non-insulin dependent diabetes 
mellitus. T2D is accounting for a combination of insulin resistance and an adequate 
compensatory insulin secretory response.
2 
Oral hypoglycaemics such as biguanides, 
sulfonylureas, and thiazolidinediones are available for the treatment of type 2 diabetes, but 
can also cause adverse effects and be ineffective against some long-term diabetic 
complications. The World Health Organization recommends the use of traditional and plant 
based medicines for the management of diabetes mellitus.
3
 Herbal medicine is an alternative 
method for the treatment of diabetes due to their perceived effectiveness, safety, 
affordability, and acceptability, with minimal side effects in clinical experience, and 
relatively low cost.
4 
 
     More than 1200 plants are used in traditional medicine for their alleged hypoglycemic 
activity. Numerous studies have reported the anti-diabetic activity of plants.
5
 In the present 
study, the rationale for selecting the 9 plants studied was their traditional use by tribal 
people for conditions involving frequent urination and elevated blood glucose levels with 
symptoms such as weakness, mouth dryness, and conditions associated and arising from 
diabetes. The tribes are from villages in the Betul and Hoshangabad districts, which are 
surrounded by the Satpuda forest ranges, and located in the state of Madhya Pradesh, India. 
In these districts, villagers consume decoctions from the young leaves of these plants early 
in the morning for the treatment of diabetes as well as for other ailments. The treatment is 
particularly common and popular in tribes of the Gond community, where the plants are 
cultivated or found in abundance around their farms or in the jungles. The plants tested were 
Centratherum anthelminticum, Parthenium hysterophorus L., Xanthium strumarium L., and 
Vicoa indica Cass, which areall from the Asteraceae family, together with five others from 
different families: Woodfordia fruticosa Kurz (Lythraceae), Sida acuta Burm F. 
(Malvaceae), Vanda tessellata (Roxb.) (Orchidaceae), Madhuca indica (Sapotaceae), and 
Cissus quadrangularis (Vitaceae). There are several reports on the antidiabetic effects of 
different parts of C. anthelminticum, Parthenium hysterophorus L., Cissus quadrangularis, 
and Woodfordia fruticosa Kurz.
6-11
The purpose of this study was to investigate and evaluate 
the potential of these plants leaves in suppressing elevated blood glucose levels in 
normoglycaemic and glucose-induced hyperglycaemic rats through the intraperitoneal (i.p.) 
and oral routes of administration. 
Materials and Methods 
Plant Materials and Preparation of Plant Extracts 
Fresh leaves from the nine plants were collected from Amritum Bio-Botanica Herbs 
Research Laboratory Pvt. Ltd., in Jogli, Madhya Pradesh, India, authenticated by the 
company’s quality control department, dried in maintained shade in a greenhouse for few 
days, ground into coarse powder, and then brought to the Department of Pharmacology in 
the Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, for further study. 
The dried, powdered samples were extracted with water: ethanol (80:20)using a soxhlet 
extractor, subsequently the obtained crude extracts were successively defatted with hexane 
and chloroform, before being extracted with methanol. The resulting methanol extracts were 
dried (evaporated) using a rotary evaporator (Rotavapor, Buchi) under reduced pressure at 
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40°C to yield a final methanolic extract, which was further stored at -20°C prior to use. 
Before administration to the rats, each extract was diluted with water and filtered. 
Preliminary Phytochemical Screening 
A phytochemical screening test for alkaloids, flavonoids, saponins, phenols, tannins, and 
terpenoids using standard procedures was performed on the defatted leaf methanolic extracts 
to identify their chemical constituents.
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Animals and Treatment 
Altogether, 400 Sprague-Dawley rats weighing (150–200 g) were procured from the Animal 
Care Unit, UMMC (University Malaya Medical Centre), Kuala Lumpur, Malaysia, and were 
acclimatized to laboratory conditions for 1 week. Rats were housed in polypropylene cages 
(6–7 rats/cage) under an ambient temperature of 23 ± 3°C and 40–65% relative humidity 
with 12 h light and dark cycles. They were maintained on a standard pellet diet and water ad 
libitum. Guidelines of the Guide for the Care and Use of Laboratory Animals were strictly 
followed throughout the study. The experimental protocol was approved by the UMMC 
Animal Ethics Committee (No: FAR/10/11/2008/AA(R)). 
       Acclimatized animals were divided into 2 sections, one for acute toxicity study, other 
section for hypoglycemic screening. Male animals were chosen for hypoglycemic screening 
test and allocated a carbohydrate-rich diet for 2 weeks before the experiments were started. 
Animals with postprandial blood glucose levels of 8–10 mmol/L were used for the screening 
test. Animals with either sex were selected for acute toxicity studies. 
Acute Oral and Intraperitoneal Toxicity Studies 
The oral and intraperitoneal acute toxicity tests of the extracts were determined in 
accordance with OECD (Organization for Economic Co-operation and Development) 
guidelines. The animals were starved overnight and divided into 36 groups (n = 6) and were 
injected intraperitoneally with extracts doses ranging 25–2500 mg/kg body weight and were 
fed with doses ranging 50–5000 mg/kg body weight. The rats were observed continuously 
for 2 h to assess their behavioural, neurological, and autonomic profiles and after 24 and 72 
h to identify lethality.  
Determination of Postprandial Blood Glucose Levels in Normoglycaemic Rats 
Screening for hypoglycemic activity of the extracts was carried out by i.p and oral 
(250mg/kg and 500mg/kg) administration based on volume (2 ml/200 g body weight). 
Normal control animals received NaCl 0.9% while positive control animals were 
administered with insulin (0.5 U/kg) i.p. or glibenclamide (50 mg/kg) given orally.  
Blood samples were collected from the tail by snipping, and blood glucose 
concentrations were determined in non-fasting conditions at different times after the above 
treatments by a glucose oxidase-peroxidase enzymatic method using a standardized 
glucometer (Accu-Check Performa, Roche Diagnostic Germany). An extract was deemed to 
have a hypoglycemic effect if the blood glucose levels of the test groups decreased 
significantly compared to that of the normal control group.    
Glucose Challenge (Glucose Tolerance Test) 
Intraperitoneal Glucose Tolerance Test (IPGTT) and Oral Glucose Tolerance Test (OGTT) 
were used to evaluate the effectiveness of the leaf extracts that had demonstrated 
hypoglycemic potential in the screening tests. Extracts (250 mg/kg or 500 mg/kg) were 
administered to overnight-fasted rats in doses of 2.0 ml/200 g (the control group was given 
NaCl 0.9%). Blood glucose concentrations were measured before and at 120 and 210 min, 
after i.p and oral extracts administration respectively. After this time point, oral glucose (3 
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g/kg) was administered and blood glucose levels were measured at 30, 60, and 120 min in 
the IPGTT and at 60, 120, and 180 min in the OGTT. 
Statistical Analysis 
The results were calculated as mean ± SEM and comparison of the data was carried out by 
1-way and 2-way repeated measures ANOVA tests where appropriate (one factor repeated), 
with all pair-wise multiple comparison procedures (Student–Newman–Keuls method). 
Significance was considered to be P<0.001. 
 
Results and Discussion 
Plants Extract Phytochemical Constituents 
Preliminary phytochemical analysis of methanolic extracts from the leaves of nine plants 
revealed the presence of flavonoids in all, except Sida acuta Burm F. and Vanda tessellata 
(Table 1). Similarly, phenolic and saponin compounds were present in all the leaves, while 
tannins were only absent in the Sida acuta Burm F. and Vicoa indica extracts.  All the 
extracts, except that from Madhuca indicatested positive for alkaloids. Amongst the leaves, 
terpenoids were not seen in Vanda tessellata (Roxb.), Parthenium hysterophorus L., and 
Sida acuta Burm F. extracts. 
 
Table 1. Phytochemical constituents of methanolic leaf extracts.  
Plants Parts Used 
Compounds 
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Centratherum anthelminticum Leaves + ++ ++ + ++ + 
Cissus quadrangularis Leaves + + + + + ++ 
Woodfordia fruticosa Kurz Leaves + + + + + + 
Madhuca indica Leaves NA + + + + + 
Vicoa indica Cass Leaves + + + + NA + 
Vanda tessellata (Roxb.) Leaves + NA + + + NA 
Parthenium hysterophorus L. Leaves + + + + + NA 
Sida acuta Burm F. Leaves + NA + + NA NA 
Xanthium strumarium L. Leaves + + + + + + 
 
Acute Oral and Intraperitoneal Toxicity Studies 
The acute oral and intraperitoneal toxicity studies demonstrated that the methanolic extracts 
from all of the selected plants leaf, other than Parthenium hysterophorus L., were non-toxic 
up to a dose of 2500mg/kg. For Parthenium hysterophorus L. the LD50 obtained via i.p 
administration was  2500 mg/kg. Based on this finding, doses with 250mg/kg and 500mg/kg 
were chosen as the maximum dose for further experiments involving administration by the 
i.p and oral routes respectively. 
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Hypoglycemic Activity of Plants Leaf Extracts by i.p. and Oral Routes 
The results of the hypoglycemic activity of the leaf extracts on normal glycemic 
rats administered through the i.p. and oral routes are shown in Tables2 and 
3. Accordingly, after i.p. and oral administration of NaCl 0.9% to normal control rats, the 
blood glucose levels did not change within the different time intervals. Administration of i.p. 
insulin (0.5 U/kg) significantly reduced blood glucose levels for 1–2 hours, then increased it 
again. A similar finding was observed following oral administration of glibenclamide (50 
mg/kg), but the level of blood glucose returned back only after 6 h (P<0.001) for all when 
compared to time 0 and normal control group at the same times. Out of the nine plants, three 
(C. anthelminticum, Cissus quadrangularis, and Woodfordia fruticosa Kurz) significantly 
altered blood glucose levels (P<0.001), while four (Madhuca indica., Vicoa indica Cass, 
Vanda tessellata (Roxb.), and Xanthium strumarium L.) did not.  
 
        Intraperitoneal administration of C. anthelminticum, Cissus quadrangularis, and 
Woodfordia fruticosa Kurzextracts at 250 mg/kg dose produced various outcomes, the blood 
glucose levels of rats decreased from 9.3 ± 0.11, 8.8 ± 0.19, and 9.1 ± 0.20 mmol/L, 
respectively to 4.9 ± 0.13, 5.6 ± 0.15, and 5.2 ± 0.18 mmol/L after the first hour. This 
reduction continued by the second hour to 4.6 ± 0.23, 5.3 ± 0.13, and 5.1 ± 0.16 mmol/L, 
respectively. Finally, unlike C. anthelminticum (4.3 ± 0.15 mmol/L after 3 h), a slight 
increase in blood glucose levels was observed with Cissus quadrangularis and Woodfordia 
fruticosa Kurz extracts after the third hour (5.5 ± 0.19 and 5.3 ± 0.13 mmol/L, respectively). 
A significant difference in blood glucose levels was observed after the first, second, and 
third hours following i.p. administration of C. anthelminticum, Cissus quadrangularis, and 
Woodfordia fruticosa Kurz extracts (P<0.001) when compared to that of the normal control.   
 
 
Table 2. Hypoglycemic activity of leaf extract by i.p. route in normal rats. 
 
Group 
Blood glucose levels(mmol/L)at different time points (h) 
                                     Time (mean ± SEM) 
0h 1h 2h 3h P-value 
Normal control (NaCl0.9%) 8.9 ± 0.09 9.0 ± 0.07 8.8 ± 0.24 8.8 ± 0.03 0.856 
Insulin 0.5 U/kg 8.8 ± 0.14 4.4 ± 0.19* 4.3 ± 0.11* 5.0 ± 0.07* <0.001 
Centratherum anthelminticum 9.3 ± 0.11 4.9 ± 0.13* 4.6 ± 0.23* 4.3 ± 0.15* <0.001 
Cissus quadrangularis 8.8 ± 0.19 5.6 ± 0.15* 5.3 ± 0.13* 5.5 ± 0.19* <0.001 
Woodfordia fruticosa Kurz 9.1 ± 0.20 5.2 ± 0.18* 5.1 ± 0.16* 5.3 ± 0.15* <0.001 
Madhuca indica 8.9 ± 0.12 9.0 ± 0.16 8.7 ± 0.21 9.1 ± 0.13 0.420 
Vicoa indica Cass 9.2 ± 0.10 9.0 ± 0.08 8.8 ± 0.21 9.0 ± 0.20 0.443 
Vanda tessellata (Roxb.) 8.7 ± 0.19 8.5 ± 0.19 8.8 ± 0.17 8.7 ± 0.10 0.765 
Parthenium hysterophorus L. 8.8 ± 0.10 8.9 ± 0.11 8.5 ± 0.14 8.6 ± 0.10 0.072 
Sida acuta Burm F. 8.6 ± 0.13 8.4 ± 0.11 8.2 ± 0.18 8.7 ± 0.74 0.065 
Xanthium strumarium L.  8.8 ± 0.19 9.0 ± 0.27 8.9 ± 0.12 8.8 ± 0.17 0.895 
*Significant compared with time 0 and normal control (P<0.001) group.
 
 
Screening for Hypoglycemic Activity on The Leaf Extracts 1201 
        In the same manner C. anthelminticum, Cissus quadrangularis, and Woodfordia 
fruticosa Kurz extracts demonstrated similar results with 500 mg/kg of oral administration, 
the blood glucose levels of rats decreased from 8.8 ± 0.11, 8.6 ± 0.10, and 9.0 ± 0.16 
mmol/L, respectively, to 4.6 ± 0.11, 4.9 ± 0.07, and 4.8 ± 0.10 mmol/L after the second 
hour. This reduction continued by the fourth hour to 4.5 ± 0.14, 5.1 ± 0.07, and 4.7 ± 0.07 
mmol/L, respectively. Finally, a slight increase was observed at 6 h (4.7 ± 0.17, 5.4 ± 0.16, 
and 5.1 ± 0.07 mmol/L). A significant difference in blood glucose levels was observed after 
the second, fourth, and sixth hours of oral administration with these extracts (P<0.001) when 
compared to that of the normal control group.  
 
      There was also a slight decrease in blood glucose levels by the Sida acuta Burm F. 
(P=0.002) and Parthenium hysterophorus L. (P=0.017) extracts after 2 and 4 h of oral 
administration, respectively. 
 
Table 3. Hypoglycemicactivityofleaf extract by oral route in normal rats. 
 
Group 
Blood glucose levels (mmol/L)at different time points (h) 
                                     Time (mean ± SEM) 
0h 2  h 4 h 6 h P-value 
Normal control (NaCl0.9%) 9.1 ± 0.12 8.9 ± 0.13 9.2 ± 0.17 9.5 ± 0.08 0.059 
Glibenclamide 50mg/kg 9.2 ± 0.13 4.4 ± 0.06* 4.9 ± 0.16* 5.9 ± 0.12* <0.001 
Centratherum anthelminticum 8.8 ± 0.11 4.6 ± 0.11* 4.5 ± 0.14*
 
4.7 ± 0.17* <0.001 
Cissus quadrangularis 8.6 ± 0.10 4.9 ± 0.07* 5.1 ± 0.07* 5.4 ± 0.16* <0.001 
Woodfordia fruticosa Kurz 9.0 ± 0.16 4.8 ± 0.10* 4.7 ± 0.07* 5.1 ± 0.07* <0.001 
Madhuca indica 8.1 ± 0.09 8.3 ± 0.17 8.2 ± 0.17 8.4 ± 0.16 0.497 
Vicoa indica Cass 8.9 ± 0.09 9.2 ± 0.06 8.8 ± 0.21 9.0 ± 0.20 0.354 
Vanda tessellata (Roxb.) 8.7 ± 0.19 8.5 ± 0.19 8.5 ± 0.08 8.9 ± 0.08 0.285 
Parthenium hysterophorus L. 9.5 ± 0.08 9.2 ± 0.09
$
 9.4 ± 0.06
$
 9.5 ± 0.12 0.017 
Sida acuta Burm F. 8.6 ± 0.13 8.0 ± 0.11
$
 8.4 ± 0.14
$
 8.7 ± 0.07 0.002 
Xanthium strumarium L.  9.2 ± 0.13 9.1 ± 0.21 9.4 ± 0.16 9.1 ± 0.13 0.747 
*Significant compared with time 0 and normal control (P<0.001).
 
$
Significant difference between treatment times in each group.
 
 
 
Intraperitoneal and Oral Glucose Tolerance Tests 
Intraperitoneal and oral glucose tolerance tests were used to evaluate the effectiveness of the 
extracts with hypoglycemic potential as identified in the screening tests. When C. 
anthelminticum, Cissus quadrangularis, and Woodfordia fruticosa Kurz extracts were 
administered to overnight-fasted normal rats, no alteration in blood glucose levels was 
observed until 120 and 210 min after i.p. (250 mg/kg) and oral (500 mg/kg) administration, 
respectively. 
 
Thereafter, at 30 min of i.p glucose injection, the level of blood glucose were greatly 
elevated in the (NaCl 0.9%) treated normal control rats (9.4 ± 0.23 mmol/L), followed by 
groups treated with Woodfordia fruticosa Kurz (7.5 ± 0.11 mmol/L),Cissus quadrangularis 
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(7.1 ± 0.13 mmol/L) and C. anthelminticum (6.4 ± 0.21 mmol/L), extracts(Fig. 1). Then at 
60 min, the blood glucose levels had decreased in C. anthelminticum (4.8 ± 0.19 mmol/L), 
Cissus quadrangularis (5.9 ± 0.25 mmol/L), Woodfordia fruticosa Kurz (6.1 ± 0.22 
mmol/L), as well as in the normal control (8.5 ± 0.15 mmol/L) groups. In the same manner 
reduction continued and was higher in the groups administered with all the three extracts 
(3.9 ± 0.22, 5.5 ± 0.19, and 5.1 ± 0.15 mmol/L, respectively) compared to that of normal 
control (6.7 ± 0.10 mmol/L) rat sup until 120 min. A significant difference in blood glucose 
levels was observed between the times for all the 3 extracts (P<0.001) respectively, when 
compared with the normal control (P<0.01) group.  
 
 
 
 
Figure 1. Intra-peritoneal glucose tolerance test on C. anthelminticum, Cissus 
quadrangularis, and Woodfordia fruticosa Kurz extracts in normal fasted rats with glucose-
induced hyperglycemia. Data are mean ± SE. n = 6 for each group. (P<0.001) for the three 
extracts when compared with normal control (P<0.01) group. 
 
 
In line with IPGTT, similar outcomes were obtained with Oral Glucose Tolerance 
Test. At 60 min, after glucose load the concentration of blood glucose were remarkably 
elevated to (11.3 ± 0.23 mmol/L) in the normal control group, followed by the groups 
treated with Cissus quadrangularis (9.0 ± 0.13 mmol/L), Woodfordia fruticosa Kurz (8.3 ± 
0.13 mmol/L) and C. anthelminticum (7.5 ± 0.23 mmol/L) extracts (Fig. 2).Thereafter, at 
120 min, the elevated blood glucose levels had significantly decreased in the groups 
administered with C. anthelminticum (4.3 ± 0.09 mmol/L), Woodfordia fruticosa Kurz (6.2 ± 
0.12 mmol/L), and Cissus quadrangularis (7.2 ± 0.15 mmol/L) extracts, compared to that of 
the normal control (10.5 ± 0.15 mmol/L) group. In the same manner, the reduction of blood 
glucose levels was sustained for all the 3 extract groups (4.1 ± 0.12, 5.2 ± 0.10 and 6.5 ± 
0.19 mmol/L, respectively) as well as for the control (7.8 ± 0.22 mmol/L) group by 180 min. 
A significant difference in blood glucose levels was observed between the times for all the 3 
extracts (P<0.001) respectively, when compared with the normal control (P<0.01) group. 
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Figure 2. Oral glucose tolerance test on C. anthelminticum, Cissus quadrangularis, and 
Woodfordia fruticosa Kurz extracts in normal fasted rats with glucose-induced 
hyperglycemia. Data are mean ± SE. n = 6 for each group. (P<0.001) for the three extracts 
when compared with normal control (P<0.01) group. 
 
 
The current study is a preliminary evaluation of the leaves from certain medicinal 
plants in the management of diabetes. The hypoglycemic activity of leaf extracts from 9 
plants were screened and evaluated in normal rats. Of these nine plant extracts monitored, 5 
(C. anthelminticum, Cissus quadrangularis, Woodfordia fruticosa Kurz, Sida acuta Burm 
F., and Parthenium hysterophorus L.) showed direct effects in reducing postprandial 
hyperglycaemia in normoglycaemic rats, while four (Vicoa indica, Vanda tessellata (Roxb.), 
Madhuca indica, and Xanthium strumarium) did not, or else might have an indirect effect. 
Overall, C. anthelminticum, Cissus quadrangularis, and Woodfordia fruticosa Kurzleaves 
demonstrated the highest hypoglycemic activity. This finding was further verified by the 
glucose tolerance tests in normal fasted rats.  
Firstly, our findings on C. anthelminticum leaf extracts supports previous data in 
which seed fraction exhibited anti-diabetic and anti-hyperlipidemic activity in diabetic rats 
without any toxicity.
6
The polyphenolic components from its seeds also exerted anti-
hyperglycemic activity in maltose-loaded normal rats.
7
Apart from this, the plant is used 
extensively in Ayurveda for the treatment of various disorders. Experimental studies have 
also reported different pharmacological effects of the seed extracts.
13-14
In the same manner, 
extracts from different parts of Cissus quadrangularis and Woodfordia fruticosa Kurz also 
supports earlier findings
9-11 
as well as with other biological activities.
15-20
Although acute 
toxicity studies point out the toxic nature of Parthenium hysterophorus L., it possess slight 
hypoglycemic effects. Thus, Parthenium hysterophorus L should not be used in man until its 
toxicity has been more thoroughly determined. However, Sida acuta Burm F. also reported 
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minor hypoglycemic effects, thus did not support any previous reports, despite of other 
pharmacological responses.
21-22
 
The different parts of C. anthelminticum, Cissus quadrangularis, and Woodfordia fruticosa 
Kurz plants are known to be a rich source of polyphenolic compounds,
7, 9, 23
therefore, our 
study plausibly propose that involvement of different active compounds in the extracts, 
including phenols might play an important role in the reduction of elevated blood glucose 
levels.
24
The availability of different medicinal plant parts in an appropriate time, the 
duration of these parts’ lifespan, and the presence of the maximum amount of active 
compounds at that time are important issues in the pharmaceutical industry. Leaves remain 
available for a longer period on the plants compared to other plant parts, which is the reason 
we used leaves in our study. However, comparison of the distribution of the effective active 
compound levels between the different parts of these plants requires further study.   
The aim in the management of diabetes mellitus is to attain blood glucose levels that are as 
close to normal as possible.
25
 In addition, controlling postprandial hyperglycemia could also 
prevent the development of macro and microvascular complications associated with 
diabetes.
26
 
Earlier studies on different plants, suggested that the administration of Mucuna 
pruriens,
27
Cynara cardunculus,
28
 Helicteres ixora,
29
and Tournefortia hartwegiana
30
extracts 
facilitate diabetic patients in controlling of postprandial hyperglycemia, thus enhanced 
glucose tolerance activity in the patients.In line with this, our findings postulated that 
utilizing C. anthelminticum, Cissus quadrangularis, and Woodfordia fruticosa Kurz leaf 
extracts as dietary or food supplements may be advantageous for diabetic patients in the 
control of postprandial hyperglycemia. 
There were some limitations in this study, and the main explanation for our results 
may varies in different solvents used during extraction due to the presence of active 
compounds, or the methods used to determine the hypoglycemic effect. Firstly, we focused 
on the leaves to test for hypoglycemic activity rather than other parts of the plants. Secondly, 
testing of the extracts was not done in a dose-dependent manner. 
Conclusion 
The current study on 9 plants, displayed that the leaf extracts of C. anthelminticum, Cissus 
quadrangularis, and Woodfordia fruticosa Kurz exhibited the highest hypoglycemic activity 
in normal glycemic rats. Therefore, further study to assess anti-diabetic activity from 
different parts of these plants is suggested in a dose-dependent manner along with new 
approaches. 
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Abstract: This study aimed to ascertain the antioxidant and hypoglycemic 
activity of methanolic extracts of the leaves of Terminalia arjuna, T. bellerica, 
and T. chebula. Extracts were evaluated for total phenolic, flavonoid, and 
tannin content, and in vitro antioxidant potential with DPPH, ORAC, and 
FRAP assays. The extracts' hypoglycemic activities were evaluated by 
hypoglycemic screening and an oral glucose tolerance test (OGTT) in normal 
rats. The methanolic extracts of T. chebula leaves exhibited the highest 
quantity of total phenolic and flavonoid content, followed by those of T. 
bellerica and T. arjuna. T. arjuna contained more tannin than T. bellerica did, 
but less than that of T. chebula. The scavenging capacity of T. chebula for the 
antioxidant DPPH was the highest of the extracts tested, as it recorded the 
lowest IC50 value of all 3 extracts. Likewise, the results attributed the T. 
chebula extract with the highest oxygen radical absorption capacity (ORAC). 
In the FRAP assay, the extracts’ ferric reducing antioxidant abilities were T. 
arjuna > T. chebula > T. bellerica. This correlates the potential of 
polyphenolic content enriched with antioxidant capabilities and substantiates 
the results of the hypoglycemic screening and OGTT, which determined that 
the T. chebula extract had a better hypoglycemic effect in normal and glucose-
induced hyperglycemic rats (p <0.001) than that of T. bellerica and T. arjuna, 
respectively. The use of these Terminalia species as food supplements may 
help in reducing oxidative stress and related diabetic complications. The 
phytoconstituents responsible for the hypoglycemic activity need to be isolated 
to elucidate the relationship between the extracts’ antioxidant capacity and 
their hypoglycemic effects. 
Keywords: Polyphenols, Antioxidant activity, Hypoglycemic activity, Oral glucose tolerance test, 
Terminalia chebula. 
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Introduction 
The use of natural products as antioxidants in the management of diabetes mellitus has 
gained importance throughout the world. There has been increasing research focused on 
natural foods and medicinal plants and their phytoconstituents due to their well-known 
abilities to scavenge free radicals, i.e., antioxidative ability
1-3
.
 
The interest in natural 
antioxidants has burgeoned since evidence of their potential interference in the production of 
reactive oxygen species (ROS) was uncovered, these ROS plays an important role in the 
progression of a great number of pathological disturbances such as inflammation, 
atherosclerosis, stroke, heart disease, diabetes mellitus, multiple sclerosis, cancer, 
Parkinson’s disease, Alzheimer’s disease, etc4-5. 
 
 The world health organization has also recommended and encouraged the use of natural 
products for the management of diabetes and in oxidative stress conditions, especially in 
countries where access to conventional treatment of diabetes is inadequate. There is an 
increased demand for natural products with antidiabetic activity due to the side effects 
associated with the use of insulin and oral hypoglycemic agents
6
. 
 
 Natural antioxidants such as flavonoids and polyphenols are believed to possess 
antioxidant properties due to their reducing and chelating capabilities. Flavonoids and 
polyphenols are secondary plant metabolites that are widely distributed in fruits, leaves, 
bark, and other parts in plants with free radical scavenging abilities
7
. The genus Terminalia 
(fam. Combretaceae), comprising 250 species, is distributed across tropical countries 
worldwide, and the Indian traditional system of medicine has documented several books and 
literatures on the medicinal values of many of its species, of which Terminalia bellerica, T. 
chebula and T. arjuna are prime examples
8-9
. It has been reported that these species are rich 
in flavonoids and polyphenols. In “Ayurveda,” a herbal formulation combining the dried 
fruits of T. chebula, T. bellerica and Emblica officinalis by the name of “Triphala” has been 
used as a food and dietary supplement to derive several health benefits such as laxation, 
detoxification, liver protection, anti-aging, and as a rejuvenator of the body
10-11
. The 
combination has also been found to have antidiabetic and cholesterol-lowering activities
12-13
. 
The fruit extracts of T. chebula and T. bellerica have been shown to contain antioxidants
14
, 
and T. arjuna bark extracts have been reported to possess cardioprotective, antioxidant, and 
antimutagenic abilities
15-17
. Despite reports of the antioxidant and antidiabetic activities of 
the fruit and bark of Terminalia species, which are a rich source of flavonoids, tannins, and 
many phenolic derivatives, concrete evidence supporting the relationship with regard to the 
leaves of the genus is lacking.  
 
 Therefore, the present study was planned to investigate methanolic leaf extracts of the 3 
popular species to determine their total phenolic (TPC), total flavonoid (TFC), and total 
tannin content (TTC), as well as their 1,1-Diphenyl-2-picrylhydrazyl (DPPH) scavenging 
activity, oxygen radical antioxidant capacity (ORAC), and ferric reducing antioxidant power 
(FRAP) in correlation to their hypoglycemic activity. 
 
Experimental 
Dried powdered leaves of T. arjuna, T. bellerica, and T. chebula were obtained from 
Amritum Bio-Botanica Herbs Research Laboratory Pvt. Ltd, Jogli, India. These samples 
were successively defatted with hexane, then chloroform, and finally with methanol using a 
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Soxhlet apparatus. The resulting methanol extracts were evaporated under reduced pressure 
at 40°C using a rotary evaporator to derive a crude methanol (MeOH) extract that was 
further lyophilized and stored at -20°C prior to use.  
 
Determination of Total Phenolic and Flavonoid Content 
The TPC and TFC of the methanolic extracts were determined by the Folin-Ciocalteu and 
Dowd methods as adapted by Lamien-Meda et al
18
. Results are expressed as mg Gallic Acid 
equivalents (GAE) and mg Quercetin (Q) equivalents. 
Determination of Total Tannin Content 
The TTC in the methanolic extracts was estimated with the method by Price and Butler
19
 
with some modifications. A 3.0 mL volume of the sample, 3.0 mL of vanillin (4%) in 
methanol and 1.5 mL con. HCl were mixed and were incubated in the dark for 10 min. 
Subsequently, the TTC content of the samples were analyzed with a UV-Vis. 
spectrophotometer at 500 nm. Results are expressed as mg Catechin (C) equivalents. 
In vitro antioxidant study 
DPPH Radical Scavenging Activity  
The scavenging activity of all the 3 methanolic extracts on DPPH (1,1-diphenyl-2-
picrylhydrazyl) was determined using the method described by Choi et al 
20 
with 
slight modifications. This method is based on the reduction of purple DPPH to a 
yellow colored diphenylpicrylhydrazine. Changes in color were measured at 518 nm. 
All the extracts were tested at final concentrations ranging 600–10 µg/mL in ethanol. 
One milliliter of 0.3 mM DPPH ethanol solution was added to 2.5 mL of sample 
solution in different concentrations to produce the test solutions, while 1 mL of 
ethanol was added to 2.5 mL of sample to produce the blank solutions. The negative 
control consisted of 1 mL of DPPH solution plus 2.5 mL of ethanol. The solutions 
were allowed to react at room temperature for 30 min in the dark. The absorbance 
values were measured at 518 nm and converted into percentage antioxidant activity 
using the following equation: 
 
% Inhibition = [(AB - AA)/AB] × 100, 
 
where AB: absorption of blank sample; AA: absorption of tested samples. The half maximal 
inhibitory concentration (IC50) and the kinetics of DPPH scavenging activity were 
determined. Ascorbic acid and butylated hydroxytoluene (BHT) were used as positive 
controls in this assay.  
ORAC Antioxidant Activity Assay 
The oxygen radical absorbance capacity (ORAC) assay was carried out based on the 
procedure described by Cao G et al
21
 with slight modifications. Briefly, 175 µL of the 
sample/blank were dissolved with PBS at concentrations of 160 µg/mL, pH 7.4. Serial 
dilutions of the standard Trolox were prepared from 75 mM. The assay was performed in 
96-well black microplates, to which 25 µL each of samples (extracts), standard (Trolox), 
blank (solvent/PBS), or positive control (quercetin) were added. Subsequently, 150 µL of 
fluorescent sodium salt solution was added, and the plate was incubated for 45 minutes at  
37°C. 2,20-azobis (2-amidinopropane) dihydrochloride (AAPH) solution (25 µL) was added 
to make up a total volume of 200 µL/well. Fluorescence was recorded at 37°C until it 
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reached 0 (excitation at 485 nm, emission at 535 nm) using a fluorescence 
spectrophotometer (Perkin-Elmer LS 55) equipped with an automatic thermostatic autocell-
holder. Data were collected every 2 min for 2 h and were analyzed by calculating the 
differences of areas under the fluorescein decay curve (AUC) between the blank and the 
sample. Values are expressed as Trolox equivalents. 
FRAP Assay 
The FRAP (ferric reducing/antioxidant power) assay was modified from the method used 
by Benzie and Strain
22
. The stock solutions included 300 mM acetate buffer (pH 3.6),         
10 mM TPTZ (2,4,6-tripyridyl-s-triazine) solution in 40 mM HCl and 20 mM FeCl3·6H2O 
solution. A fresh working solution was prepared by mixing 25 mL acetate buffer, 2.5 mL 
TPTZ, and 2.5 mL FeCl3·6H2O. The temperature of the solution was raised to 37°C before 
use. Extracts (10 μL) were allowed to react with 190 μL of FRAP solution for 30 min in 
the dark. Colorimetric readings of the product, i.e., the ferrous-TPTZ complex, were taken 
at 593 nm for 10 min and a steady state was reached within 5 min for the different test 
substance concentrations. The EC1 value was calculated from the regression curve as the 
concentration of antioxidant (lM) giving an absorbance reading equivalent to that obtained 
with a 1 mM Fe(II) solution. The standard curve was linear between 200 and 1000 μM 
FeSO4. Results are expressed as μM Fe (II)/g dry mass and compared with those of 
ascorbic acid and BHT. 
In Vivo Study 
Animals and Treatment 
Male Sprague-Dawley rats weighing 200–250 g were procured from the Animal Care Unit 
of the University Malaya Medical Centre (UMMC) in Kuala Lumpur, Malaysia and 
maintained under pathogen-free conditions in the animal housing unit in a temperature-       
(23±2°C) and light-controlled (12 h light/dark cycle) room with 35–60% humidity. Animals 
were provided with carbohydrate-enriched rodent chow and water ad libitum. The Animal 
Ethics Committee from the UMMC Faculty of Medicine approved the study under Approval 
No. FAR/10/11/2008/AA(R).  
Acute Oral Toxicity  
The acute oral toxicity test of the 3 plants’ methanolic extracts was planned according to the 
Organization for Economic Co-operation and Development (OECD) guidelines. Healthy 
male Sprague-Dawley rats weighing 150–200 g were used for this study. After an overnight 
fast, the rats were divided into 6 groups (n = 9–10) and orally fed with the methanolic leaf 
extracts. Three groups were fed with doses of 50 mg/kg body weight and the other 3 groups 
were fed doses of 2500 mg/kg body weight. The rats were observed continuously for 24 h 
for any behavioral, neurological, and autonomic profiles, and after 72 h for any lethality. 
According to this toxicity study, 1/10 of the maximum dose administered was used for the 
hypoglycemic screening study. 
Determination of Postprandial Blood Glucose Levels in Normal Rats  
Animals were divided into 5 groups of 8–9 in a group. One group was used as a positive 
control and received glibenclamide (5 mg/kg) orally; the negative control group received 
NaCl (0.9%, dose 2 mL/200 g), while the other 3 groups received methanolic leaf extracts 
(250 mg/kg). The lyophilized powder of all leaf extracts was reconstituted with filtered 
water and administered orally using a gavage (2 mL/200 g body weight). Blood samples 
were obtained by amputation of the tail tip in non-fasting conditions after 2, 4 and 6 h of 
treatment. Glycemia was determined using the glucose oxidase-peroxidase enzymatic 
method (Accu-Check Performa, Roche Diagnostic Germany) through electronic glucometer. 
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An extract was deemed to have a hypoglycemic effect if the blood glucose levels of the rats 
decreased significantly compared to those of the normal control group
23
.  
Glucose Challenge (Glucose Tolerance Test) 
An oral glucose tolerance test (OGTT) was used to evaluate the effectiveness of the leaf 
extracts with hypoglycemic potential on glucose induced hyperglycemic rats, which was 
derived from prior screening tests and from which the positive results formed the basis of 
this hypoglycemic screening. In rats fasted overnight, extracts (250 mg/kg) were fed in 
doses of 2.0 mL/200 g body weight and the control group was given NaCl (0.9%). 
Concentration of glucose level in blood was measured before and 120 min after extracts 
administration. After this time point, glucose (3 g/kg) was introduced orally, then glucose 
concentration in blood was measured at 30, 60 and 120 min post-challenge
23
. 
Statistical Analysis 
The data are expressed as the mean ±SD of 3 measurements. Statistical analysis was 
performed using one-way and two-way repeated measures ANOVA and comparison of the 
data was done by Tukey’s test with all pair-wise multiple comparison procedures. p <0.001 
was considered statistically significant. 
Results and Discussion 
In this study, we evaluated the total phenolic, total flavonoid, and total tannin content in the 
methanolic extract of T. chebula, T. bellerica and T. arjuna leaves, followed by evaluation 
of the extracts’ antioxidant activities and in vivo hypoglycemic screening in normal rats.  
Total Phenolic, Flavonoid and Tannin Content 
There has been an increased desire in consumers for functional foods with antioxidant 
capabilities. The fruit and leafy parts of plants are considered rich in polyphenols and 
flavonoids, which contributes to their antioxidant capacity
24
. The antioxidant property 
of phenolic compounds is attributed to their ability to absorb and neutralize free 
radicals. 
 The results in Table 1 demonstrate that the methanolic extract of T. chebula leaves 
contained the highest TPC, followed by those of T. bellerica and T. arjuna (266.16, 259.28, 
and 147.23 mg GAE/g extract, respectively), likewise, the TFC were 29.23, 16.15, and 8.19 
mg Q/g extract, respectively. T. chebula possessed the highest TTC, followed by T. arjuna 
and T. bellerica (8.36, 4.68 and 6.31 mg C/g extract, respectively). T. chebula fruits have 
been found to contain higher amounts of total phenolics, total flavonoids and total tannin, 
and are reported to contain gallic acid, chebulic acid, 1,6-di-O-galloyl-β-D-glucose, 
punicalagin,3,4,6-tri-O-galloyl-β-D-glucose, casuarinin, chebulanin, chebulagic acid, 
chebulinic acid and 1,2,3,4,6-penta-O-galloyl-β-D-glucosein, which might be responsible for 
its high antioxidant activity
25
. 
 
Table 1. Total phenolic, flavonoid, and tannin content in methanolic extracts of Terminalia 
chebula, T. bellerica, and T. arjuna leaves. 
No. Plants 
Total Phenolic 
Content
a 
(mg GAE/g 
extract) 
Total Flavonoid 
Content
a 
(mg 
Quercetin/g extract) 
Total Tannin 
Content
a 
(mg 
Catechin/g extract) 
1 T. chebula 266.16 ± 7.81 29.23 ± 3.81 8.36 ± 0.37 
2 T. bellerica 259.28 ± 6.42 16.15 ± 2.42 4.68 ± 1.31 
3 T. arjuna 147.23 ± 2.34 8.19 ± 1.41 6.31 ± 0.17 
aValues expressed are mean ± SD of triplicate measurements. 
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In Vitro Antioxidant Activities 
The antioxidant activities of the T. chebula, T. bellerica and T. arjuna leaf extracts were 
determined with DPPH, ORAC and FRAP assays. These assays were measured in triplicate 
at different concentrations to determine the extracts’ IC50 values. The results are listed in 
Table 2.  
DPPH Radical Scavenging Activity 
The DPPH radical is used commonly and extensively to determine the in vitro antioxidative 
activity of antioxidant compounds. When treated with substances or samples that are 
hydrogen atom donors, the DPPH radical is converted into a stable DPPH radical, indicated 
by a color change from purple to yellow (Kriengsak Thaipong, 2006). DPPH radical 
reduction is analyzed by measuring the absorbance of samples at a 518 nm wavelength. The 
DPPH scavenging capacity of T. chebula (11.6 µg/mL) was the highest of the 3 extracts 
tested, as it recorded the lowest IC50 value of all the extracts, while T. bellerica                 
(16.4 µg/mL) demonstrated better scavenging activity than T. arjuna (21.8 µg/mL) did. 
Among the positive controls, ascorbic acid (1.6 µg/mL) was found to have better DPPH 
radical scavenging ability than BHT (1.7 µg/mL). Flavonoids are well-known antioxidant 
constituents of plants and possess a broad spectrum of chemical and biological activities, 
including radical-scavenging or chelating activities
26
. 
ORAC Assay 
All the extracts demonstrated good oxygen radical absorption capacity; IC50 values are 
expressed in Trolox (μM/mL) equivalent (TE) concentrations as listed in Table 2. T. chebula 
exhibited lower IC50 values (18.23 μM TE/mL) than the other 2 species did. T. arjuna had an 
IC50 value of 42.31 μM TE/mL, whereas that of T. bellerica was 29.17 μM TE/mL. The 
positive control (Quercetin) had the lowest IC50 value (12.16 μM TE/mL). Therefore, the 
results attribute T. chebula extracts with the highest oxygen radical absorption capacity. The 
ORAC assay is based upon the inhibition of the peroxyl-radical-induced oxidation initiated 
by thermal decomposition of azo-compounds such as [2,2’-azobis(2-amidino-propane) 
dihydrochloride (AAPH)].  
 Reactive oxygen species (ROS) are hazardous to cellular structures and functional 
molecules (i.e DNA, proteins, lipids) as they act as strong oxidizing mediators or free 
radicals. Biological antioxidants are able to dispose of ROS; as they are found to be safe and 
effective in eliminating all of the free radicals, oxygen ions and peroxides that can do 
damage to the body
7
. In this manner, the ORAC assay uses a biological relevant radical 
source and it combines both inhibition time and degree of inhibition into one quantity
21
.  
FRAP Assay 
The principle of a FRAP assay involves the reduction of ferric ions to ferrous ions by plant 
extracts due to the presence of reducing substances in the extracts
27. The extracts’ ability to 
reduce ferric ions was determined using the FRAP assay developed by Benzie and Strain
10
. 
Electron-donating antioxidant compounds are capable of reducing the ferric-TPTZ (Fe(III)-
TPTZ) complex to a blue ferrous-TPTZ (Fe(II)-TPTZ) complex that exhibits strong 
absorbance at 593 nm. Evaluation of the extracts’ ferric reducing antioxidant ability 
determined that the EC1 value of T. arjuna (232 µg/mL) was lower than that of T. chebula 
(243 µg/mL) and T. bellerica (265 µg/mL). The lower the EC1 value, the higher the ferric 
reducing antioxidant abilities of the extract. The BHT (3.2 µg/mL)  standard had greater 
ferric ion reducing capability than ascorbic acid (3.7 µg/mL) did. The reducing capacity of 
T. arjuna leaf extract may have been due to a large number of polyphenolic compounds with 
electron-donating hydroxyl groups. 
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Table 2. Antioxidant activities of Terminalia chebula, T. bellerica and T. arjuna methanolic 
leaf extracts in DPPH, ORAC and FRAP assays. 
No. Samples 
a
DPPH
  
IC50, 
µg/mL 
a 
ORAC IC50,  
μM/mL 
a
FRAP
  
EC1, 
μg/mL 
1 T. chebula 11.6±0.43 18.23±0.9 243±5.8 
2 T. bellerica 16.4±0.55 29.17±1.8 265±6.7 
3 T. arjuna 21.8±0.37 42.31±2.7 232±8.3 
4 Ascorbic acid 1.6±0.14 Not applicable 3.7±0.8 
5 BHT 1.7±0.07 Not applicable 3.2±0.5 
6 Quercetin Not applicable 12.16±1.3 Not applicable 
ORAC: Equivalent conc. Trolox (20 μg/mL) (μM) aDPPH, aORAC and aFRAP assays 
demonstrating low values indicate high antioxidant activity. Standard deviation (SD) 
values of a minimum of 3 replicates. 
 
 
In Vivo Study 
 
Acute Oral Toxicity Studies 
The leaf extracts of the 3 selected species were found to be non-toxic in rats, as neither 
mortality nor any considerable symptoms of toxicity were observed after oral administration 
of extracts at 2 dose levels (50 and 2500 mg/kg body weight) over a 72-hr period. 
 
Hypoglycemic Activity in Methanolic Leaf Extracts by Oral Route 
There was a reduction in blood glucose levels at 2 and 4 hr, with a slight increase at 6 h after 
oral administration of T. chebula, T. bellerica and T. arjuna leaf extracts. After 
glibenclamide administration, blood glucose levels were significantly reduced at 2, 4, as 
well as 6 h, but blood glucose levels did not change significantly within the different time 
intervals after oral administration of the negative control (0.9% NaCl). The results are listed 
in Table 3. There was a significant difference in blood glucose levels at 2, 4 and 6 h after 
oral administration of glibenclamide, T. chebula, T. bellerica, and T. arjuna extracts                   
(p <0.001) as compared to levels at 0 h and in the negative control (NaCl) group.  
 
 The control of postprandial hyperglycemia is one of the beneficial therapies for 
management of type 2 diabetes mellitus
28
, along with nutrition and oral hypoglycemic and 
insulin therapies
29
. In order to determine a scientific basis for the utilization of T. chebula, T. 
bellerica and T. arjuna leaves in the treatment of diabetes, we decided to evaluate their 
extracts’ hypoglycemic effect in normal rats. Earlier reports revealed that T. chebula and          
T. bellerica fruits and T. arjuna bark possessed antidiabetic effects when studied in STZ-
induced diabetic animals, and suggested that most diabetic complications were mediated 
through oxidative stress
30
. Production of ROS and its related oxidative stress was reported as 
the root cause for the development of insulin resistance, β-cell dysfunction, impaired 
glucose tolerance and type 2 diabetes mellitus
31
. The present study demonstrated that                
T. chebula leaf extract was more effective at decreasing blood glucose in normal rats, 
followed by T. bellerica and T. arjuna when compared to the negative control. This may be 
due to their flavonoid and phenolic contents, which are known to be involved in the healing 
process of free radical-mediated diseases, including diabetes
32
.  
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Time group, min 
Table 3. Hypoglycemic activity of methanolic leaf extracts by oral route in normal rats. 
 
Group 
 
Alteration in blood glucose levels (mmol/L) before and after 
administration of test samples (mean ± SD) 
0 h 2 h 4 h 6 h p-value 
NaCl control 7.5±0.32 7.1±0.23 6.6±0.37 6.7±0.28 0.059 
Glibenclamide 7.2±0.41 4.6±0.33
*
 4.5±0.24
*
 4.1±0.45
*
 <0.001 
T. chebula 6.9±0.37 5.4±0.26* 4.9±0.52
*
 5.1±0.31
*
 <0.001 
T. bellerica 6.6±0.29 4.9±0.17
*
 5.1±0.37
*
 5.4±0.46
*
 <0.001 
T. arjuna 7.0±0.36 5.8±0.24
*
 5.2±0.38
*
 5.7±0.29
*
 <0.001 
*Comparison with time 0 and negative control (NaCl) indicates significance (p <0.001). 
 
Oral Glucose Tolerance Test 
An oral glucose tolerance test was used to confirm the result of the hypoglycemic effects. 
The results depicted in Fig 1. indicate that there was no major alteration in blood glucose 
levels until 120 min following administration of extracts and NaCl in overnight-fasted 
normal rats. However, after 30 min of glucose load, blood glucose levels were considerably 
elevated in all treated groups up until 60 min, followed by a fall in glucose concentration 
until 120 min. Hence, there was a significant difference in blood glucose levels throughout 
the observation period for all 3 leaf extracts (p <0.001 when compared with the normal 
control group). This suggests that methanolic leaf extracts of Terminalia species have the 
ability to improve glucose tolerance activity in normal rats. This observation indicates that 
the extracts may interfere with the intestinal glucose absorption in the gut by various 
mechanism, this may be postulated that the positive results of these extracts might stimulates 
glycogenesis in the liver, which is enhanced by feeding and is hypothesized that the glucose 
tolerance activity induced by the extracts could be due to a mixture of active compounds that 
reduce the concentration of glucose and improve glucose tolerance activity
33-34
.  
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Figure 1. In normal fasted rats blood glucose levels, significantly changed at different time 
intervals after oral administration of extracts and glucose load (p <0.001). 
 
Conclusion 
The present study indicates that the leaf extracts of the selected Terminalia species possess 
antioxidant and hypoglycemic activities, which is probably due to their phenolic groups, and 
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brings new hope to research on the management of type 2 diabetic conditions. The use of 
these species as food supplements may aid in reduction of oxidative stress and related 
diabetic complications. However, the mechanism of action by which these species exert 
their action needs to be established by a thorough phytochemical investigation to identify the 
constituents responsible for the antioxidant and hypoglycemic activity. Furthermore, long-
term studies on type 2 diabetic models must be carried out to describe the exact mechanism 
of action at the cellular level. 
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Ethnopharmacological relevance: Seeds of Centratherum anthelminticum (Asteraceae) have been popu-
larly used in Ayurvedic medicine to treat diabetes and skin disorders. Folk medicine from Rayalaseema
(Andhra Pradesh, India) reported wide spread usage in diabetes.
Aim of the study: To investigate the hypoglycemic properties and mechanism of the methanolic fraction
of C. anthelminticum seeds (CAMFs) on mouse b-TC6 pancreatic cell line and streptozotocin
(STZ)-induced diabetic rat models.
Materials and Methods: We investigated the crude methanolic fraction of C. anthelminticum seeds
(CAMFs) on b-TC6 cell line and conﬁrmed its effects on type 1 and type 2 diabetic rats to understand its
mechanism in managing diabetes mellitus. CAMFs were initially tested on b-TC6 cells for cytotoxicity,
2-NBDG glucose uptake, insulin secretion and glucose transporter (GLUT-1, 2 and 4) protein expression.
Furthermore, streptozotocin (STZ)-induced type 1 diabetic and STZ-nicotinamide-induced type 2
diabetic rats were intraperitoneally (i.p) injected or administered orally with CAMFs daily for 28 days.
The effect of CAMFs on blood glucose and insulin levels was subsequently evaluated.
Results: In cell line studies, CAMFs showed non-cytotoxic effect on b-TC6 cell proliferation compared to
untreated control cells at 50 mg/ml. CAMFs increased glucose uptake and insulin secretion dose-
dependently by up-regulating GLUT-2 and GLUT-4 expression in these cells. Further in vivo studies on
streptozotocin induced diabetic rat models revealed that CAMFs signiﬁcantly reduced hyperglycemia
by augmenting insulin secretion in type 2 diabetic rats. However, CAMFs displayed less signiﬁcant
effects on type 1 diabetic rats.
Conclusions: CAMFs demonstrated anti-diabetic potential on b-TC6 cells and type 2 diabetic rat model,
plausibly through enhancing glucose uptake and insulin secretion.
& 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Diabetes mellitus (DM) is a complex metabolic disorder
characterized by high blood glucose level due to defects in insulin
secretion, insulin action or both. It affects the metabolism of
carbohydrates, fats, proteins and electrolytes in the body. Type I
diabetes (DM1) or insulin-dependent diabetes mellitus (IDDM)
occurs due to immunological destruction of pancreatic b cells and
consequent insulin deﬁciency. Type II diabetes (DM2) or non-
insulin-dependent diabetes mellitus (NIDDM) is characterized by
impaired insulin secretion or insulin resistance. DM2 is usually
associated with obesity and hereditary disposition and it is the
most common form of diabetes, affecting 90–95% of cases
(Tamrakara et al., 2011). Resistance to insulin impairs the sensi-
tivity of the main target organs (muscle, liver and adipose tissues)
to the hormone, which increases circulating FFA concentrations,
inhibits muscle cell’s glucose uptake and enhances glucose
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Abbreviations: 2-NBDG, 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-
2-deoxyglucose; ATCC, American Type Culture Collection; bw, body weight;
CA, Centratherum anthelminticum; CAMFs, methanolic fraction of C. anthelminticum
seeds; CI, cell index; DM1, type 1 diabetes; DM2, type 2 diabetes; DMEM,
Dulbecco’s modiﬁed Eagle medium; FBS, fetal bovine serum; GC–MS, gas
chromatography–mass spectrometry; GLUT, glucose transporter; FFA, free fatty
acid; HCS, high content screening; HRP, horseradish peroxidase; IC50, 50%
inhibitory concentration; IDDM, insulin-dependent diabetes mellitus; IP, intra-
peritoneal; LCMS-MS, liquid chromatography–tandem mass spectrometry;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NIDDM,
non-insulin-dependent diabetes mellitus; OECD, Organization for Economic
Co-operation and Development; OGTT, oral glucose tolerance test; PBS,
phosphate-buffered saline; PBS-T, PBS-Tween 20; PPARs, peroxisome proliferator-
activated receptors; PVDF, polyvinylidene ﬂuoride; r2, coefﬁcient of determina-
tion; RTCA, Real-Time Cellular Analysis; SD, standard deviation; SDS, sodium
dodecyl sulfate; STZ, streptozotocin; TMB, 3,3’,5,5’-tetramethylbenzidine
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production by the liver. These conditions are considered as DM2
hallmarks ( Reaven, 1988; Defronzo, 2009). Currently, the range
of medication is limited. None of the available options is able to
vigorously enhance insulin secretion and sensitivity simulta-
neously (Cohen and Horton, 2007). Thus, it is obvious that there
is an urgent need for more effective therapeutic agents.
The plant kingdom holds great potential to meet this need.
However, scientiﬁc testing and validation of the efﬁcacy of most
medicinal plants in alleviating DM1 and DM2 is rare. Thus, we
have limited knowledge of their safety and efﬁcacy, as most of the
data is based on information obtained from traditional medicinal
plant practitioners (Smirin et al., 2010). Folk medicine from
Rayalaseema reports 26 plants for the management of diabetes.
One such plant is Centratherum anthelminticum (L.) Kuntze, which
belongs to the family Asteraceae (Nagaraju and Rao, 1990). Seed
of this plant is being used by Indian traditional healers to treat
diabetic conditions. The trade name of C. anthelminticum is wild
cumin and it is also known as Kalizeeri in Hindi. C. anthelminticum
is one of the major contents for the Ayurvedic formulation, e.g.,
Kayakalp, a preparation used for the whole-body rejuvenation.
Pharmacological investigations of C. anthelminticum (CA) seeds
demonstrated various biological activities, including anti-cancer,
anti-diabetes and anti-inﬂammation (Ani and Naidu, 2008;
Fatima et al., 2010; Arya et al., 2012). However, little is known
on the anti-diabetic effect of the defatted crude methanolic
fraction of C. anthelminticum seeds (CAMFs).
The present study was undertaken to scientiﬁcally investi-
gate anti-diabetic potential of CAMFs using in vitro mouse
pancreatic b-TC6 cells and in vivo diabetic rat models. We ﬁrst
studied cytotoxicity and cell proliferation assay on b-TC6 cells.
Furthermore, we investigated CAMFs effects on in vitro glucose
uptake in b-TC6 cells using 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-
4-yl)amino]-2-deoxyglucose (2-NBDG) and insulin secretion.
Next, we performed Western blotting to evaluate glucose
transporter protein (GLUT-1, 2 and 4) expression after CAMFs
treatment. Subsequently, we investigated the effect of CAMFs
on glucose levels and insulin secretions in streptozotocin
(STZ)-induced type 1 and STZ-nicotinamide-induced type 2
diabetic rat models.
2. Material and methods
2.1. Preparation of CAMFs
2.1.1. Collection of plant material
Dried seeds of C. anthelminticum were obtained from the
medicinal plant cultivation zone of Amritum Bio-Botanica Herbs
Research Laboratory Pvt. Ltd. (Madhya Pradesh, India). The dried
seeds were authenticated by the company’s quality control depart-
ment. Voucher specimens of the seeds (CA-9) were deposited with
the company and in the Department of Pharmacology, Faculty of
Medicine, University of Malaya (UM).
2.1.2. Extraction and fractionation
The seeds of C. anthelminticum (2 kg) were pounded using
grinder and extracted with 100% n-hexane using a Soxhlet extrac-
tor for 24 h. The solvents were then removed under reduced
pressure at a maximal temperature of 40 1C to get viscous greenish
oil. Then, the obtained residue was further fractionated by 100%
chloroform, to get semisolid fraction. Finally, the defatted residue
was again fractionated with absolute methanol to get defatted
crude methanolic fraction (CAMFs). The ﬁnal fraction was then
freeze-dried and stored at 20 1C until further use.
2.1.3. Phytochemical analysis of CAMFs by LCMS-MS
Analysis of the major compounds in CAMFs was done using
liquid chromatography–tandem mass spectrometry (LCMS-MS).
A triple quadrupole mass spectrometer equipped with a turbo ion
spray source (AB SciexQTrap 5500, Ontario, Canada) was used to
obtain the MS/MS data in negative ion mode. 0.1% formic acid in
water and in acetonitrile (ACN) were used as mobile phase by
eluting at a ﬂow rate of 0.4 mL/min with an injection volume of
20 mL. Separation of the compounds was performed using a Luna
3-mm RP C18 column (100 mm2.00 mm; Phenomenex).
The turbo ion source settings were as follows: capillary voltage,
4000 V; dry gas ﬂow (N2), 9 L/min; nebulizer pressure, 35 psi;
and capillary temperature, 365 1C. A full scan of the mass spectra
was recorded from m/z 50 to m/z 1000. The acquisition data was
processed with Analyst Software version 1.5.1. Compounds were
characterized based on their UV spectra and MS2 and MS3
fragmentations spectra data by correlation with the previous
reports.
2.1.4. Phytochemical analysis of CAMFs by GC–MS
The analysis of CAMFs by GC/MS was carried out using a
Shimadzu GC-17A network GC system coupled to a mass detector
with a SGE BPX35 MS (25 m0.22 mm0.25 mm) capillary col-
umn. Helium gas was used as the carrier gas at a ﬂow rate of 1 mL/
min. The injection volume was 1 mL and the samples were injected
in split mode as 10:1. The column temperature was initially set at
100 1C for 3 min, raised to 250 1C at the rate of 10 1C/min, and
maintained at this temperature for 3 min. The injector and detector
temperatures were set at 250 1C and 280 1C, respectively. The
ionization voltage was 70 eV with the mass scan operating in the
range of 40–450 amu. Identiﬁcation of the major compounds was
based on the comparison of mass spectra and retention times with
those of standards from the database of National Institute Stan-
dards and Technology (NIST21 and NIST Wiley).
2.2. In vitro assays
2.2.1. Cell culture
Mouse b-TC6 cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA) and cultured in
15% fetal bovine serum (FBS) in Dulbecco’s Modiﬁed Eagle
Medium (DMEM). Cultures were maintained at 37 1C in 5% CO2
in a humidiﬁed incubator. The growth medium was changed
every 3 days.
2.2.2. Cellular viability
The b-TC6 cells were used to determine the effect of CAMFs on
cell growth using the MTT assay. The MTT assay was performed as
described by Mosmann (1983) with slight modiﬁcation. Brieﬂy,
cells were seeded at a density of 1.5104 cells/mL in a 96-well
plate and incubated for 24 h at 37 1C in 5% CO2. The next day, cells
were treated with CAMFs and incubated for another 24 h, following
which 2 mg/mL MTT solution was added for 1 h. Absorbance at
570 nm was measured and recorded using a Plate Chameleon V
microplate reader (Hidex, Turku, Finland). Results are expressed as
a percentage of control cells demonstrating percentage cell viability
after 24-h exposure to CAMFs. The potency of cell growth was
expressed. Viability was deﬁned as the ratio (expressed as a
percentage) of the absorbance of treated cells to that of the
untreated cells.
2.2.3. Real-time cell proliferation
In vitro cell proliferation was assessed using an xCELLigence
Real-Time Cellular Analysis (RTCA) system (Roche, Manheim,
Germany). Brieﬂy, background measurements were obtained after
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adding 50 mL of the appropriate medium to the wells of the 16X
E-plate, and 1.5104 cells were added to each well. Cell attach-
ment and proliferation were monitored every 5 min using the
RTCA system. Approximately 17 h after seeding, when the cells
were in the log growth phase, the cells were treated with 100 mL
of CAMFs in concentrations of 3.125, 6.25, 12.5, 25, 50, and
100 mg/mL dissolved in cell culture media, and continuously
monitored for up to 72 h. The cells were also treated with
medium alone, which served as the vehicle control. Cell sensor
impedance was expressed as an arbitrary unit called the cell
index (CI).
2.2.4. 2-NBDG glucose uptake
The uptake of the ﬂuorescent hexose 2-NBDG, a glucose
analog, was assayed as described by Loaiza et al. (2003) with
modiﬁcations. Brieﬂy, 1.5104 cells were seeded onto a 96-well
plate and allowed to attach, spread, and proliferate to near
conﬂuence at 37 1C in 5% CO2. The medium was then removed
and the cells were washed with phosphate-buffered saline (PBS)
twice. The PBS was then replaced with 2.5 mM glucose in basal
medium comprising DMEM without glucose or pyruvate supple-
mented with L-glutamine and 15% (v/v) FBS (ﬁnal serum glucose
concentration of approximately 0.25 mM). Conditioning of the
cells proceeded at 37 1C in 5% CO2 for 60 min. The conditioning
medium was then removed and replaced with 10 mM 2-NBDG
(Invitrogen, Carlsbad, CA, USA) in basal medium in the presence
or absence of CAMFs. The cells were then incubated at 37 1C in 5%
CO2 for 30 min to permit endocytosis of the 2-NBDG, with the
selected concentration being the minimum concentration capable
of producing an adequate signal-to-noise ratio. The 2-NBDG was
then removed, the cells washed with PBS, and stained with the
nucleic dye Hoechst 33342 for another 30 min. The cells were
then observed for intra-cellular ﬂuorescence at Ex/Em¼350 nm/
461 nm and Ex/Em¼475 nm/550 nm for Hoechst 33342 and
2-NBDG, respectively. Plates were evaluated using the ArrayScan
High Content Screening (HCS) system (Cellomics Inc., Pittsburgh,
PA, USA) and analyzed with Target Activation BioApplication
software (Cellomics Inc.).
2.2.5. In vitro insulin secretion
The b-TC6 cells (1.5105 cells/mL) were seeded onto a
24-well plate and allowed to attach, spread, and proliferate at
37 1C in 5% CO2. After reaching 80–90% conﬂuence, the cells were
washed with glucose-free Krebs/HEPES Ringer solution (115 mM
NaCl, 24 mM NaHCO3, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2,
25 mM HEPES [pH 7.4]) twice and pre-incubated at 37 1C for
30 min with the glucose-free Krebs/HEPES Ringer solution. Fol-
lowing this, the cells were incubated in Krebs/HEPES Ringer
solution containing 1 mg/mL bovine serum albumin and 6.25,
12.5, 25, or 50 mg/mL of glucose in the presence or absence of
CAMFs for 60 min. An aliquot of the supernatant was collected for
ELISA. The amount of insulin released was measured with a
Mouse Insulin ELISA kit (Mercodia, Uppsala, Sweden) according
to the manufacturer protocol. Results (in pmol) are expressed as
the means7SE of at least two independent experiments.
2.2.6. Western blotting analysis
To determine protein expression, 1106 cells/mL were seeded
onto 25-cm2 tissue culture ﬂasks. Cells were treated with 6.25, 12.5,
or 25 mg/mL of CAMFs for 24 h; whole cell extracts were prepared as
described by Looi et al. (2011). Brieﬂy, cells were collected and lysed
in lysis buffer (20 mM Tris [pH 7.4], 250 mM NaCl, 0.1% Triton
X-100, 2 mM EDTA, 10 mg/mL leupeptin, 10 mg/mL aprotinin,
0.5 mM phenylmethylsulfonyl ﬂuoride, 4 mM sodium orthovana-
date, 1 mM DTT), and 60 mg of the protein was resolved on 10%
SDS-polyacrylamide gels. After electrophoresis, the proteins were
transferred to PVDF membranes (Millipore). The membranes were
blocked with 5% non-fat dry milk in PBS-T (0.05% Tween 20) for 1 h
at room temperature. Membranes were probed with primary goat
anti-GLUT-1, GLUT-2, or GLUT-4 antibody followed by horseradish
peroxidase (HRP)–conjugated secondary donkey anti-goat antibody
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Protein-
antibody complexes were detected with a ProteoQwestTM Colori-
metric Western Blotting Kit with 3,3’,5,5’-tetramethylbenzidine
(TMB) substrate (Sigma-Aldrich, St. Louis, MO, USA). To ensure
equal loading, membranes were stripped and re-probed with mouse
anti-b-actin antibody (Santa Cruz Biotechnology Inc.).
2.3. In vivo studies
2.3.1. Experimental animals
Sprague–Dawley rats (180–200 g) were obtained from the
Animal Care Unit of the UM Medical Centre (Kuala Lumpur,
Malaysia), and maintained under pathogen-free conditions in a
temperature (2372 1C) and light-controlled (12-h light/dark
cycle) room with 35–60% humidity in the animal housing unit.
The animals were acclimatized for 10 days prior to the experi-
ments and provided rodent chow and water ad libitum.
We performed the animal experiments in accordance with the
animal experimentation guidelines issued by the UM Animal Care
and Use Committee (Ethics Number: FAR/10/11/2008/AA[R]) and
in accordance with the internationally accepted principles for
laboratory animal use and care.
2.3.2. In vivo acute oral and intraperitoneal toxicity studies
CAMFs oral and intraperitoneal acute toxicity tests were
determined according to the guidelines of the Organization for
Economic Co-operation and Development (OECD). We used
healthy adult Sprague Dawley rats of either sex. The rats were
fasted overnight, divided into 12 groups (n¼6), and injected
intraperitoneally (IP) or orally fed CAMFs at doses 10, 20, 50,
100 and 500 mg/kg body weight (bw), CAMFs was completely
dissolved in distilled water and ﬁltered before injecting i.p to the
animals; the control groups were given distilled water alone. We
observed the rats for 1 h continuously and then hourly for 4 h and
ﬁnally after every 24 h up to 14 days for any physical signs of
toxicity such as writhing, gasping, palpitation, and decreased
respiratory rate or for any lethality.
2.3.3. Induction of DM1
We induced DM1 in overnight-fasted normal male rats
through intraperitoneal administration of 65 mg/kg of freshly
prepared STZ (Sigma-Aldrich, St. Louis, MO, USA) in 0.1 M citrate
buffer (pH 4.5) in a volume of 1 mL/kg bw. STZ-injected rats were
given 20% glucose solution for 12 h to prevent initial drug-
induced hypoglycemic mortality. Hyperglycemia was conﬁrmed
by elevation in blood glucose levels, determined at 96 h after the
STZ administration. Rats with fasting blood glucose range of
22–26 mmol/L were considered DM1 and used for the study.
2.3.4. Induction of DM2
DM2 was induced (Masiello et al., 1998) with slight modiﬁca-
tions, by using standardized dose of STZ. Intraperitoneal injec-
tion of freshly prepared STZ (55 mg/kg) in 0.1 M citrate buffer
(pH 4.5) in a volume of 1 mL/kg was injected to overnight-fasted
normal male rats, 15 min after i.p administration of nicotinamide
(210 mg/kg). Hyperglycemia was conﬁrmed by elevation in blood
glucose levels, determined at 96 h after the STZ-nicotinamide
administration. Rats with a fasting blood glucose range of
A. Arya et al. / Journal of Ethnopharmacology 144 (2012) 22–3224
11–14 mmol/L were considered DM2 and subsequently used for
the study.
2.3.5. Division of animals for type 1 and type 2 diabetic model study
The rats were divided into two segments: one each for the
type 1 and type 2 diabetic model study. The type 1 segment was
divided into the following groups, Group 1: normal control rats,
Group 2: type 1 diabetic control rats, Group 3: type 1 diabetic rats
treated with 6 U/kg of insulin (standard positive), Group 4:
diabetic rats treated with 100 mg/kg of CAMFs, and Group 5:
diabetic rats treated with 50 mg/kg of CAMFs. The type 2 segment
was divided into the following groups, Group 1: normal control
rats, Group 2: type 2 diabetic control rats, Group 3: type 2 diabetic
rats treated with 50 mg/kg of glibenclamide (standard positive),
Group 4: diabetic rats treated with 100 mg/kg of CAMFs, and
Group 5: diabetic rats treated with 50 mg/kg of CAMFs. All groups
were injected and fed once daily with the respective doses of
CAMFs or drugs for 4 weeks (28 days). Administration was based
on volume (2 mL/200 g bw). CAMFs was completely dissolved in
distilled water and ﬁltered before i.p. injection.
2.3.6. Experimental procedure
We collected blood samples from the tail by snipping; fasting
blood glucose concentrations were determined weekly after the
above treatments by a glucose oxidase-peroxidase enzymatic
method using a standardized glucometer (Accu-Check Performa,
Roche Diagnostic Germany). Changes in body weight, food intake,
and water intake were recorded daily. After the 4-week treatment
period, all groups from both segments were fasted overnight and
sacriﬁced by cervical dislocation under mild anesthesia. Blood
was collected upon decapitation into heparinized tubes and
centrifuged at 2000 rpm for 10 min, the serum was collected
and stored at 80 1C until analysis.
2.3.7. Glucose challenge (glucose tolerance test)
We used the oral glucose tolerance test (OGTT) to evaluate the
effectiveness of CAMFs that had demonstrated the highest
glycemic control as studied in the type 1 and type 2 diabetic rat
models described earlier. CAMFs (100 or 50 mg/kg) was adminis-
tered to overnight-fasted rats in 2 mL/200 g bw doses. Fasting
blood glucose concentrations were measured before the respec-
tive CAMFs administrations, following which oral glucose (3 g/kg)
was administered and blood glucose levels were measured at 30,
60, 90, and 120 min, respectively.
2.3.8. Estimation of insulin and body weight
We determined serum insulin by using radioimmunoassay kit
(Packard, USA) according to the manufacturer protocol. In addi-
tion, the whole body weight of type 1 and type 2 diabetic rats
were examined at the end of study period in normal, treated, and
untreated diabetic rats.
2.4. Statistical analysis
The results are expressed as mean7standard deviation (SD).
Signiﬁcant differences between the means of the experimental
groups were identiﬁed with analysis of variance (ANOVA),
followed by the Tukey–Kramer multiple comparisons test (Graph-
Pad version 5.0; GraphPad Software Inc., San Diego, CA, USA).
Statistical signiﬁcance was set at Po0.001, Po0.01, Po0.05.
We performed log IC50 calculations using the built-in algorithms
for dose–response curves with variable slope. We set a ﬁxed
maximum value of the dose–response curve to each sample’s
maximum obtained value.
CAFFEIC ACID
NARINGENIN-7-O-GLUCOSIDE
3,4 -O- DICAFFEOYLQUINIC ACID 
QUERCETIN GLYCOSIDEKAEMPFEROL
Fig. 1. The mass spectrometric main (parent) chromatogram of CAMFs indicates the presence of characterized compounds on the basis of their mass fragmentation pattern
as (compound A) quercetin glycoside, (compound B) 3,4-O-dicaffeoylquinic acid, (compound C) caffeic acid, (compound D) naringenin-7-O glucoside, and (compound E)
kaempferol with other unknown compounds.
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3. Results
3.1. Fraction yield and LCMS-MS analysis
The ﬁnal yield of the obtained CAMFs fractions, was 12.6%
w/w. Phytochemical analysis using LCMS-MS demonstrated the
presence of quercetin glycoside, 3,4-O-dicaffeoylquinic acid, caf-
feic acid, naringenin-7-O glucoside, and kaempferol, as the major
compounds in CAMFs based on the main peaks selected, as well as
other unknown compounds (Fig. 1). The fragmentation patterns
of known compounds were in agreement with those documented
in the literatures. The mass spectrometric characterization of
Compound A indicates the presence of quercetin glycosides (Lin
and Harnly, 2007). The fragmentation pattern of Compound B
displays an ion peak at m/z 515, indicating the loss of the ﬁrst
caffeoyl, loss of the second caffeoyl at m/z 353, and loss of the
third caffeoyl at m/z 191 to yield quinic acid, a loss of caffeic acid
at m/z 179, and another caffeoyl at m/z 135. Thus, the compound
was characterized as 3,4-O-dicaffeoylquinic acid (Lin and Harnly,
2008; Gouveia and Castilho, 2011). Compound C exhibits frag-
ment ions atm/z 179 andm/z 135, the characteristic ions of caffeic
acid (Luo et al., 2003; Lin and Harnly, 2008; Plazonic et al., 2011).
Compound D was identiﬁed as naringenin-7-O-glucoside based
on mass fragment ions at m/z 433 and at m/z 271 and 153
(Charrouf, et al., 2007). (E) Compound E was identiﬁed as
kaempferol based on mass fragments at m/z 287 and m/z
151(Sun et al., 2007).
3.2. GC–MS analysis
The possible chemical composition in CAMFs analyzed by
GC/MS is presented in Table 1. Major peaks were selected and
identiﬁed on the basis of similarity index. The most abundant
components determined are decanoic acid, dodecanamide,
pentadecanoic acid, 14-methyl-methyl ester, tetradecanamide,
hexadecanoic acid, ethyl ester, octadecanoic acid, and ethyl ester.
Compounds with lower percentage (less than 80 similarity index,
SI) were considered as minor constituents and these compounds
were excluded from the list.
3.3. Effect of CAMFs on b-TC6 cell proliferation
To evaluate whether CAMFs is cytotoxic towards b-TC6 cells,
we apply various concentrations of CAMFs and cell viability was
analyzed using MTT assays 24 h after treatment. Fig. 2a illustrates
the dose–response curves in the end-point cytotoxicity assay.
CAMFs concentrations of up to100 mg/mL did not exert cytotoxic
effects on b-TC6 cell viability. Next we monitored treated b-TC6
cells for 3 days using Xcelligence Real-time Cell Proliferation
(RTCA) assays. RTCA data showed that b-TC6 cells treated with 50,
25, 12.5, 6.25 or 3.125 mg/mL of CAMFs proliferated in a similar
manner compared to control cells throughout the 72-h treatment,
as shown by an increase in the CI values, (Fig. 2b). However, high-
concentration treatment (100 mg/mL) decreased the CI values
after 72 h, suggesting that high concentration of CAMFs may
inhibit b-TC6 cell proliferation after prolonged treatment. The
IC50 values of CAMFs on b-TC6 cells at 24, 48, and 72 h were 518,
416, and 94 mg/mL, respectively.
3.4. Effect of CAMFs on 2-NBDG uptake
Fig. 3 illustrates the endocytosis of the ﬂuorescent glucose
analog 2-NBDG by mouse b-TC6 cells and increased intracellular
2-NBDG ﬂuorescence is visible in distinct groups of cells. Fluor-
escence appeared to be restricted to the cytoplasm. As the
duration deﬁned for 2-NBDG uptake would have been sufﬁcient
for the stabilization of 2-NBDG uptake and metabolism,
Table 1
Compounds tentatively identiﬁed in CAMFs.
Peak No. RTa Compoundsb SIc MW Molecular Formula
1 9.40 Decanoic acid, ethyl ester 95 200 C12H24O2
2 11.57 Tetradecanamide 86 227 C14H29NO
3 12.41 Octadecanamide 81 281 C18H35NO
4 13.10 Dodecanamide 93 287 C16H33NO3
5 16.30 Pentadecanoic acid, 14-methyl-methyl ester 91 270 C17H34O2
6 17.70 Hexadecanoic acid, ethyl ester 86 284 C18H36O2
7 20.80 Octadecanoic acid, ethyl ester 81 312 C20H40O2
a RT, Retention time (min).
b Compounds listed according to their relative area percentage (peak area relative to the total peak area percentage.
c SI, Similarity index.
Fig. 2. (a) MTT assay growth dose–response curves of CAMFs tested on mouse
b-TC6 cells. (b) Dynamic monitoring of cell proliferation using RTCA. b-TC6 cells
were seeded in a 16X E-plate device and continuously monitored up to 90 h after
treatment with various concentrations of CAMFs. CI values were normalized to the
time point of CAMFs addition, indicated by the vertical black line.
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this heterogeneous intracellular ﬂuorescence suggests that b-TC6
cells retain the heterogeneous glucose uptake activity of native b-
cells.
3.5. Effect of CAMFs on insulin secretion
Fig. 4 displayed the result of insulin secretion. In the absence of
glucose, insulin secretion was low in the b-TC6 cells. However,
CAMFs increased insulin secretion in a dose-dependent manner at
glucose concentrations of 6.25, 12.5, 25, and 50 mM). In particular,
at 12.5 mg/mL CAMFs elicited a marked increase in insulin secretion
in the b-TC6 cells (nPo0.05, nnPo0.01 or nnnPo0.001).
3.6. Effect of CAMFs on glucose transporter proteins
At 24 h after CAMFs treatment, the protein level of GLUT-1,
GLUT-2 and GLUT-4 in b-TC6 cells were examined by Western
blotting analysis. As presented in Fig. 5a–c, CAMFs increased
GLUT-2 and GLUT-4 protein levels in a dose-dependent manner
compared to control (nPo0.05 or nnPo0.01). In contrast, CAMFs
did not alter GLUT-1 protein level (Fig. 5a).
3.7. Acute oral and intraperitoneal toxicity study
The acute oral and i.p toxicity studies revealed CAMFs non-
toxic nature; no lethality or toxic reactions were observed at any
of the doses tested. Based on these ﬁndings, 100 mg/kg and
50 mg/kg doses were chosen as the maximum doses for further
experiments involving i.p and oral routes of administration,
respectively.
3.8. Effect of CAMFs on blood glucose levels of type 1 diabetic rats
Blood glucose levels were evaluated weekly in normal, CAMFs-
treated, and untreated diabetic rats, the outcomes of which are
listed in Table 2. The standard drug insulin (6 U/kg) produced
Fig. 3. (a) Fluorescence images of b-TC6 cells exposed to 10 mM 2-NBDG for 30 min revealing heterogeneous 2-NBDG uptake and metabolic activity. The cells were
imaged after a 10-min washout of 2-NBDG. (b) Glucose uptake in b-TC6 cells after 60-min exposure to 10 mM 2-NBDG and CAMFs. Signiﬁcant difference compared to
negative control (nnPo0.01 or nnnPo0.001).
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signiﬁcant decrease in blood glucose levels, compared to untreated
diabetic rats, starting from week 1 and produced maximal fall of
64.08% after end of the study period (4-week). While administra-
tion of 100 and 50 mg/kg of CAMFs demonstrated signiﬁcant
reduction in blood glucose levels at week-4 when compared with
untreated diabetic rats, and exhibited decreases of 23.21% and
21.05% after 4-week treatment period. The blood glucose levels of
normal rats were not changed, whereas in the untreated diabetic
rat blood glucose levels were signiﬁcantly and continuously ele-
vated, until end of the study period.
3.9. Effect of CAMFs on blood glucose levels of type 2 diabetic rats
The results of the weekly blood glucose evaluations in normal,
CAMFs-treated, and untreated diabetic rats are presented in
Table 3. The blood glucose levels of normal rats were not altered
until the end of the study period, while that in the untreated
diabetic rats were signiﬁcantly elevated. Oral administration of
100 and 50 mg/kg of CAMFs and 50 mg/kg of glibenclamide
produced a signiﬁcant reduction in blood glucose levels at weeks
1–4 when compared with untreated diabetic rats. In the ﬁnal
week of study period, 100 mg/kg of CAMFs produced the maximal
decrease of blood glucose level (51.40%) as compared to untreated
diabetic rats, and 50 mg/kg of CAMFs caused 46.47% decline,
whereas glibenclamide group achieved 50% drop in blood glucose
levels.
3.10. Effect of CAMFs on OGTT of type 2 diabetic rats
Result of OGTT is showed in Table 4. In diabetic rats, CAMFs at
100 and 50 mg/kg demonstrated a signiﬁcant reduction in blood
glucose levels after 60-min of glucose load, compared to
untreated diabetic rats. Similarly, after 90 min the blood glucose
levels were continuously reduced to 66.31% and 52.94% after
CAMFs treatment, whereas the glibenclamide-treated group
caused (60.96%) reduction, respectively. This was followed by a
reduction as great as 67.59% and 54.74% following the respective
CAMFs doses at 120 min, whereas glibenclamide showed 62.01%
markdown in the blood glucose levels.
3.11. Effect of CAMFs on insulin level and body weight of type 1 and
type 2 diabetic rats
Fig. 6a illustrates the insulin levels in the experimental
animals. In type 1 and type 2 groups, untreated diabetic rats
exhibited signiﬁcant reduction of insulin in the serum, compared
to the normal control rats. Upon daily treatment of standard
positive and 100 or 50 mg/kg bw of CAMFs to diabetic rats for
4 weeks, demonstrated signiﬁcant improvement in insulin levels
of type 2 diabetic rats as compared to untreated diabetic rats,
whereas type 1 diabetic rats did not produce any signiﬁcant sign
of improvement.
Moreover, we observed a signiﬁcant loss in the body weight of
untreated type 1 and type 2 diabetic rats, as compared to normal
control rats after 4 weeks of study period (Fig. 6b). While daily
intake of food and water was signiﬁcantly increased only in type
2 diabetic rats (Fig. S1a and S1b). Standard positive and CAMFs
treatment signiﬁcantly increased the body weight of type 2
diabetic rats compared to untreated diabetic rats. In contrast,
only 100 mg/kg of CAMFs resulted in elevation of body weight in
type 1 diabetic rats.
Fig. 4. Insulin release elicited by CAMFs in b-TC6 cells. The cells were incubated in
Krebs/HEPES buffer (pH 7.4) containing no glucose or 6.25, 12.5, or 25 mM glucose
in the absence or presence of CAMFs for 60 min at 37 1C.
Fig. 5. (a) Western blot analysis of GLUT-1, GLUT-2 and GLUT-4 expression in
control and CAMFs-treated samples. Membranes were stripped and reprobed with
b-actin. Histogram (b and c) denotes band intensity ratio of GLUT-2 and GLUT-4
after normalization with b-actin in non-treated b-TC6 cells.
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4. Discussion
Centratherum anthelminticum seeds are commonly used in India
to treat diabetes. The seed extracts are available in Ayurvedic
formulation for treating diabetes and various disorders. However,
the anti-diabetic potential and the mechanism of CAMFs have not
been thoroughly investigated. In the present study, we demon-
strated that CAMFs exhibited potential anti-diabetic effects on
pancreatic b-TC6 cells. Moreover, our in vivo results indicate that
CAMFs possess glibenclamide-like activities in type 2 diabetic rats
with lesser effects seen in type 1 diabetic rats.
Both MTT assays and RTCA results showed that CAMFs is not toxic
to b-TC6 cells at 50 mg/ml, which is in agreement with the in vivo
acute toxicity studies. We further investigated the effect of CAMFs on
glucose uptake and insulin secretion by b-TC6 cells. Our results
revealed that CAMFs dose-dependently stimulates glucose uptake
and enhances insulin secretion in b-TC6 cells. The ﬂuorescent glucose
analog 2-NBDG has been used to determine cell viability as well as to
estimate glucose uptake rates in a variety of cell types ( Poitout et al.,
1995; Yoshioka et al., 1996; Yamada et al., 2000; Leira et al., 2002;
Zou et al., 2005; Yamada et al., 2007). b-TC6 cell is a b cell derivative,
which can endocytose the glucose analog 2-NBDG as shown by
increasing intracellular ﬂuorescence in the cytoplasmic regions after
CAMFs treatment. In addition, we detected higher insulin secretion in
these cells, corresponding with enhanced 2-NBDG glucose uptake.
These observations on b-TC6 cell lines clearly establish the potent
ability of CAMFs in increasing insulin release and glucose uptake.
Following characterization of CAMFs effects in promoting glucose
uptake and insulin secretion, we studied the most crucial factor in
the insulin-signaling cascade, glucose transporter proteins, which
are essential transporters responsible for the translocation of
insulin-regulated glucose into the cells. Our results showed that
CAMFs treatment increased GLUT-2 and GLUT-4 protein expression
without any signiﬁcant changes in GLUT-1 protein level compared
with the control group. GLUT-4 is classically referred as ‘‘insulin-
responsive transporter’’ and increased GLUT-4 expression may result
in higher sensitivity to insulin which subsequently potentiates the
inﬂux of glucose into the cell (Suzuki and Kono, 1980; Slot et al.,
1991; Kraegen et al., 1993). Whereas GLUT-2 is a transmembrane
carrier protein mainly found in pancreatic b-cells. Increased GLUT-2
Table 2
Effects of CAMFs on fasting blood glucose level of type 1 diabetic rats.
Group Fasting blood glucose level (mmol/L)
Pretreatment week Treatment weeks
Week 0 Week 1 Week 2 Week 3 Week 4
Normal control 4.270.13 4.470.26 3.970.18 3.670.22 4.170.32
Diabetic control 23.871.19 25.671.41 27.571.24 28.771.77 32.372.69
Insulin (6 U/kg) 24.671.21 9.970.67a (61.32) 9.170.97a (66.90) 10.471.16a(63.76) 11.671.36a(64.08)
CAMFs (100 mg/kg) 24.97 0.94 23.871.08(7.03) 22.271.37(19.27) 23.171.08(19.51) 24.871.27a(23.21)
CAMFs (50 mg/kg) 25.27 0.67 23.370.88(8.98) 23.770.97(13.81) 24.671.21(14.28) 25.571.03a(21.05)
Values denote mean7SD, n¼6.
a Represents statistical signiﬁcance compared to diabetic control (Po0.05).
Values given in parenthesis represent percent decline in the blood glucose level in comparison with diabetic control group within the same week.
Table 3
Effects of CAMFs on fasting blood glucose level of type 2 diabetic rats.
Group Fasting blood glucose level (mmol/L)
Pretreatment week Treatment weeks
Week 0 Week 1 Week 2 Week 3 Week 4
Normal control 4.070.21 4.270.19 4.470.25 4.370.34 4.170.29
Diabetic control 11.870.57 12.170.91 12.971.04 13.771.17 14.271.37
Glibenclamide (50 mg/kg) 11.970.65 7.670.32a(37.19) 7.470.43a(42.63) 7.570.66a(45.25) 7.170.36a(50.00)
CAMFs (100 mg/kg) 12.270.56 7.870.44a(35.53) 7.770.51a(40.31) 7.370.33a(46.71) 6.970.49a(51.40)
CAMFs (50 mg/kg) 12.77 0.71 8.470.39a(30.57) 8.970.39a(31.00) 8.170.46a(40.87) 7.670.53a(46.47)
Values denote mean7SD, n¼6.
a Represents statistical signiﬁcance compared to diabetic control (Po0.05).
Values given in parenthesis represent percent decline in the blood glucose level in comparison with diabetic control group within the same week.
Table 4
Effects of CAMFs on fasting blood glucose level of type 2 diabetic rats after glucose load.
Group 0 min 30 min 60 min 90 min 120 min
Normal control 3.970.17 7.970.25 7.170.29 6.370.32 5.170.41
Diabetic control 15.370.52 22.270.64 19.270.4 18.770.53 17.970.35
Glibenclamide (50 mg/kg) 7.370.39 9.870.23a(55.85) 8.170.42a(57.81) 7.370.59a(60.96) 6.870.44a(62.01)
CAMFs (100 mg/kg) 6.870.26 9.570.37a(57.20) 7.370.31a(61.97) 6.370.28a(66.31) 5.870.48a(67.59)
CAMFs (50 mg/kg) 8.270.71 10.470.43a(53.15) 8.870.47a(54.16) 8.870.35a(52.94) 8.170.29a(54.74)
Values denote mean7SD, n¼6.
a Represents statistical signiﬁcance compared to diabetic control (P o0.05).
Values given in parenthesis represent percent decline in the blood glucose level in comparison with diabetic control group in that time period.
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expression is thought to play a constitutive role and responsible for
higher glucose uptake in b-cells (Hyo-Sup et al., 2008). In contrast,
loss of GLUT-2 may accompany the onset and contribute to the
pathogenesis of insulin-dependent (DM1) and non-insulin-
dependent diabetes mellitus (DM2) (Bjornholm and Zierath, 2005).
Thus, phytochemicals in CAMFs could stimulate insulin-signaling
cascade by upregulating GLUT-2 and GLUT-4 expression, leading to
increased glucose uptake in the pancreatic b-TC6 cells.
Based on these positive ﬁndings, we studied the anti-diabetic
potential of CAMFs in the management of type 1 or type 2 diabetic
rats. Daily administration of varying concentrations of CAMFs to both
groups of animals for 4 weeks produced differential reduction in the
blood glucose levels. We found that only type 2 diabetic rats
exhibited marked reduction of blood glucose, with less effect
observed in the type 1 diabetic rats. Although type 1 diabetic rats
displayed signiﬁcant reduction of blood glucose levels after second
week of treatment period, the overall percentage declined were less
signiﬁcant compared to type 2 diabetic rats. This was probably
caused by the severe destruction of pancreatic b-cells by STZ in type
1 diabetic rats as these rats had very low to non-detectable serum
insulin levels that were not signiﬁcantly improved upon treatment
with CAMFs. On the other hand, in the type 2 diabetic rats,
nicotinamide administration prior to STZ injectionmay have partially
protected b-cells by scavenging nitric oxide (NO) and rescued the b-
cells from STZ-induced apoptosis (Masiello et al., 1998). Thus, the
beneﬁcial effects of CAMFs treatment in type 2 diabetic rats was
likely due to improved insulin release and glucose uptake in remnant
b-cells. Moreover, elevated insulin secretion by CAMFs can promote
conversion of inactive glycogen synthetase to the active form, which
increases the conversion of blood glucose into glycogen by enhancing
the glycolytic and glycogenic processes with concomitant decrease in
glycogenolysis and gluconeogenesis (Mahomed and Ojewole, 2003;
Andrade-Cetto and Wiedenfeld, 2004).
In the present study, we observed signiﬁcant loss in the body
weight of type 1 and type 2 diabetic rats, a symptom synonymous
with diabetes mellitus (Pupim et al., 2005). The characteristic loss of
body weight associated with STZ-induced diabetes could be due to
dehydration and catabolism of fats or breakdown of tissue proteins,
which leads to wasting of muscle. CAMFs treated type 2 diabetic rats
exhibited comparable increases in body weight. This could be the
result of increased glucose uptake, insulin secretion and decreased
fasting blood glucose levels, indicating improved glycemic control in
the rats. Such ﬁndings of improvement in body weight amongst
diabetic animals are consistent with treatment of other medicinal
Fig. 6. Effects of CAMFs on insulin level and body weight of type 1 and type 2 diabetic rat models after 28 days (4 weeks) in comparison with diabetic and normal control
rats. At the end of the treatment, rats were fasted for 12 h and blood was drawn to collect the serum for insulin measurement. Panel denotes (a) serum insulin and
(b) whole body weight. The data are presented as means7SD (n¼6). $Signiﬁcant difference compared to the normal control group (Po0.05). nSigniﬁcant difference
compared to the diabetic control (Po0.05).
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plants reported to have potential anti-diabetic effects (Pari and
Saravanan, 2004; Nagarajan et al., 2005).
In this study, we have scientiﬁcally veriﬁed the traditional basis
for the use of C. anthelminticum seeds in diabetes mellitus. The anti-
diabetic potential of CAMFs may be attributed to the polyphenolic
constituents as identiﬁed by LCMS-MS including quercetin
glycoside, 3,4-O-dicaffeoylquinic acid, caffeic acid, naringenin-7-O-
glucoside and kaempferol. These dietary polyphenols possess wide
therapeutic beneﬁts and many researchers have demonstrated the
anti-diabetic, anti-oxidant, and anti-inﬂammatory activities with
these compounds (Jung et al., 2006; Ortiz-Andrade et al., 2007; Shih
et al., 2012). In addition, decanoic and pentadecanoic acid which are
characterized by GC–MS with high similarity index in CAMFs have
previously been shown as potential modulating ligands for peroxi-
some proliferator-activated receptors (PPARs) (Malapaka et al.,
2012). Thus, combination of these compounds in CAMFs may exert
synergistic anti-diabetic effects in the type 2 diabetic rats.
5. Conclusions
In summary, the present ﬁndings suggest that the anti-diabetic
effects of CAMFs may be due to the enhancement of 2-NBDG glucose
uptake, stimulation of insulin secretion and inducing higher GLUT-2
and GLUT-4 transporter protein expression in b-TC6 cells. These
observations were corroborated by the beneﬁcial effects of CAMFs in
attenuating hyperglycemia and augmenting insulin secretion in type
2 diabetic rat model. These ﬁndings supports the use of CAMFs as a
potential adjunct dietary treatment of insulin-resistant type 2
diabetes and a potential source for the discovery of new orally
active agent(s) for future therapy of diabetes.
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a b s t r a c t
This study aimed to ascertain the potential of Centratherum anthelminticum seeds methanolic fraction
(CAMFs) for the management of type 2 diabetes and its associated complications. CAMFs was initially
tested on b-TC6 cells for H2O2-induced nuclear factor-jB (NF-jB) translocation effects. The result dis-
played that CAMFs signiﬁcantly inhibited NF-jB translocation from cytoplasm into the nucleus, dose-
dependently. Furthermore, a 12-week sub-chronic CAMFs study was carried out on streptozotocin
(STZ)-nicotinamide–induced type 2 diabetic rat model to evaluate glycemia, essential biochemical
parameters, lipid levels, oxidative stress markers, and pro-inﬂammatory cytokines level. Our study result
showed that CAMFs reduced hyperglycemia by increasing serum insulin, C-peptide, total protein, and
albumin levels, signiﬁcantly. Whereas, elevated blood glucose, glycated hemoglobin, lipids and enzyme
activities were restored to near normal. CAMFs conﬁrmed antioxidant potential by elevating glutathione
(GSH) and reducing malondialdehyde (MDA) levels in diabetic rats. Interestingly, CAMFs down-regulated
elevated tumor necrosis factor a (TNF-a), interleukin (IL)-1b and IL-6 in the tissues and serum of the
diabetic rats. We conclude that CAMFs exerted apparent antidiabetic effects and demonstrated as a
valuable candidate nutraceutical for insulin-resistant type 2 diabetes and its associated complications
such as dyslipidemia, oxidative stress, and inﬂammation.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Despite the great strides that have been made in the under-
standing and management of diabetes, the incidence of the disease
and its complications are increasing unabated. A combination of
insulin resistance and an inadequate compensatory insulin secre-
tory response accounts for non–insulin-dependent type 2 diabetes
mellitus (DM2). It is the most prevalent disease in the world,
affecting 7% of the population, or 285 million people worldwide.
If untreated, DM2 may lead to insulin-dependent type 1 diabetes.
Clinical, preclinical, and epidemiological studies indicate an
association between oxidative stress and inﬂammation in the
development of DM2 and its complications (Zozulinska and
Wierusz-Wysocka, 2006). In DM2, production of reactive oxygen
species (ROS) is increased due to insulin resistance and hypergly-
cemia (Brownlee, 2001). Compared to healthy subjects, DM2
patients have a lower ratio of reduced glutathione (GSH) to
oxidized glutathione (GSSG), a major endogenous antioxidant. In
contrast, malondialdehyde (MDA), a highly toxic by-product gen-
erated partially by lipid oxidation and ROS, is increased in patients
with diabetes (Evans, 2007). The generated ROS create oxidative
stress and exert major effects on signaling pathways, which further
affect cellular metabolism and trigger a low-grade inﬂammatory
reaction (Dominiczak, 2003). Lipid accumulation in adipose tissue
and expansion of the fat mass in the liver initiate steatosis that
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promotes low-grade inﬂammation via activation of nuclear factor-
jB (NF-jB) (Arkan et al., 2005) and provokes an inﬂammatory
process accompanied by local production and secretion of pro-
inﬂammatory cytokines and chemokines (Hotamisligil et al.,
1995; Jager et al., 2007). It has been hypothesized that DM2 is a
manifestation of an ongoing acute-phase response that is primarily
characterized by alterations of the so-called acute-phase proteins,
such as C-reactive protein (CRP) (Pickup and Crook, 1998; Pickup
et al., 1997), with other cytokines that are central mediators of
inﬂammatory reactions, such as interleukin (IL) 6, IL-1b, or tumor
necrosis factor a (TNF-a). It is well established that cytokines
operate as a network in stimulating the production of acute-phase
proteins. For example, the effects of IL-6 on CRP synthesis largely
depend on its interaction with IL-1b (Joachim, 2003). The pro-
inﬂammatory cytokine TNF-a reduces insulin sensitivity in muscle
tissue and stimulates hepatic lipogenesis and hyperlipidemia
(Franckhauser et al., 2008). However, it appears that treatments
aimed at reducing the degree of oxidative stress and the produc-
tion of pro-inﬂammatory cytokines in DM2 is warranted.
Centratherum anthelminticum (L.) Kuntze (bitter cumin) is a
member of the Asteraceae family, an important plant of great sig-
niﬁcance and usage in Ayurvedic medicine. The records from tradi-
tional healers and ethno-botanists state that it is useful in
alleviating diabetes. Experimental studies have proven the phar-
macological potential of this plant in diverse biological activities,
some of which are anti-diabetic, anti-cancer with anti-oxidant
and anti-inﬂammatory activity (Ani and Naidu, 2008; Fatima
et al., 2010; Arya et al., 2012a,b,c). Nevertheless, researchers have
yet to investigate the hypoglycemic action of sub-chronic adminis-
tration of C. anthelminticum seeds defatted crude methanolic frac-
tion (CAMFs) or the plant’s other healing properties, some of which
might act against other inﬂammatory processes and oxidative
stress associated with DM2.
Therefore, we attempted to gain a better understanding of the
effect of CAMFs on ROS-induced oxidative stress associated with
insulin resistance signaling pathway in H2O2-induced NF-jB acti-
vation on mouse pancreatic b-TC6 cells. Subsequently, we carried
out in vivo studies to determine whether long-term administration
of CAMFs for 12-weeks exerts anti-hyperglycemic, anti-hyperlipi-
demic, anti-oxidant, and inﬂammatory cytokines inhibitory effects
in STZ-nicotinamide–induced type 2 diabetic rats.
2. Materials and methods
2.1. Preparation of CAMFs
2.1.1. Collection of plant material
Dried C. anthelminticum seeds were procured from the medicinal plant cultiva-
tion zone of Amritum Bio-Botanica Herbs Research Laboratory Pvt. Ltd., (Madhya
Pradesh, India) in April 2008. The seeds were botanically classiﬁed and authenti-
cated by the company’s quality control department. Voucher specimens (CA-9)
were deposited with the company and with the Department of Pharmacology in
the Faculty of Medicine at the University of Malaya.
2.1.2. Extraction and fractionation
Two kilogram of seeds were coarsely powdered and ﬁrst extracted with 100% n-
hexane using hot extraction with a Soxhlet extractor for 24 h. Further fractionation
of the obtained defatted residue was carried out using 100% chloroform, and lastly
with 100% (absolute) methanol. The solvents from each crude fractions were dried
by rotary evaporation under reduced pressure at a maximal temperature of 40 C.
The ﬁnal fraction was then freeze-dried to yield a crude methanolic fraction (CAM-
Fs), that was stored at 20 C until further use. Thereafter, CAMFs was subjected to
mass spectometry analysis by using LCMS–MS, for the qualitative analysis of major
compounds, as well as evaluated for the total phenolic and ﬂavonoid contents.
2.1.3. Phytochemical analysis of CAMFs by LCMS–MS
Phytochemical analysis of the major compounds in CAMFs was carried out with
liquid chromatography–tandem mass spectrometry (LCMS–MS). A triple quadru-
pole mass spectrometer equipped with a turbo ion spray source (AB Sciex QTrap
5500, Ontario, Canada) was used to obtain the MS/MS data in negative ion mode.
The mobile phase consists of 0.1% formic acid in water and 0.1% formic acid in
acetonitrile (ACN), were eluted by gradient elution at a ﬂow rate of 0.4 mL/min with
an injection volume of 20 lL. Separation of the compounds was performed using a
Luna 3-lm RP C18 column (100  2.00 mm; Phenomenex). The turbo ion source
settings were as follows: capillary voltage, 4000 V; dry gas ﬂow (N2), 9 L/min;
nebulizer pressure, 35 psi; and capillary temperature, 365 C. A full scan of the mass
spectra was recorded from m/z 50 to m/z 1000. The acquisition data was processed
with Analyst Software version 1.5.1. Compounds were characterized based on their
UV spectra and MS2 and MS3 fragmentations spectra data by correlation with
previous reports (Table 1). Whereas, compounds F, G, H, I and J in the table are
unknown compounds.
2.1.4. Determination of total phenolic content
The total phenolic content in CAMFs was determined by adapting the method as
published in our previous article (Arya et al., 2012a,b). In brief, CAMFs was initially
prepared in methanol with concentration of 10 mg/mL. From this solution 5 lL was
transferred to 96-well mircoplate (TPP, USA). To this, 80 lL of Folin–Ciocalteu re-
agent (1:10) were added and mixed thoroughly. After 5 min, 160 lL of sodium
bicarbonate solution (NaHCO3 7.5%) were added and the mixture was allowed to
stand for 30 min with intermittent shaking. Absorbance was measured at 765 nm
using microplate reader (Molecular Devices, Sunnyvale, USA). The TPC was ex-
pressed as gallic acid equivalent (GAE) in mg/g fraction, obtained from the standard
curve of gallic acid.
The gallic acid standard curve was established by plotting concentration (mg/
mL) versus absorbance (nm) (y = 0.001x + 0.045; R2 = 0.9975), where y is absor-
bance and x is concentration in GAE (n = 3).
2.1.5. Determination of total ﬂavonoid content
The total ﬂavonoid content in CAMFs was determined by following the method
published in our previous article (Arya et al., 2012a,b). In brief, 5 mL of 2% alumi-
num trichloride was mixed with the same volume of CAMFs. Absorbance readings
at 415 nm were taken after 10 min against a blank sample consisting of 5 mL of
sample solution and 5 mL of methanol without aluminum trichloride. The total ﬂa-
vonoid content was determined using a standard curve of mg Quercetin (Q) equiv-
alents. The average of three readings was used and then expressed as quercetin
equivalents (QE) on a dry weight (DW) basis.
2.2. In vitro assay
2.2.1. Cell culture
Mouse pancreas b-TC6 cells were purchased from American Type Culture Col-
lection (ATCC, Manassas, VA, USA) and cultured in 15% fetal bovine serum (FBS)
in Dulbecco’s Modiﬁed Eagle Medium (DMEM). Cultures were maintained at
37 C in 5% CO2 in a humidiﬁed incubator. The growth medium was changed every
3 days.
2.2.2. NF-jB translocation assay
We seeded 1.5  104 cells/mL onto a 96-well plate. The cells were pre-treated
for 1 h with 6.25, 12.5, or 25 lg/mL CAMFs, or were left untreated. The cells were
then stimulated for NF-jB translocation with 50 lM of H2O2 for 30 min. NF-jB
staining was performed according to the manufacturer’s instructions with an NF-
jB activation kit (Cellomics Inc., Pittsburgh, PA, USA). We used the ArrayScan high
content screening (HCS) system (Cellomics Inc., Pittsburgh, PA, USA) to quantify the
difference between the intensity of nuclear and cytoplasmic NF-jB–associated
ﬂuorescence.
2.3. Preclinical studies
2.3.1. Experimental animals
We obtained Sprague–Dawley rats weighing 180–200 g from the Animal Care
Unit of the University Malaya Medical Centre (Kuala Lumpur, Malaysia) and main-
tained them under pathogen-free conditions in the animal housing unit in a tem-
perature (23 ± 2 C) and light-controlled (12-h light/dark cycle) room with 35–
60% humidity. The animals were acclimatized for 10 days prior to the experiments
and were provided rodent chow and water ad libitum.
The animal experiments were performed in accordance with the guidelines for
animal experimentation issued by the Animal Care and Use Committee at the Uni-
versity of Malaya (Ethics Number: FAR/10/11/2008/AA[R]) and was conducted in
accordance with internationally accepted principles for laboratory animal use and
care.
2.3.2. Oral acute toxicity studies
CAMFs oral acute toxicity tests were carried out according to the guidelines of
the Organization for Economic Co-operation and Development (OECD). For these
test, we used healthy adult Sprague Dawley rats of either sex (180–200 g). These
rats were fasted overnight, divided into 6 groups (n = 6), and orally fed with CAMFs
in doses of 10, 20, 50, 100 and 500 mg/kg; the control group was given distilled
water. We observed the rats for 1 h continuously and then hourly for 4 h for any
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changes in the blood glucose levels and ﬁnally after every 24 h up to 14 days for any
physical signs of toxicity, such as writhing, gasping, palpitation and decreased
respiratory rate or for any lethality.
2.3.3. Induction of DM2
DM2 was induced by following the methods of Masiello et al. (1998) with slight
modiﬁcations. In brief, after standardization of STZ (Sigma-Aldrich, St. Louis, MO,
USA) doses, single intraperitoneal injection of freshly prepared STZ (55 mg/kg b.wt)
in 0.1 M citrate buffer (pH 4.5) in a volume of 1 ml/kg b.wt was injected to overnight
fasted normal male rats, 15min after i.p administration of nicotinamide (210mg/kg).
Hyperglycemia was conﬁrmed by elevated blood glucose levels, determined at 96 h
after the STZ-nicotinamide administration. Rats with fasting blood glucose range of
11–14 mmol/L were considered as type 2 diabetic and further used for the study.
2.3.4. Experimental procedure
The rats were divided into the following 6 groups (9 or 10 rats per group):
normal control rats, diabetic control rats, diabetic rats treated with 50 mg/kg bw
of glibenclamide (a standard drug), and diabetic rats treated with 50, 25, and
10 mg/kg bw of CAMFs, respectively. All groups were fed their respective doses of
CAMFs or glibenclamide once daily for 12 weeks. After the 12-week treatment per-
iod, all 6 groups were fasted for 12 h and then anesthetized using pentobarbital; the
blood was collected into heparinized tubes. Any residual blood was removed by
perfusion using phosphate-buffered saline (PBS; pH 7.4) through the abdominal
aorta. The blood was centrifuged at 2000 rpm for 10 min and the serum was
collected and stored at 80 C until analysis. The liver, kidney, and pancreas were
removed, washed in ice-cold isotonic saline, and blotted individually on ash-free
ﬁlter paper; the organs were weighed and tissues were collected and ﬁxed in 10%
formalin for histology and markers estimation. Tissues were then homogenized in
ice-cold 5% metaphosphoric acid or PBS (pH 7.4). The homogenates collected were
used for the enzyme estimations before being centrifuged at 4500 rpm for 30 min at
4 C, and the supernatant was collected for the analysis of oxidative stress markers
and pro-inﬂammatory cytokines.
2.3.5. Assessment of biochemical parameters
Glycemia in fasted animals with free access to water was quantiﬁed weekly
from tail vein blood using a standardized glucometer (Accu-Chek; Roche, Mann-
heim, Germany) until the end of the treatment period, as well as intake of food
was also monitored on daily basis. Serum insulin and C-peptide levels were mea-
sured using a radioimmunoassay kit (Packard, USA) according to the manufacturer
protocol. Glycated hemoglobin (HbA1c) was estimated by a DCA 2000 device
(Bayer, Sunnyvale, CA, USA). Serum total protein, albumin and lipids, i.e., triglycer-
ides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), and free fatty acid (FFA) levels were mea-
sured in triplicate using an automatic biochemical analyzer (Beckman-700, Fuller-
ton, CA, USA). The aspartate transaminase (AST), alanine transaminase (ALT),
alkaline phosphatase (ALP), and c-glutamyl transpeptidase (c-GT) enzymes in ser-
um and in liver and kidney tissues were analyzed according to the method in King
and Armstrong (1988), and Rosalki and Rau (1972).
2.3.6. Assessment of oxidative stress markers
The supernatants collected after centrifugation of the liver, kidney, and pan-
creas homogenates were used to determine the GSH and MDA levels. GSH was mea-
sured as described in Draper and Hadley (1990) using 5,5 ı-dithiobis-2-nitrobenzoic
acid (DTNB, Ellman’s reagent), which produces a yellow-colored 5-thio-2-nitroben-
zoic acid (TNB). The absorbance of TNB at 412 nm provides an accurate estimation
of the level of GSH in a sample. A lipid peroxidation assay was used to determine
the amount of MDA, an end product of fatty acid peroxidation that reacts with thio-
barbituric acid to form a colored complex with a maximum absorbance at 532 nm,
as stated in Shain and Gusmuslu (2007).
2.3.7. Assessment of pro-inﬂammatory cytokines
Serum and the supernatant collected after centrifugation of the pancreas and
kidney homogenates were used for the measurement of TNF-a, IL-1b, and IL-6 lev-
els with a rat TNF-a, IL-1b, and IL-6 ELISA kit (eBioscience, San Diego, CA, USA)
according to the manufacturer protocol.
2.4. Statistical analysis
All values are expressed as mean ± standard deviation (SD). The signiﬁcant dif-
ferences between the means of the experimental groups was determined with anal-
ysis of variance (ANOVA), followed by a Tukey–Kramer multiple comparisons test
(Graph Pad version 5.0; Graph Pad Software Inc., San Diego, CA, USA).
3. Results
3.1. Total phenolic and ﬂavonoid contents in CAMFs
The ﬁnal yield of the obtained CAMFs was 12.6% w/w. The total
phenolic and ﬂavonoid contents in CAMFs was determined to be
(665.3 ± 188.8 mg GAE/g, and 98.2 ± 27.6 mg Quercetin/g).
3.2. CAMFs analysis by LCMS–MS
The LCMS–MS phytochemical analysis detected quercetin gly-
coside, 3,4–0-dicaffeoylquinic acid, caffeic acid, naringenin-7-O
glucoside and kaempferol as the major compounds in CAMFs, as
well as with other unknown compounds (Table 1 and Fig. 1). The
fragmentation patterns of known compounds were in agreement
with those documented in the literatures as reported in our other
study (Arya et al., 2012c).
3.3. Effect of CAMFs on NF-jB activation
We tested CAMFs for its in vitro inhibitory effects against H2O2-
induced NF-jB translocation. NF-jB was detected in the cyto-
plasm, but not in the nucleus of non-H2O2–induced cells. There
was a signiﬁcant increase in NF-jB staining in the nucleus area
when cells were stimulated with H2O2 alone, suggesting that NF-
jB translocated from the cytoplasm into the nucleus. However,
treatment with 25 lg/mL CAMFs signiﬁcantly inhibited H2O2-
induced NF-jB translocation (Fig. 2).
3.4. Acute toxicity study
No lethality or toxic reactions were observed at any graded
doses of CAMFs up to a dosage of 500 mg/kg. Hence, produced no
alterations in the blood glucose levels, and on the general behavior
or appearance of the rats during the whole experimental period.
Based on these ﬁndings, the concentration was ﬁxed as 50, 25
and 10 mg/kg bw; which were used as the maximum doses for
Table 1
Characterization of phenolic compounds in CAMFs by LC–MS/MS.
Tentative compounds [M–H](m/z) Major fragment ions (m/z) UV kmax (nm) References
A Quercetin glycoside
C21H20O12
463 301, 287, 271 220, 300 Lin and Harnly (2007)
B 3,4–0-Dicaffeoylquinic acid
C25H24O12
515 353, 191, 179, 135 240, 300 Gouveia and Castilho (2011) and Lin and Harnly (2008)
C Caffeic acid
C9H8O4
179 135 220, 325 Luo et al. (2003), Lin and Harnly (2008) and Plazonic et al., 2011
D Naringenin-7–0-glucoside
C21H22O10
433 271, 153 200, 300 Charrouf et al., (2007)
E Kaempferol
C15H10O6
287 287, 151 220, 340 Sun et al. (2007)
F Unknown 377 253, 215, 135 200,300 –
G Unknown 303 181, 167, 135 220,300 –
H Unknown 341 303, 167, 135 200,300 –
I Unknown 539 503, 377, 221 200,300 –
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the subsequent experiments involving oral administration as re-
ported in our other study on CAMFs (Arya et al., 2012c).
3.5. Effect of CAMFs on blood glucose levels
From the ﬁrst day up until the end of the 12-week treatment
period, monitoring of the rats’ fasting blood glucose levels revealed
a signiﬁcant reduction in the elevated blood glucose levels of
diabetic rats treated with CAMFs compared to that of untreated
diabetic rats (Table 2). At weeks 3 and 6, the inhibition percentage
of blood glucose levels in CAMFs-treated diabetic rats was lower
compared to that of glibenclamide-treated diabetic rats. At weeks
9 and 12, the percentage inhibition in rats treated with a higher
concentration of CAMFs was greater than that in glibenclamide-
treated rats. At the end of the treatment period, the percentage
inhibition effected by 50, 25, and 10 mg/kg bw CAMFs was
Fig. 1. (A) The mass spectrometric characterization of compound A indicates the presence of quercetin glycosides. (B) The fragmentation pattern of compound B displays an
ion peak at m/z 515, indicating the loss of the ﬁrst caffeoyl, loss of the second caffeoyl at m/z 353, and loss of the third caffeoyl at m/z 191 to yield quinic acid, a loss of caffeic
acid atm/z 179, and another caffeoyl atm/z 135. Thus, the compound was characterized as 3,4–0-dicaffeoylquinic acid. (C) Compound C exhibits fragment ions atm/z 179 and
m/z 135, the characteristic ions of caffeic acid. (D) Compound D was identiﬁed as naringenin-7–0-glucoside based on mass fragment ions at m/z 433 and at m/z 271 and 153.
(E) Compound E was identiﬁed as kaempferol based on mass fragments at m/z 287 and m/z 151.
4212 A. Arya et al. / Food and Chemical Toxicology 50 (2012) 4209–4220
75.86%, 69.82%, and 65.08%, respectively, compared to that of gli-
benclamide (68.53%). The blood glucose levels of normal rats were
not greatly altered after week 12 when compared to that of week 0,
whereas that of the untreated diabetic rats increased to
23.2 mmol/L after 12 weeks as compared to 12.3 mmol/L at week 0.
3.6. Effect of CAMFs on serum biochemical parameters
After the 12-week treatment period, serum insulin, C-peptide,
total protein, and albumin levels in diabetic untreated rats were
signiﬁcantly reduced, while their HbA1c levels were signiﬁcantly
elevated compared to that of the normal control group. Upon treat-
ment with CAMFs or glibenclamide, serum insulin, C-peptide, total
protein, and albumin levels in diabetic rats were signiﬁcantly ele-
vated, and CAMFs signiﬁcantly inhibited HbA1c levels in a dose-
dependent manner compared to that of the diabetic control rats
(Fig. 3), indicating signiﬁcant improvement in glycemic control
by CAMFs in diabetic rats.
In addition, there was a signiﬁcant improvement in the overall
body weights of CAMFs-treated diabetic rats compared to
untreated diabetic rats at the end of the treatment period, and
we recorded weight recovery in the liver and kidney. Whereas
Fig. 1. (continued)
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there was a signiﬁcant reduction in the daily consumption of food
by diabetic treated rats (Fig. 4).
3.7. Effect of CAMFs on hyperlipidemia
Fig. 5 depicts the effect of CAMFs and glibenclamide on serum
TG, TC, HDL-C, LDL-C, and FFA activity in treated and untreated dia-
betic rats and in normal control rats. Serum TG, TC, LDL-C, and FFA
levels in untreated diabetic rats were signiﬁcantly elevated when
compared to that of normal control rats, while the HDL-C levels
in untreated diabetic rats were signiﬁcantly decreased compared
to those in normal rats.
Serum TG, TC, LDL-C, and FFA levels were signiﬁcantly reduced
after treatment with glibenclamide and CAMFs; CAMFs effected a
dose-dependent reduction, and HDL-C levels were signiﬁcantly ele-
vated compared to that of untreated diabetic rats after the 12-week
treatment period. Evidently, continuous treatment with CAMFs de-
creased these lipid parameters in diabetic rats to near normal levels.
3.8. Effect of CAMFs on enzyme markers
Table 3 illustrates the effects of CAMFs on AST, ALT, ALP, and c-
GT enzyme activities in the serum, liver, and kidney of treated and
untreated diabetic rats and in that of normal rats. The enzyme
activities in the serum and liver of the untreated diabetic rats were
signiﬁcantly increased; ALP and c-GT activities in the kidney were
increased, while AST and ALT activities were not affected. Near-nor-
malization of the AST, ALT, ALP, and c-GT activities in the serum,
liver, and kidney of diabetic rats was achieved after 12-week
administration of glibenclamide and CAMFs; CAMFs effected
normalization dose-dependently.
3.9. Effect of CAMFs on oxidative stress markers
GSH levels in untreated diabetic rats were reduced while MDA
levels were signiﬁcantly elevated compared to that of normal
control rats (Fig. 6). Compared to untreated diabetic rats, GSH levels
in the liver and pancreas of diabetic rats were signiﬁcantly elevated
upon administration of glibenclamide and CAMFs; CAMFs effected
elevation dose-dependently, although not much change was ob-
served in kidney GSH levels. There was maximum reduction of
MDA levels in the liver of diabetic rats treated with glibenclamide
and CAMFs compared to that of untreated diabetic control rats;
reduction was effected dose-dependently by CAMFs, while there
was a signiﬁcant reduction of MDA in the pancreas following
administration of glibenclamide and 50 mg/kg bw CAMFs. In the
kidney, only glibenclamide suppressed MDA levels signiﬁcantly,
with CAMFs effecting a slight reduction in a dose-dependent
manner.
3.10. Effect of CAMFs on pro-inﬂammatory cytokines level
The levels of pro-inﬂammatory cytokines TNF-a, IL-1b, and IL-6
in the pancreas, kidney, and serum of diabetic untreated rats were
signiﬁcantly elevated compared to that of normal control rats
(Fig. 7). Compared to untreated diabetic rats, the levels of TNF-a
in the pancreas, kidney and serum of diabetic rats were signiﬁ-
cantly down-regulated by daily administration of glibenclamide
and CAMFs after the 12-week period; CAMFs down-regulated these
parameters dose-dependently. In the same manner, glibenclamide
and CAMFs signiﬁcantly reduced the IL-1b and IL-6 levels in the
pancreas, with non-signiﬁcant reduction being observed in the kid-
ney and serum after the 12-week study period.
4. Discussion
In an effort to uncover novel and effective treatment from
plants traditionally used in India for the management of diabetes
mellitus and its associated complications, we evaluated the hypo-
glycemic effects of a number of plants in an in vivo experiment and
selected the most potent plant, C. anthelminticum, (Arya et al.,
2012c) whose seed yields a crude fraction that exerts maximum
glycemic control. To the best of our knowledge, this is the ﬁrst
Fig. 1. (continued)
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in vitro cell–based and in vivo preclinical study on the crude meth-
anolic fraction of the seed (CAMFs), which demonstrated great
therapeutic utility in the management of complications associated
with type 2 diabetes.
We evaluated the effects of CAMFs in an animal model of insulin
resistance, STZ-nicotinamide–induced DM2, which produces
greatly similar features to DM2 in rats (Like and Rossini, 1976;
Shima et al., 1998). Daily administration of varying concentrations
Fig. 2. Stained b-TC6 cells were treated with different concentrations of CAMFs for 1 h and stimulated for 30 min with 50 lM H2O2 (NF-jB activation). (A) Dose–response
histogram of CAMFs-treated b-TC6 cells for quantitative image analysis of NF-jB translocation. (B) Representative images of control, H2O2, and H2O2 pre-treated cells treated
with 25.0 lg/mL CAMFs. $Signiﬁcant difference compared to non-H2O2–treated cells (P < 0.05). ⁄Signiﬁcant difference compared to H2O2-treated cells (P < 0.05).
Table 2
Effects of CAMFs and glibenclamide on blood glucose levels of normal, diabetic control, and diabetic treated rats.
Group Fasting blood glucose level (mmol/L)
Pretreatment period Treatment period
Week 0 Week 3 Week 6 Week 9 Week 12
Normal control 3.9 ± 0.23 3.4 ± 0.26 4.2 ± 0.32 4.1 ± 0.39 4.6 ± 0.37
Diabetic control 12.3 ± 0.44 14.9 ± 0.64 17.8 ± 0.89 19.9 ± 1.09 23.2 ± 2.03
Glibenclamide (50 mg/kg) 12.2 ± 0.65 6.9 ± 0.33a (53.69) 6.6 ± 0.48a (62.92) 7.0 ± 0.76a (64.82) 7.3 ± 0.79a (68.53)
CAMFs (50 mg/kg) 11.9 ± 0.53 7.8 ± 0.34ª (47.65) 6.7 ± 0.32a (62.35) 6.2 ± 0.48a (68.84) 5.6 ± 0.46a (75.86)
CAMFs (25 mg/kg) 12.1 ± 0.46 8.8 ± 0.65a (40.93) 7.5 ± 0.47a (57.85) 7.1 ± 0.65a (64.32) 7.0 ± 0.57a (69.82)
CAMFs (10 mg/kg) 12.3 ± 0.51 9.8 ± 0.43a (34.22) 8.7 ± 0.77a (51.12) 8.9 ± 0.70a (55.27) 8.1 ± 0.83a (65.08)
Values denote mean ± SD, n = 9–10.
Values in parentheses denote that group’s percentage decrease in blood glucose level when compared to the diabetic control group in that week.
a Mean values that are signiﬁcantly different from diabetic control group as revealed by the Tukey–Kramer multiple comparisons test (P < 0.05).
A. Arya et al. / Food and Chemical Toxicology 50 (2012) 4209–4220 4215
of CAMFs to diabetic rats for 12 weeks signiﬁcantly reduced blood
glucose levels, thereby increased insulin and C-peptide levels. Ele-
vated insulin levels in diabetics usually normalize the serum and
tissue proteins by increasing protein synthesis, decreasing protein
degradation or protein glycosylation, supporting our study (Almdal
and Vilstrup, 1988). In addition, we observed a reduction in HbA1c
level. High HbA1c level has been linked to micro- and macrovascu-
lar diabetes complications (Selvin et al., 2004), while decline in
HbA1c level reduced morbidity and mortality (Wagner et al.,
2001). The recovery of body and organ weights observed in the
CAMFs-treated diabetic rats could be due to an improvement in
insulin secretion and glycemic control produced by CAMFs. In line
with the normalized serum lipid levels, CAMFs restored elevated
levels of the enzyme markers AST, ALT, ALP, and c-GT to normal
in the serum, liver, and kidney of diabetic rats. This suggests that
CAMFs can be helpful in preventing hepatocellular damage and tis-
sue necrosis through suppression of gluconeogenesis.
Furthermore, we studied the role of ROS in the development of
DM2 by activating stress signaling pathways known to participate
in insulin signaling pathways, such as the ROS-induced NF-jB
activation pathway (Bierhaus et al., 2001; Mohamed et al., 1999;
Schreck et al., 1992). Our study result demonstrated that CAMFs
inhibited the H2O2-induced NF-jB translocation from the cyto-
plasm into the nucleus in b-TC6 cells (Fig. 2). Moreover, in line with
the inhibitory effects of NF-jB translocation, we conﬁrmed antiox-
idant effects by investigating oxidative stress markers, i.e., GSH and
MDA levels in CAMFs treated and untreated diabetic rats, which
showed that CAMFs dose-dependently augmented GSH production
in the pancreas, kidney, and liver of diabetic rats, with reduction
caused in MDA levels, suggesting CAMFs antioxidant ability. It is
well established thatGSH is an intracellular antioxidantwith several
biological functions, such as cellular protection against oxidation,
which is one of the more important GSH functions because its sulf-
hydryl (SH) group is a strong nucleophile that confers antioxidant
protection and protects DNA, proteins, and other biomolecules from
ROS (Fang et al., 2002). In this regard, an increased level of GSH
implicates augmentation of the antioxidant capacity and reduced
peroxidation of membrane lipids, whose principal end product is
MDA, which is a marker of damage caused by oxidative stress
(Johansen et al., 2005; Pastore et al., 2003). However, we should
not disregard the fact that the antioxidant potential of CAMFs may
be, in part, a result of the reduction in hyperglycemia and elevated
pro-inﬂammatory cytokines levels as observed in the diabetic rats.
As we know, DM2 is linked with oxidative stress resulting from
free radicals/ROS. ROS act as intercellular second messengers
downstream of many signaling molecules, including transcription
factors (NF-jB), which mediate vascular smooth muscle cell
(SMc) growth/migration and the expression of pro-inﬂammatory
cytokines such as TNF-a, IL-1b, and IL-6 (Reuter et al., 2010; Touyz,
2004).These elevated pro-inﬂammatory cytokines possess antago-
nistic properties to insulin because of their ability to augment insu-
lin receptor substrate (IRS) phosphorylation, leading to insulin
resistance (Emanuelli et al., 2000; Senn et al., 2003; Steinberg,
2007; Tataranni and Ortega, 2005). Therefore, inhibition of H2O2-
induced NF-jB translocation in b-TC6 cells and ameliorating
oxidative stress in diabetic rats explains an associative relationship
between the inﬂammatory cytokines and type 2 diabetes, as shown
by our study results on the elevated levels of TNF-a, IL-1b, and IL-6
Fig. 3. Effects of CAMFs on serum biochemical parameters of STZ-nicotinamide–induced diabetic rats in comparison with normal and diabetic control rats after the 12-week
treatment period. At the end of the treatment, rats were fasted for 12 h and blood was drawn to collect the serum. Panels denote (A) insulin, (B) C-peptide, (C) HbA1c, and (D)
total protein and albumin levels. Data are presented as means ± SD (n = 9–10). $Signiﬁcant difference compared to normal control group (P < 0.05). ⁄Signiﬁcant difference
compared to diabetic control (P < 0.05).
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in the serum and tissues of CAMFs treated diabetic rats, suggesting
beneﬁcial anti-inﬂammatory effect of CAMFs on inulin resistance
in DM2.
Taken together, our data indicate that 50 mg/kg bw of CAMFs
possessed effects that were highly similar to the same dose of
glibenclamide. Interestingly, this might be due to the presence of
Fig. 4. Effects of CAMFs on (A) whole body weight (B) weight of liver and kidney and (C) daily food intake of STZ-nicotinamide–induced diabetic rats after 12 weeks in
comparison with normal and diabetic control rats. Data are presented as means ± SD (n = 9–10). $Signiﬁcant difference compared to normal control group (P < 0.05).
⁄Signiﬁcant difference compared to diabetic control (P < 0.05).
Fig. 5. Effects of CAMFs on serum lipid proﬁles of STZ-nicotinamide–induced diabetic rats in comparison with normal and diabetic control rats after the 12-week treatment
period. At the end of the treatment, rats were fasted for 12 h and blood was drawn to collect the serum. Figure represents TG, TC, HDL-C, LDL-C, and FFA levels in 6 groups.
Data are presented as means ± SD (n = 9–10). $Signiﬁcant difference compared to normal control group (P < 0.05). ⁄Signiﬁcant difference compared to diabetic control
(P < 0.05).
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Table 3
Effect of CAMFs and glibenclamide on enzymes marker in the serum, liver, and kidney of STZ-nicotinamide–induced diabetic rats in comparison with normal and diabetic control
rats after the 12-week treatment period.
Group ASTa ALTb ALPc c-GTd
Serum
Normal control 49.9 ± 3.66e 43.7 ± 2.64e 67.1 ± 3.14e 19.7 ± 1.63e
Diabetic control 87.5 ± 3.73 72.2 ± 3.65 107.3 ± 4.49 33.4 ± 1.05
Glibenclamide (50 mg/kg) 55.4 ± 2.92e 48.6 ± 2.03e 69.4 ± 4.23e 21.1 ± 1.01e
CAMFs (50 mg/kg) 52.3 ± 2.53e 44.2 ± 1.36e 57.6 ± 2.07e 19.8 ± 1.75e
CAMFs (25 mg/kg) 62.2 ± 3.23e 57.8 ± 2.02e 77.4 ± 5.32e 25.7 ± 1.26
CAMFs (10 mg/kg) 73.7 ± 3.12 63.7 ± 2.47 81.2 ± 6.41e 30.1 ± 2.73
Liver
Normal control 723.7 ± 13.6e 883.8 ± 17.25e 0.19 ± 0.52e 3.11 ± 0.26e
Diabetic control 937.2 ± 20.18 1259.6 ± 26.31 0.36 ± 0.21 5.53 ± 1.21
Glibenclamide (50 mg/kg) 754.3 ± 17.38e 905.2 ± 16.42e 0.22 ± 0.23 3.31 ± 0.87
CAMFs (50 mg/kg) 757.5 ± 18.23e 876.8 ± 22.43e 0.20 ± 0.13 3.01 ± 0.13e
CAMFs (25 mg/kg) 807.2 ± 19.36 923.4 ± 21.41 0.29 ± 0.76 3.82 ± 0.17
CAMFs (10 mg/kg) 893.4 ± 22.46 1033.5 ± 21.32 0.33 ± 0.26 4.23 ± 0.72
Kidney
Normal control 848.2 ± 19.31 935.7 ± 21.67 0.43 ± 0.16e 2.96 ± 0.87e
Diabetic control 839.4 ± 18.36 929.4 ± 21.61 0.98 ± 0.56 4.21 ± 0.74
Glibenclamide (50 mg/kg) 852.4 ± 24.26 927.3 ± 24.18 0.50 ± 0.32e 3.02 ± 0.21
CAMFs (50 mg/kg) 846.3 ± 22.43 944.5 ± 20.78 0.39 ± 0.13e 2.79 ± 0.32e
CAMFs (25 mg/kg) 826.1 ± 18.21 903.2 ± 20.13 0.58 ± 0.34 3.16 ± 0.56
CAMFs (10 mg/kg) 818.9 ± 21.23 896.5 ± 22.79 0.68 ± 0.23 3.53 ± 0.19
Values denote mean ± SD, n = 9–10.
Units of measurement (per L) for AST and ALT: lmol of pyruvate liberated/h; ALP: lmol of phenol liberated/min; c-GT: mol of p-nitroaniline liberated/min.
a Aspartate transaminase.
b Alanine transaminase.
c Alkaline phosphatase.
d c-Glutamyltranspeptidase.
e Mean values that are signiﬁcantly different from diabetic control in the same group, as revealed by the Tukey–Kramer multiple comparisons test (P < 0.05).
Fig. 6. Antioxidant effect of CAMFs on the pancreas, kidney, and liver of STZ-nicotinamide–induced diabetic rats in comparison with normal and diabetic control rats after the
12-week treatment period. At the end of the treatment, the organs were removed, homogenized, and centrifuged to collect the tissue supernatant. Panels denote (A) pancreas,
(B) kidney, and (C) liver, GSH and MDA levels respectively. Data are presented as means ± SD (n = 9–10). $Signiﬁcant difference compared to the normal control group
(P < 0.05). ⁄Signiﬁcant difference compared to the diabetic control (P < 0.05).
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the phytochemicals in CAMFs, such as quercetin glycoside, 3,4–0-
dicaffeoylquinic acid, caffeic acid, naringenin-7–0-glucoside and
kaempferol. Several studies on these compounds have demon-
strated antidiabetic, antioxidant and anti-inﬂammatory properties
(Jung et al., 2006; Ortiz-Andrade et al., 2008; Shih et al., 2012).
Thus, the combination of these compounds in CAMFs may be
responsible for the synergistic effects observed in STZ-nicotin-
amide induced type 2 diabetic rats.
5. Conclusion
The crude methanolic fraction of C. anthelminticum seeds (CAM-
Fs) displayed inhibitory effects on NF-jB translocation in H2O2-
stimulated b-TC6 cells. This observation was corroborated with
the beneﬁcial effects of CAMFs in attenuating hyperglycemia, by
down-regulating elevated levels of pro-inﬂammatory cytokines,
oxidative stress and hyperlipidemia in an animal model of type 2
diabetes. These ﬁndings pave the way for a novel approach to po-
tential treatments of insulin-resistant type 2 diabetes and propose
CAMFs as a valuable candidate nutraceutical for the type 2 diabetic
complications.
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3.3.4.1 Histopathological study (unpublished data)  
 
At the end of 12-week study period, all the experimental animals (SD rats): normal 
control, STZ-nicotinamide-induced diabetic and CAMFs treated diabetic rats were fasted 
for 12 hours and blood was collected for serum analysis, thereafter all the group animals 
were sacrificed by cervical dislocation. The liver, kidney and pancreas were removed, 
washed in ice-cold isotonic saline, and blotted individually on ash-free filter paper; the 
organs were weighed and cut into pieces for the estimation of markers as well as for 
histology. For histology, organs were fixed in 10% buffered formalin for 48 hours, after 
that rinsed with xylene and embedded in paraffin. Thereafter, (5 μm thick) sections were 
prepared and stained with hematoxylin and eosin dye (H&E). Finally, all the sections were 
mounted using neutral deparaffinated xylene (DPX) medium for microscopic examination 
on a Motic BA 400 microscope using Motic Advance 3.0 software.  
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Figure 3.2: Histology of liver 
Photomicrographs (40xx) displaying liver of normal control rats, diabetic control and 
diabetic rats treated with CAMFs. (A) Liver of normal rats showed normal hepatic structure 
without any abnormallity. (B) Liver of STZ-nicotinamide-induced diabetic rats showed 
disorganized hepatic cords, reduced sinusoids with dilation, feathery degeneration and 
many hepatocytes having cytoplasmic vacuolar degeneration, pyknotic nuclei and central 
inflammatory cell infiltration with abscess formation. (C) CAMFs (50 mg/kg) treated 
diabetic rats prevented cytoplasmic vacuolar degeneration of hepatocytes and recovered 
accumulated inflammatory cell infiltration, with fewer pyknotic nuclei, compared to 
diabetic control rats.  
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Figure 3.3: Histology of kidney 
Photomicrographs (40xx) displaying kidney of normal control rats, diabetic control and 
diabetic rats treated with CAMFs. (A) Kidney of normal rats, showed normal parenchymal 
structure of kidney. (B) Kidney of STZ-nicotinamide-induced diabetic rats showed severe 
tubular epithelial atrophy with mesangial proliferation, abnormal sclerotic changes in the 
glomerulus, as well as congestion in the capillaries with infiltaration of mononuclear cells 
in renal parenchyma. (C) Diabetic rats treated with CAMFs (50 mg/kg), demonstrated mild 
tubular epithelial atrophy with less congestion in capillaries and recovery of inflammed 
mononuclear cells in renal parenchyma.  
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Figure 3.4: Histology of pancreas 
Photomicrographs (40xx) displaying pancreas of normal control rats, diabetic control and 
diabetic rats treated with CAMFs. (A) Pancreas of normal rats, exhibited normal pancreatic 
structure with intact alpha, beta and delta islets cells of Langerhans. (B) Pancreas of STZ-
nicotinamide-induced diabetic rats showed marked decrease in number of constituting islet 
cells with hyperplasia and exhibiting necrosis, vacuolations, hydropic cells with pyknotic 
nuclei, and also congestion in pancreatic parenchyma with infiltration of cells. (C) Diabetic 
rats treated with CAMFs (50 mg/kg) increased number of constituting islet cells and 
reduced necrosis, vacuolations, hydropic cells and pyknotic nuclei with recovery in the 
infiltration of inflammatory cells.   
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We investigated the antioxidant potential, cytotoxic eﬀect, and TNF-α inhibition activity with NF-κB activation response in a
chloroform fraction ofCentratherum anthelminticum seeds (CACF). The antioxidant property of CACF was evaluated with DPPH,
ORAC, and FRAP assays, which demonstrated significant antioxidant activity. The cytotoxicity of CACF was tested using the MTT
assay; CACF eﬀective inhibitory concentrations (IC50) for A549, PC-3, MCF-7, and WRL-68 cells were 31.42 ± 5.4, 22.61 ± 1.7,
8.1±0.9, and 54.93±8.3μg/mL, respectively. CACF eﬀectively and dose-dependently inhibited TNF-α release, in vitro and in vivo.
CACF inhibited TNF-α secretion in stimulated RAW264.7macrophage supernatants with an IC50 of 0.012 μg/mL, without aﬀecting
their viability; the highest dose tested reduced serum TNF-α by 61%. Acute toxicity testing in rats revealed that CACF was non-
toxic at all doses tested. Matching the cytotoxic activity towards a mechanistic approach, CACF dose-dependently exhibited in vitro
inhibitory eﬀects against the activation of NF-κB translocation in MCF-7 cells. Preliminary phytochemical screening with GC/MS
analysis detected 22 compounds in CACF, of which morpholinoethyl isothiocyanate was the most abundant (29.04%). The study
reveals the potential of CACF in the treatment of breast cancer and in oxidative stress conditions with associated inflammatory
responses.
1. Introduction
Since time immemorial, traditional herbs have been used as
remedies for several diseases [1]. Even though new synthetic
drugs are available, traditional medicine is still being utilized
today as part of primary healthcare in several parts of the
world. Traditional medicine is often sought because it is
economical, readily available, and trusted by its advocate
[2]. Studies on herbal medicines have shown the positive
correlation of traditional claims and scientific data [3]. Some
of these traditional treatments are part of clinical practice,
and few are found to be not beneficial [4]. Support for
traditional medicine and the numerous natural products
with biological activity have led to multidisciplinary inves-
tigations utilizing preliminary screening procedures as well
as advanced mechanistic studies to develop drugs which may
be used clinically.
Centratherum anthelminticum (L.) KUNTZE (family:
Asteraceae) is an erect, pubescent annual herb found widely
in the Indian subcontinent which is locally known as
“Somraj,” and its seeds are known as “Kalijiri” in Hindi
[5, 6]; scientific synonyms for this plant include Vernonia
anthelmintica and Conyza anthelmintica, among others. This
plant is used extensively in Ayurveda for the treatment of
cough and diarrhoea, as well as an anthelmintic, stomachic,
diuretic, and antiphlegmatic agent [5, 7]. Experimental
studies proved the pharmacological eﬀects of this plant’s
seeds extract, including antihelminthic [8], larvicidal [9],
antipyretic [10], antifilarial [11], antihyperglycemic [12],
antimicrobial [13], and diuretic [14] activities. In addition
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to primary metabolites, the seeds of this plant contain gly-
cosides, phenolic compounds, tannins, flavonoids, saponins,
and sterols [15]. Examples of secondary metabolites found
in C. anthelminticum include the following: flavonoids such
as 2′,3,4,4-tetrahydroxychalcone (Butein); 5,6,7,4′-tetra-
hydroxy flavone and 7,3′,4′-trihydroxydihydroflavone [16];
sterols such as sterol-4-alpha-methylvernosterol, vernosterol,
and avernosterol [17]; steroids such as (24a/R)-stigmasta-
7-en-3-one, 24(a/R)-stigmasta-7, 9(11)-dien-3-one, 24(a/S)-
stigmasta-5 and 22-dien-3β-ol, stigmasta-7, and 22-dien-3β-
ol [18].
While several studies investigated the pharmacological
eﬀects of this plant, the antiinflammatory and anti-cancer
activities are yet to be investigated. Inflammation is a natural
defense mechanism by the host which plays a role in
various diseases. Immune cells are particularly important in
inflammation because they orchestrate the release of several
mediators such as cytokines, prostaglandins, and nitric
oxide, which play a part in the defense process. However,
uncontrolled production of these mediators is associated
with tissue damage due to oxidative stress [19]. Oxidative
stress resulting from reactive oxygen and nitrogen species
(ROS and RNS) was shown to cause DNA mutations and
cell death and aﬀect cell proliferation. Cells which survive
the DNA damage caused by oxidative stress are likely to
have aberrant repair mechanisms, the proliferation of these
genetically instable cells might eventually progress toward
carcinogenesis. Therefore, this study looked into the antiox-
idant approaches, the in vitro and in vivo TNF inhibition
activity counting cytotoxic eﬀect in the chloroform fraction
with further evaluation of linkage between NF-κB activation
on breast cancer (MCF-7) cell lines.
2. Materials and Methods
2.1. Cell Lines and Reagents. All cell lines were purchased
fromATCC (Rockville, MD, USA). RPMImedium, penicillin
and streptomycin solution, and phosphate buﬀer Saline
(PBS) were purchased from Invitrogen (Rockville, MD,
USA). MTT, DMSO, and heat-inactivated fetal bovine
serum and 0.25% trypsin solution were purchased from
Sigma-Aldrich Chemicals (Saint Louis, MO, USA). Cell
culture treated 96-well plates, and cell culture flasks were
purchased from Orange Scientific (Braine-l’Alleud, Bel-
gium). PBS 75 nM, pH Dulbecco’s Modified Eagle Medium
(DMEM), phosphate buﬀered saline, Hanks’ balanced
salt solution (HBSS), and 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were from Invitrogen
(Carlsbad, USA). Fetal bovine serum (FBS), LPS from E.
coli serotype 0111:B4, and dimethylsulfoxide (DMSO) were
obtained from Sigma (St. Louis, USA). Murine TNF-α ELISA
kit was from eBioscience (SanDiego, USA). NF-κB activation
kit from Thermo Scientific Cellomics, fluorescence sodium
salt, DPPH and FRAP reagents, Pentoxifylline and Pacli-
taxel (Sigma-Aldrich), AAPH, Quercetin, and Trolox were
from Sigma-Aldrich Chemicals (S. Louis, MO, USA). Plates
were read using Chameleon V Multilabel microplate reader
(Hidex, Turku; Finland) in 96-well format black plate.
2.2. Plant Materials. The seeds of the plant Centratherum
anthelminticum were procured from the medicinal plant
cultivation zone of Amritum Bio-Botanica Herbs Research
Laboratory Pvt. Ltd, Betul, Madhya Pradesh, India. The
seeds of the plant were authenticated by the Quality Control
department of the company itself. Voucher specimen (CA-
9) is deposited in the Pharmacology Department of the
University of Malaya, Malaysia.
2.3. Extraction Procedure. The coarsely powdered seeds
(100 g) were extracted with water : ethanol (80 : 20) using
a Soxhlet extractor for 24 h (Figure 1). The solvent was
completely evaporated using rotary evaporator. The brown
viscous crude extract weighing (49% w/w) obtained was
further fractionated successively with hexane, chloroform
and methanol, then the solvent from each fraction was
completely recovered with the help of rotary evaporator
under reduced pressure. After drying, the final yields with
hexane (CAHF), chloroform (CACF), and methanol fraction
(CAMF) were (19.41% w/w), (4.11 w/w), and (11.3% w/w),
respectively. Then the dried fractions were kept below
−20◦C before being used. The in pilot bioactivity testing,
chloroform fraction (CACF) had shown the positive eﬀect
and hence was chosen for further analysis.
2.4. Animals. Altogether 72 Sprague Dawley rats of 150–
200 g were obtained from the University of Malaya Medical
Centre Animal House and maintained under standard
conditions of lighting (12 h of light and darkness) and
nutrition (food and water ad libitum) throughout the
experimental period. Studies were performed in accordance
with the Medical Research Council Guidelines on Ethics in
Animal Experimentation. This study was approved by the
Animal Experimentation ethics committee at the University
of Malaya Medical Center-(UMMC), Animal Ethics no:
FAR/10/11/2008/AA(R).
2.5. Total Phenolic Content (TPC). TPC of CACF was
determined using Folin-Ciocalteu method [20]. CACF was
prepared in a concentration of 10mg/mL in methanol.
Five microliters of this solution were transferred to 96-well
mircoplate (TPP, USA). To this, 80 μL of Folin-Ciocalteu
reagent (1 : 10) was added and mixed thoroughly. After
5min, 160 μL of sodium bicarbonate solution (NaHCO3
7.5%) was added, and the mixture was allowed to stand for
30min with intermittent shaking. Absorbance was measured
at 765 nm using microplate reader (Molecular Devices,
Sunnyvale, USA). The TPC was expressed as gallic acid
equivalent (GAE) in mg/g extract and obtained from the
standard curve of gallic acid. The gallic acid standard curve
was established by plotting concentration (mg/mL) versus
absorbance (nm) (y = 0.001x + 0.045; R2 = 0.9975), where
y is absorbance and x is concentration in GAE (n = 3).
2.6. Antioxidant Activity of C. anthelminticum
2.6.1. 1,1-Diphenyl-2-picrylhydrazyl (DPPH) Radical Scav-
enging Activity of CACF. The scavenging activity of CACF
on DPPH was determined using the method described in
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Figure 1: Schematic diagram of extraction/fractionation of C. anthelminticum seeds.
[21]. This method is based on the reduction of purple DPPH
to a yellow-colored diphenyl picrylhydrazine. Changes in
color were measured at 518 nm. CACF was tested at final
concentrations ranging from 600 to 10 μg/mL in ethanol.
One milliliter of 0.3mM DPPH ethanol solution was added
to 2.5mL of sample solution of diﬀerent concentrations to
make the test solutions, while 1mL of ethanol was added
to 2.5mL of samples to make the blank solutions. The
negative control (blank) consisted of 1mL DPPH solution
plus 2.5mL of ethanol. These solutions were allowed to
react at room temperature for 30 minutes in the dark. The
absorbance values were measured at 518 nm and converted
into percentage antioxidant activity using the following
equation:
% Inhibition =
[
(AB − AA)
AB
]
× 100, (1)
where AB is the absorption of blank sample; AA is the
absorption of tested samples.
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The IC50 as well as the kinetics of DPPH scavenging
activity was determined. Ascorbic acid and butylated hydrox-
ytoluene (BHT) was used as a positive control in this assay.
2.6.2. ORAC Antioxidant Activity Assay. The oxygen radical
absorbance capacity (ORAC) assay was done based on the
procedure described earlier by Choi et al. [21] with slight
modifications. Briefly, 175 μL of the sample/blank were
dissolved with PBS at concentrations of 160 μg/mL, pH
7.4. Serial dilutions of the standard Trolox were prepared
from 75mM. The assay was performed in 96-well black
microplates 25 μL of samples (CACF), standard (Trolox),
blank (solvent/PBS), or the positive control (quercetin) was
added to the wells. Subsequently, 150 μL of fluorescent
sodium salt solution was added, and the plate was then
incubated for 45 minutes at 37◦C. Twenty five microliters
of 2,20-azobis (2-amidinopropane) dihydrochloride (AAPH)
solution was added for a total volume of 200 μL/well.
Fluorescence was recorded until it reached zero (excitation
at 485 nm, emission at 535 nm) using a fluorescence spec-
trophotometer (Perkin—Elmer LS 55), equipped with an
automatic thermostatic autocell holder at 37◦C. Data were
collected every 2mins for a duration of 2 hrs and were
analyzed by calculating the diﬀerences of areas under the
fluorescein decay curve (AUC) between the blank and the
sample. Values were expressed as Trolox equivalents.
2.6.3. Ferric Reducing/Antioxidant Power (FRAP) Assay. The
FRAP assay was slightly modified from the method of
Benzie and Strain [22]. The stock solutions included 300mM
acetate buﬀer (pH 3.6), 10mM TPTZ (2,4,6-tripyridyl-s-
triazine) solution in 40mM HCl, and 20mM FeCl3·6H2O.
The fresh working solution was prepared by mixing 25mL
acetate buﬀer, 2.5mL TPTZ, and 2.5mL FeCl3·6H2O. The
temperature of the solution was raised to 37◦C before use.
CACF (10 μL) was allowed to react with 190 μL of the FRAP
solution for 30min in the dark. Colorimetric readings of
the product ferrous tripyridyltriazine complex were taken
at 593 nm. The standard curve was linear between 200 and
1000 μM FeSO4. Results are expressed as μM Fe (II)/g dry
mass and compared with those of Ascorbic acid and BHT.
2.7. Cell Viability and Cytotoxicity
2.7.1. Cell Culture. All cell lines were obtained from Amer-
ican Type Cell Collection (ATCC) and maintained in a
37◦C incubator with 5% CO2 saturation. Human breast
carcinoma (MCF-7) and normal hepatic (WRL-68) cell lines
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM), while nonsmall cell lung cancer cells (A549)
and prostate adenocarcinoma cells (PC-3) were maintained
in RPMI medium. Both media were supplemented with
10% fetus calf serum (FCS), 100 units/mL penicillin, and
0.1mg/mL streptomycin. Cells were cultured using standard
aseptic techniques and were seeded at the indicated densities
below.
2.7.2. Cellular Viability. The inhibitory eﬀects of CACF on
the indicated cell lines’ growth were tested using the MTT
assay [23]. Cells were seeded at a density of 1 × 105cells/mL
in a 96-well plate and incubated for 24 hours at 37◦C and 5%
CO2. Cells were then treated with CACF and incubated for
another 24 hours, after which the MTT solution at 2mg/mL
was added for 1 hour. The insoluble formazan product was
dissolved in DMSO, and absorbance was measured at 570 nm
using Plate Chameleon V microplate reader (Hidex, Turku,
Finland). Results were expressed as a percentage calculated
from the ratio of absorbance of treated cells to untreated
cells. The concentration that caused a 50% loss of cell growth
(IC50) was used to measure the CACF growth inhibition
potency.
2.8. TNF-α Inhibition Activity of CACF
2.8.1. In Vitro Cell Viability and TNF-α Production Assays.
Murine macrophage cells RAW 264.7 were seeded in 96-well
plates at 5 × 105cells/mL. Cells were either left untreated in
DMEM or pretreated with CACF at the indicated concen-
trations for 30 minutes. Cell stimulation, viability, and TNF
production measurements were conducted exactly as in [24].
Percentage viability was calculated as follows: cell viability
(%) = [(OD570 (sample)/OD570 (control)) ×100].
Whereas percentage TNF inhibition was calculated as
follows:
% inhibition = 100×
[(
[TNF] control− [TNF] sample)
[TNF] control
]
,
(2)
where control indicates cells treated in LPS alone.
2.8.2. Measurement of In Vivo Serum TNF. Healthy male rats
were selected and divided into 6 groups (n = 8 for each
group). The rats were pretreated with the indicated solutions
for 30 minutes before lipopolysaccharide (LPS) stimulation:
group 1 was pretreated intraperitoneally (i. p.) with 1mL
of PBS alone, group 2 with dexamethasone (6mg/kg BW)
in 25% DMSO, group 3 with CACF (25mg/kg BW) in 25%
DMSO, group 4 with CACF (50mg/kg BW) in 25% DMSO,
and group 5 with CACF (100mg/kg BW) in 25% DMSO.
Groups 1–5 were treatment groups stimulated with LPS,
while group 6 made up the untreated negative control in
which rats were given a solution of 25% DMSO in PBS
and no LPS. Subsequent to pretreatment, LPS (1mg/kg) was
then administered in 1mL of pyrogen-free normal saline
i. p for five treatment groups, and PBS was administered
i. p. for the negative control group. Blood was withdrawn
from the animals under ether anesthesia after 90 minutes
of LPS or PBS administration. Serum was collected and
stored at −80◦C until analysis. Serum levels of TNF-α were
determined using rat TNF-α ELISA kit according to the
manufacturer’s protocol (e Bioscience, San Diego, USA).
2.9. Acute Toxicity Study. Healthy adult rats of either sex
were divided into 4 groups (n = 6) and were orally fed
with increasing doses of CACF: 10, 20, 100, and 1000mg/kg
body weight (BW). The rats were observed continuously for
2 hours for behavioral, neurological, and autonomic profiles
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Table 1: Antioxidant activity profile of the chloroform fraction of Centratherum anthelminticum (CACF).
Samples DPPH IC50, μg/mL FRAP (μmol/L) ORAC Equivalent conc. Trolox (20 μg/mL (μM)∗∗ IC50 TPC μg GAE/mg
CACF 22.56a ± 1.4 1048.3a ± 21.2 992.34a ± 45.12 86.62 37.16± 0.85
Ascorbic acid 15a ± 0.3 6240b ± 56.2 — — —
BHT 17a ± 0.4 907.7a ± 54.8 — — —
Quercetin — — 1018.00b ± 34.82 74.52 —
∗
The net AUC was calculated by subtracting the blank AUC from the AUC of each sample, the standards, and the positive control. Final ORAC values were
expressed as the equivalent concentration of Trolox (TE) that gives the same level of antioxidant activity as the samples at 20 μg/mL. ∗∗Means with diﬀerent
alphabets are statistically significant.
and after 24 and 72 hours for any lethality. All procedures
were according to the guidelines stated by OECD.
2.10. NF-κB Translocation Assay. NF-kB translocation in
MCF-7 cells was examined using NF-kB activation HCS
kit which contains Hoechst 33342 and Alexa Fluor 488
conjugated anti-NF-kB dyes. MCF-7 cells were seeded into
96-well plates (Perkin-Elmer Inc., Wellesley, MA, USA) at
6000 cells/well. After overnight, cells were treated with diﬀer-
ent concentrations of CACF for 1 hr, followed by treatment
with 10 μg/mL TNF-α for another 30 minutes. Fixation,
permeabilization, and immunofluorescence staining of cells
were performed according to the manufacturer’s instruc-
tions. ArrayScan reader was used to quantify the diﬀerence
between the intensity of nuclear and cytoplasmic NF-κB-
associated fluorescence, reported as translocation parameter.
2.11. Identification and Chemical Analysis Using GC-MS.
Gas chromatography mass spectrometry (GC-MS) analysis
of the selected fraction was carried out on a Shimadzu
GC-17 A network GC system coupled to a mass-selective
detector: MS-QP50-50. Separation was conducted on an HP-
5 MS column (30m × 0.32mm × 3.0 μm), with helium as
the carrier gas at a flow rate of 1.0mL/min. The injection
volume was 1 μL with a split ratio of 10 : 1. The column
temperature was initially held at 100◦C for 3min and then
increased to 290◦C at a rate of 10◦C/min. The column
temperature was then maintained at 290◦C for 3min. The
temperatures of the injector and detector were 250◦C and
280◦C, respectively. Mass acquisition was performed in the
range of 40–550 atomic mass units (a. m. u) using electron
impact ionization at 70 eV. The major components in this
sample were predicted by a spectral database matching
against the library of National Institute of Standards and
Technology (NIST21 and NIST Wiley).
2.12. Statistical Analysis. Experimental values were expressed
as the means ± standard deviation (SD) of the number of
experiments indicated in the legends. Statistical significance
was assessed using one-way analysis of variance (ANOVA)
followed by a multiple comparison test (Tukey’s post-hoc
test), were P < 0.001, P < 0.01, and P < 0.05 were considered
significant. Pearson correlation coeﬃcient was used to assess
the correlation between phenolic content and antioxidant
activities.
3. Results
3.1. Antioxidant Activity. Table 1 provides a summary of the
antioxidant and total phenolic content of CACF. The total
phenolic content of CACF was determined to be 37.16 ±
0.85μg GAE/mg extract.
3.1.1. DPPH Scavenging Activity of CACF. CACF exhibited
a significant dose-dependent inhibition of DPPH activity
(P < 0.05), with an IC50 value of 22.56 ± 1.4μg/mL
(Table 1). Maximal DPPH scavenging activity occurred at
41 ± 1.2 μg/mL of CACF with an inhibition of 89%.
3.1.2. Ferric Reducing Antioxidant Power of CACF. CACF
showed a significant dose-dependent FRAP value (P <
0.05) with a 1048.3 μmol/L for the fraction, while the
positive control used in this study displayed a value of 6240
and 907.7 μmol/L for ascorbic acid and BHT, respectively
(Table 1).
3.1.3. ORAC Activity of CACF. The area under the curve
(AUC) was calculated for oxygen radical absorbance capacity
of CACF, trolox, and the positive control quercetin. ORAC
results are demonstrated in Table 1. CACF had an ORAC
value of 992.34 ± 45.12μM trolox equivalent at 20 μg/mL.
On the other hand, quercetin had an ORAC value of
1018.00± 34.82μM of Trolox equivalent at 5 μg/mL.
3.2. Cytotoxic Activity of CACF. To evaluate the cytotoxic
activity, CACF was tested with a series of diﬀerent doses
on nonsmall cell lung cancer (A549), prostate cancer (PC-
3), breast cancer (MCF-7), and normal hepatic cells (WRL-
68), respectively. After 24 hours, cell viability was determined
by the MTT assay. CACF induced cell cytotoxicity in
a concentration-dependent manner. These dose titration
curves allowed determination of IC50 for the CACF towards
diﬀerent cell lines. CACF demonstrated dose-dependent
cytotoxic eﬀects with IC50 values of 31.42± 5.4, 22.61± 1.7,
8.1± 0.9, and 54.93± 8.3μg/mL; in A549, PC-3, MCF-7 and
WRL-68, respectively (Figure 2). In line with these screening,
reference drug (Paclitaxel) was used as a positive control
whose IC50 on tested A549, PC-3, MCF-7 and WRL-68 were
5.675 ± 1.03, 0.37 ± 0.03, 1.583 ± 0.24, and 0.666 ± 0.05,
respectively. Hence, these results point out that cell lines vary
in their sensitivity.
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Figure 2: CACF was tested with a series of diﬀerent doses on A549,
MCF-7, PC-3, and WRL-68 cells, respectively. After 24 hours, cell
viability was determined by the MTT assay. Test agents induced
cell cytotoxicity in a concentration-dependent manner. These dose
titration curves allowed determining IC50 for the test agents towards
diﬀerent cell lines. The IC50 value of CACF on the viability of A549,
PC-3, MCF-7, and WRL-68 has been determined to be 31.42± 5.4,
22.61± 1.7, 8.1± 0.9, and 54.93± 8.3μg/mL, respectively.
3.3. In Vitro Inhibitory Eﬀects of CACF on TNF Production
and RAW264.7 Cell Viability. Stimulation of RAW264.7 with
LPS for 4 hours caused a significant increase in TNF-α
production (Figure 3). CACF eﬀectively and dose depen-
dently inhibited TNF-α release with an IC50 of 0.012 μg/mL
as depicted in Figure 4. CACF exhibited maximal TNF
inhibition of 90% at 0.31 μg/mL. This significant inhibitory
eﬀect was observed at noncytotoxic doses ranging from 0.031
to 0.002 μg/mL (Figure 5).
3.4. In Vivo Activity
3.4.1. Acute Toxic Eﬀects of CACF. The acute toxicity study
revealed the nontoxic nature of CACF. There was a 100%
survival rate of the animals treated with CACF at doses
ranging from 10 to 1000mg/kg. Moreover, no toxic eﬀects
were observed throughout the study.
3.4.2. The Inhibitory Eﬀect of CACF on Serum TNF. Stim-
ulation of animals with LPS leads to an increase in serum
TNF levels up to 2 ng/mL in rats pretreated with PBS alone.
On the other hand, animals pretreated with dexamethasone
and CACF have shown a significant reduction in TNF
levels (Figure 6). Moreover, CACF showed a dose-dependent
inhibitory eﬀect of serum TNF in LPS-stimulated rats, and
this eﬀect in rats pretreated with 100mg/kg was almost 61%,
to that of dexamethasone 67%, respectively.
3.5. CACF Inhibits NF-kB Activity. In this study, we tested
CACF for its in vitro inhibitory eﬀects against NF-κB
translocation activated by TNF-α and illustrated by HCS
assay. CACF displayed significant inhibitory eﬀects on the
activation of NF-κB (Figure 7). In parallel, the morphologi-
cal changes of NF-κB translocation indicated by immunoflu-
orescence staining (Figure 8) showed an inhibitory eﬀect of
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Figure 3: The eﬀects of CACF on TNF production in RAW264.7
cells. Cells were pretreated with the indicated concentrations
of CACF, or the TNF inhibitor pentoxifylline (PTX). The cells
were stimulated with LPS (1 μg/mL) for four hours or were left
untreated (DMSO). The protein concentration was measured using
ELISA. Data is representative of three independent experiments and
was analyzed using one-way ANOVA with Tukey’s post hoc test.
The inhibitory eﬀect of CA chloroform fraction was significantly
diﬀerent from stimulated cells (LPS) (∗∗∗P < 0.001).
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Figure 4: Dose-response eﬀect of the CACF on TNF inhibition:
the chloroform fraction had an IC50 of 0.012 μg/mL (LOG IC50:
−1.931).
CACF on TNF-α-induced NF-κB translocation in a dose-
dependent manner. When cells remain untreated, most of
the fluorescence staining for NF-κB were in the cytoplasm
and rare NF-κB staining found in nuclei area. While cells
were stimulated with the TNF-α alone, NF-κB staining
significantly increased in nuclei area, suggesting that NF-
κB translocated from cytoplasm into the nucleus. However,
MCF-7 cells were treated with 8, 4, and 2 μg/mL of CACF,
and NF-κB translocation induced by TNF-α was inhibited.
3.6. Chemical Composition. The possible chemical composi-
tion of CACF analyzed by GC/MS is presented in (Table 2).
Based on the similarity index out of major peaks, total
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Figure 5: The eﬀects of CACF on RAW264.7 cells’ viability. Cells
were pretreated with the indicated concentrations of CACF for 4
hours or were left untreated (DMEM). Data is the average of three
independent experiments (± SD) and was analyzed using one-way
ANOVA with Tukey’s posttest (∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P <
0.001).
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Figure 6: Eﬀect of CACF on serum TNF levels in rats. Diﬀerent
treatment groups were pretreated i.p with 25, 50, and 100mg/kg
of (LPS + CACF), 6mg/kg of dexamethasone (LPS + DEX) or
with phosphate buﬀer saline (LPS + PBS), and DMSO (Untreated)
for 30mins. All the treatment groups were then either injected
with 1mg/kg of lipopolysaccharides (LPS) or with PBS for 90mins.
Blood was withdrawn, and serum TNF was quantified using ELISA.
One-way ANOVA with Tukey’s post-analysis was used to calculate
the statistical significance among the groups when compared to LPS
+ PBS. ∗∗∗P < 0.001, ∗∗P < 0.01, and ∗P < 0.05.
22 compounds were detected in this fraction. The most
abundant component comprise of 2-Morpholinoethyl isoth-
iocyanate (29.04%), 1,E-11,Z-13-Octadecatriene (16.48%),
and Octadecanoic acid, butyl ester (16.15%). Eight com-
pounds (<5%) were not reported in Table 2 due to their
minority.
4. Discussion
The current study revealed the pleiotropic bioactivities of
the chloroform fraction of Centratherum anthelminticum
(CACF) seeds. The antioxidant assays performed using the
DPPH, ORAC, and FRAP methodologies revealed the free
radical-scavenging possibilities of this fraction. Antioxidants
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Figure 7: Dose-response histogram of CACF treated MCF-7 cells
for 1 hours and then stimulated for 30minutes with 10 ng/mL TNF-
α for quantitative image analysis of intracellular targets.
are substances that may protect cells from the damage
caused by unstable molecules known as free radicals. Several
factors can lead to the accumulation of free radicals in the
cell; examples are certain chemicals, ultraviolet radiations,
inflammatory cytokines, and bacterial lipopolysacharides,
and other pesticides further generate oxidative stress con-
ditions and extend their contribution in the progression
of various ailments including neurodegenerative diseases,
atherosclerosis, diabetes, inflammation, and carcinogenesis
[19, 25–27]. However, present work demonstrated that
CACF fraction is grouped with certain antioxidant com-
pounds. Our results warrant the probability of the CACF as
a natural source of antioxidants which could be promising
in hunting free radicals and treating diseases related to free
radical reactions. Hence, the ability to scavenge free radicals
may attenuate the several signalling pathways triggering
tissue damage and inflammation, which in turn will have a
protective eﬀect on the cells [28, 29].
Having uncovered the antioxidant nature of CACF, we
then turned to look at its eﬀects in a living cell system.
Cytotoxic screening models provide important preliminary
data to select plant extracts or natural compounds with
potential anticancer properties [30]. In this study, the
cytotoxic eﬀect of CACF was investigated by the addition
of the MTT tetrazolium salt [23] to various cancer cell
lines previously treated with CACF. CACF showed selective
cytotoxic eﬀect on MCF-7 compared with other tested cell
lines with low IC50 value, nevertheless it was not cytotoxic to
normal cell line, WRL-68. These results specify that cell lines
diﬀer in their sensitivity to the same CACF, which may be
determined by multiple-cell type-specific signalling cascades
and transcription factor activities [31].
In addition to that, CACF exhibited inhibition of TNF
production both in vitro and in vivo without aﬀecting cell
viability and animal survival, respectively. This also warrants
the ethnomedical uses of this plant in the treatment of
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Figure 8: Stained MCF-7 cells were treated with CACF (8 μg/mL) for 1 hour and then stimulated for 30 minutes with 10 ng/mL TNF-α
(NF-κB activation).
inflammatory conditions. The ability of CACF to inhibit
TNF production may attribute to several factors. Previous
studies on C. anthelminticum have shown the presence of
several bioactive components [18], for example, butein
which is one of the secondary metabolites isolated from the
seeds of this plant shown to possess both antioxidant and
anti-inflammatory activities [14]. The ability of CACF to
interfere with inflammatory signallingmay in turn explain its
cytotoxic eﬀects on cancer cells, since these pathways are also
involved in the survival, proliferation, invasion, angiogenesis
and metastasis of tumours [32].
Moreover, this fraction along with pleotropic bioactivi-
ties demonstrated the in vitro inhibitory eﬀects on cell pro-
liferation in MCF-7 cells, which moves our line of study
towards carrying out additional experiments to get a better
understanding in elucidating mechanisms of breast carcino-
genesis with possible future strategies. It is well known that
antioxidants are known for their ability to scavenge free
radicals from the various stimuli, resulting in activation of
transcription factors involved in the transcription of survival
and inflammatory genes such as nuclear factor kappa B
(NF-κB) [24]. NF-κB is a transcription factor involved in
copious inflammatory and cancer-related ailments and has
developed as a foremost target in drug discovery [33]. The
consequences of NF-κB transcription factors in constitutive
activation includes increased survival signalling, cell prolif-
eration, angiogenesis, and invasion, which are key features
of the malignant phenotype [34]. Our study demonstrated
that CACF in a concentration-dependent manner inhibited
constitutive activation of NF-kB translocation stimulated by
TNF-α in MCF-7 cells. TNF-α-induced transcript levels for
the adhesion molecules, and this might interfer at an early
stage of signaling event induced by TNF-α. This suggests
that CACF may inhibit the expression of the cell adhesion
molecules by interfering with the transcription of their
respective genes and may inhibit either the initiation of
transcription or the stability of the mRNAs encoding in these
molecules. It is well understood that NF-κB is an important
transcription factor involved in the gene regulation and con-
tributing in immune and inflammatory responses, including
genes encoding [35, 36]. Moreover, tumors with constitutive
NF-kB activity have inherent resistance to many anticancer
therapies. Thus, NF-κB is believed to play an important role
in the regulation of inflammatory response associated with
cancer therapy [37, 38].
Analysis of the nonpolar extractable of plant material
using GC/MS has been applied before [39]. Our results
demonstrate that CACF contains various bioactive com-
ponents such as 2-morpholinoethyl isothiocyanate which
represents 29.04%. Isothiocyanates have been shown to
inhibit carcinogenesis and also useful as chemopreventive
agents against cancers. They work on a variety of levels. These
compounds are shown to induce apoptosis in certain cancer
cell lines and in some cases and are even able to induce
apoptosis in cells that are resistant to some currently used
chemotherapeutic drugs [40–44].
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Table 2: Compounds tentatively identified in the chloroform fraction of Centratherum anthelminticum (CACF).
Peak number RTa
Percentage of
the peakb
Molecular
weight
Molecular
formula
Similarity
index
Compoundc
1 5.279 5.97 116 C6H12O2 89 2-Pentanone-4-hydroxy-4-methyl
2 8.086 29.04 172 C7H12N2OS 92 2-Morpholinoethyl isothiocyanate
3 11.278 5.97 180 C6H12O6 85 d-Allose
4 11.547 3.62 346 C22H34O3 65 Drostanolone AC
5 11.650 1.62 162 C10H10O2 62
3(2H)-Benzofuranone,
2,6-dimethyl
6 15.533 6.36 326 C21H42O2 67 Nonadecanoic acid, ethyl ester
7 17.676 16.48 248 C18H32 78 1,E-11,Z-13-Octadecatriene
8 17.933 1.85 312 C20H40O2 68
Hexadecanoic acid,
1,1-dimethylethyl ester
9 17.950 0.45 145 C6H11NO3 46 Adipic acid monoamide
10 17.967 2.45 282 C12H26O5S 55 d-Mannitol, 1-thiohexyl
11 18.117 0.83 173 C7H11NO2 45 Ethyl 4-isothiocyanatobutyrate
12 21.450 16.15 340 C22H44O2 85 Octadecanoic acid, butyl ester
13 23.350 1.68 172 C9H16O3 50
Arabino-hetitol,
2,3 : 5,6-dianhydro-1,7-dideoxy-
2,6-di-e-methyl
14 23.942 2.62 298 C17H14O5 42
4H-1-Benzopyran-4-one,5-
hydroxy-7-methoxy-2-(3-
methoxyphenyl)
Total 95.09
a
RT: retention time (min).
bRelative area percentage (peak area relative to the total peak area percentage).
cCompounds listed in order of their relative area percentage.
In summary, the chloroform fraction of Centratherum
anthelminticum seed (CACF) displayed a range of inter-
related in vitro activities, ranging between antioxidant,
cytotoxic and in vitro and in vivo TNF-α inhibition while
remaining safe. Furthermore, CACF is maintained concern-
ing mechanistic approach linked with cytotoxic activity on
targeted cell line which positively inhibited NF-kB translo-
cation in MCF-7 cells. Therefore, these results merit further
pharmacological investigations with detailed phytochemical
analysis on C. anthelminticum.
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CHAPTER 4  
CONCLUSION AND FUTURE DIRECTIONS   
 
In search of phytomedicine for diabetes and its associated complications, nine (9) plants 
were initially screened for their hypoglycemic activity on postprandial hyperglycemia, 
followed by three Terminalia species for potential antioxidant and hypoglycemic 
effects. Finally, selection of the Centratherum anthelminticum seeds among the tested 
plants with positive effects for the detailed antidiabetic activity, followed by targeted 
biological activities.           
 
The significant findings in this study which have not been reported elsewhere are:  
 
(1) Amongst the nine (9) plants investigated for hypoglycemic screening, the leaf 
extracts of three (3) plants - Centratherum anthelminticum, Cissus quadrangularis, and 
Woodfordia fruticosa Kurz exhibited maximum hypoglycemic activity by reducing 
postprandial hyperglycemia in normoglycemic rats, without any toxicity. Therefore, it 
can be suggested that these plants have potential in postprandial hyperglycemia which 
might help in preventing the development of macro and microvascular complications 
associated with diabetes.   
 
(2) Study on the leaf extracts of the three (3) selected Terminalia species 
demonstrated antioxidant and hypoglycemic activities, which is probably due to the 
presence of high polyphenolic contents. This brings new hope in the research on the 
management of type 2 diabetic complications, and suggest that the use of leaf extracts 
from these species as food supplements may aid in the reduction of oxidative stress and 
hyperglycemia.   
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(3) Based on the pilot screening result of six different plant parts, the defatted crude 
methanolic fraction of Centratherum anthelminticum seeds (CAMFs) was selected for 
the detailed antidiabetic studies on mouse pancreatic β-TC6 cells, as well as on the 
diabetic rat models.  
 
(4) Antidiabetic studies on β-TC6 cell lines and in vivo studies on type 1 and type 2 
diabetic rats demonstrated that CAMFs is helpful in mediating antidiabetic effect by 
enhancing 2-NBDG glucose uptake, stimulating insulin secretion and inducing higher 
GLUT-2 and GLUT-4 transporter protein expressions on pancreatic β-TC6 cells. These 
observations corroborated the beneficial effects of CAMFs by attenuating 
hyperglycemia and augmenting insulin secretion in the type 2 diabetic rat model. These 
findings support the use of CAMFs as a possible dietary adjunct for the management of 
insulin-resistant type 2 diabetes and as a potential source for the discovery of new orally 
active agent(s) for future diabetes therapy.       
 
(5) Furthermore, to determine the potential of CAMFs on type 2 diabetes and its 
associated complications, a 12-week study was carried out on type 2 diabetic rats. The 
study results revealed that CAMFs ameliorated hyperglycemia by down-regulating type 
2 diabetic complications such as pro-inflammatory cytokines, oxidative stress and 
dyslipidemia. In addition, CAMFs inhibited NF-κB translocation in H2O2-stimulated β-
TC6 cells. Altogether, these findings pave the way for a novel approach to potential 
treatments of insulin-resistant type 2 diabetes and propose CAMFs as a valuable 
nutraceutical candidate for type 2 diabetic complications.      
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(6) Moreover, studies on the chloroform fraction of Centratherum anthelminticum 
seeds (CACF) possesses highest pleotropic bioactivities. Thus, CACF was selected for 
further studies on TNF-α inhibitory effect and for anticancer potential on RAW264.7 
macrophages and certain cancer cells. The results of these studies showed that CACF 
possesses interrelated activities, ranging between antioxidant, cytotoxic and in vitro and 
in vivo TNF-α inhibition effects, without any toxic signs in acute toxicity study. In 
addition, CACF maintains concerning mechanistic approach linked with cytotoxic 
activity on MCF-7 cells which positively inhibited NF-κB translocation. Taken 
together, these findings suggest the use of CACF as an alternative for the management 
of inflammatory response against elevated TNF-α as well as in oxidative stress 
conditions. CACF may be helpful in combatting breast cancer, suggestive of its usage 
after detailed mechanistic studies on targeted MCF-7 cells, including in vivo models.   
 
Further studies 
This study provides information on different plants that exhibit hypoglycemic and 
antioxidant potential. However, on the basis of positive results obtained, this study 
focused on the most potent plant, Centratherum anthelminticum seeds for more 
extensive biological evaluations. 
 
(1)      Antidiabetic study on the defatted crude methanolic fraction of Centratherum 
anthelminticum seeds (CAMFs) showed potential antidiabetic properties in the in vitro 
and in vivo study models, this activity might attribute to its group of compounds which 
demonstrate the effects in a synergestic manner. Therefore, it is suggested to isolate 
different compounds present in CAMFs and evaluate their response on the insulin 
regulated inflammatory cytokines signaling pathways as well as on the specific targeted 
proteins through gene expression study. Furthermore, genotoxicity and metabolic 
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studies with bioavailability test would provide essential safety information on the 
compounds isolated from the CAMFs.  
 
(2)   Pleotropic biological activities on the chloroform fraction of Centratherum 
anthelminticum seeds (CACF) showed potential cytotoxic effects on the human breast 
cancer cells (MCF-7) through the inhibition of NF-κB translocation. As we know, NF-
κB plays an important role in anticancer research and works as a regulator of genes that 
controls cell proliferation and cell survival. Furthermore, studies on the isolation of 
active compounds present in CACF is in progress to determine their role on the targeted 
cancer cells to elucidate their effectiveness on the induction of cell death and apoptosis 
by utilising different pathways. Moreover, isolated active compounds from CACF 
would be investigated on in vivo mice xenograft model for the anticancer properties.    
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